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I. INTRODUCTION 
Transdermal drug delivery (TDD) is one of the earliest forms of of medication 
employed by humans. For a long time, however, TDD was limited to topical 
application of e.g. creams and ointments [1]. This is due to the effectiveness of the 
natural skin barrier which made systemical drug administration via the skin very 
difficult. With modern technique and pharmaceutical knowledge, this obstacle 
was passed and the numerous advantages of TDD could be made use of.  
Some of these advantages are the following: 
 Circumvention of the so-called “first pass effect” by direct absorption of 
the drug into the circulation. This results in enhanced efficacy of the 
treatment. 
 For TDD generally lower dosages are required than for oral or parenteral 
drug administration, resulting in decreased risk for toxicity and side-
effects. This, together with the aforementioned point, can also help 
keeping the costs low [1]. 
 By circumvention of gastrointestinal metabolism, the drug intake can be 
better controlled and monitored than in most other application ways [1, 2], 
as the extent and speed of these metabolic processes differ between 
species and individuals, making predictions about drug behavior often 
difficult [3, 4]. 
 This also leads to a higher stability of plasma levels compared to the other 
methods which may be vital for certain patients [1, 2] 
 Application of the drug is easy and pain-free and therefore may increase 
compliance by the patients and, in case of an animal patient, their owners. 
In our current society, an increasing number of people keep one or several pets at 
home. These animals are ubiquitously seen as a family member and quite often 
even replace having a child. They tend sometimes to also have the same types of 
diseases than humans do, and skin related problems are quite common [5-7]. 
Chronic skin diseases and associated infections with multiresistant organisms are 
especially difficult to treat. The increasing prevalence of antibiotic resistance has 
made the treatment much more challenging [8, 9]. 
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Two types of drug administration can be differentiated: Systemic administration 
and local (topical) administration. Systemic administration by transdermal drug 
delivery means that the drug permeates through all the skin layers and is then 
absorbed into the circulatory system and haematogenously transported to the 
target site. A local effect is achieved when the goal is treating the skin itself, with 
no need to reach relevant serum concentrations. The ability of any drug to 
penetrate the skin or permeate through it depends on the galenic formulation. 
Every drug or active pharmacological ingredient (API) needs a vehicle to 
transport it to its place of action; sometimes additional agents are required as well. 
Potential interactions and incompatibilities between the different substances have 
to be avoided. The pharmacokinetic properties of new drug candidates have to be 
recognized as early as possible during the development process. When developing 
a formulation with a new (unknown/uncharacterized) API, frequently only small 
amounts of the drug will be available because of the high production cost. 
Therefore, strategies to reduce the costs and shorten and facilitate the preclinical 
development process are desirable.  
Furthermore, ethical concern arose with the gradual change of many animals from 
a mere resource to companions and friends and the increased criticism of studies 
using animals for research. The general acceptance of animal experimentation in 
science decreased considerably during the last few decades [10, 11]. 
Consequently, new rules and guidelines about animal handling were formulated. 
In 1956, the 3R-principle was established by William Russell and Rex Burch in 
their “Principles of humane experimentation techniques” which is still valid 
today. These three “Rs” stand for Replacement of animal testing with another 
method wherever possible, Reduction of animals used if unavoidable and 
Refinement of the experimental conditions in such a way that suffering and pain of 
those animals are decreased to the absolute minimum [12]. Legislation followed 
with the creation of the European Centre for the Validation of Alternative 
Methods (ECVAM) in 1991, the adoption of the “Declaration of Bologna” in 
1999, the enactment of Registration, Evaluation and Authorization of Chemicals 
(REACH) by the European commission in 2007 and further laws in the European 
and American economic and scientific sectors.  
Therefore, transferring the pharmaceutical development from in vivo to in vitro 
studies has been the focus of a lot of research in recent years. For such in vitro 
studies appropriate models are required [13]. Although a variety of skin models 
I. Introduction    15 
 
for many different purposes exist, most of them can be characterized as “stand 
alone” approaches rather than validated and standardized procedures that are 
widely known and accepted [14, 15]. 
In addition, only few studies concentrate on veterinary drug development. 
Whether human or animal skin was used, the focus was on human health, and 
animal models were evaluated solely based on their ability to imitate human skin 
[14-16].  
OBJECTIVE 
The overall aim of this dissertation was to develop, validate and establish an in 
vitro skin model with viable human and animal skin. In this way it could be of 
greatest use for investigating skin properties and later disease development. This 
model ideally should keep the experimental conditions as simple, inexpensive and 
consistent as possible to enable several laboratories to reproduce the same results 
and use this model for a wide variety of research studies. 
Individual goals of the research were: 
 Selection of a suitable marker to determine skin viability and investigation 
of suitable storage and measurement conditions for this marker in a 
stability trial 
 Adaption and optimization of the viability assay and validation based on 
FDA bioanalytical guidelines. 
 Establishment of a viable human skin model with healthy skin in 
unsupplemented cultivation medium (DMEM). 
 Establishment of a similar model using porcine and canine skin. 
 Maintaining the skin samples viable for two weeks in supplemented and 
basic medium and simultaneous evaluation of the influence of different 
medium supplements on the skin viability. 
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II.  LITERATURE REVIEW 
1. Pharmacology 
Pharmacology can be defined as the science of investigating the interactions of 
substances and organisms in health or disease state, without regard to usefulness 
or adverse character of these interactions. In a second step by narrowing the 
definition, pharmacology investigates the interactions between drugs and the 
organism of human and animal [17]. In a further step, the possible unwanted 
effects of a substance or drug are analyzed in the field of toxicology. It is of 
absolute necessity to know about the normal processes in the organism, which is 
the related field of physiology, to notice if structures and processes in the 
organism are altered which is the equally related field of pathology [17]. 
Pharmacology itself can be viewed from two directions: 
“How does a substance influence the organism?” This question is addressed by 
the field of pharmacodynamics whereas the question: “How does the organism 
influence the substance?” may be answered by the field of pharmacokinetics 
[18]. 
 
Dose-effect relationship 
The potency of a drug is described as the dose or concentration which elicits a 
defined pharmacological effect. A measure for the potency is the ED50 value 
(effective dose; causing the desired effect in 50% of the tested population, 
respectively as relative value causing 50% of the possible effect). A drug is the 
more potent the less the needed concentration for causing an effect. The efficacy 
of a drug on the other hand measures the extent of an effect caused by a given 
concentration. The LD50 (median lethal dose) value gives information about the 
dose required to kill half of the tested population. The smaller this number is, the 
higher is the danger of a lethal effect of a drug. Referring to this value, also a 
TD50 is defined, which indicates toxic effects in 50% of the tested population. The 
so-called therapeutic index (TI, also known as therapeutic ratio) is a measure to 
determine the safety of a drug by comparing the dose causing effect with the dose 
causing toxicity or death [48]: 
TI=
LD50
ED50
  or TI=
TD50
ED50
     Eq. 1 
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A higher therapeutic index hereby suggests an increased drug safety as the dose 
needed for therapeutic effects is significantly lower than the dose for toxicity. 
Based on this index, the therapeutic window can be calculated. It is defined as the 
range of doses which display an acceptable to optimum relationship between 
therapeutic and toxic effects. The quotient 
LD5
ED95
 is utilized as measure for the 
therapeutic window. Substances with a narrow therapeutic range have to be 
applied and monitored with care [19]. 
1.1. Drug properties 
In order to achieve optimum therapeutic efficacy, any drug or drug candidate has 
to fulfill certain criteria regarding drug potency, target selectivity and the ability 
to reach a sufficient target tissue concentration.  The so-called (L)ADME 
processes (see the following section 1.2) are of highest importance for defining 
the disposition of a drug candidate [20]. The optimization of the chemical drug 
structure in view of the (L)ADME processes is essential for drug discovery and 
drug design [20]. Significant drug related (L)ADME characteristics are: 
 Solubility  
 Partition coefficient LogP 
 Acid dissociation constant pKa  
 Molecular weight 
 Protein binding 
 Half life 
Solubility:  
The solubility of a chemical substance, termed as solute, is its ability to dissolve 
in a solvent by forming a homogenous solution. It is fundamentally dependent on 
the solvent, on temperature and pressure. The solubility of a substance in a 
defined solvent is limited by the saturation concentration. Above this threshold 
concentration, adding more solute to the solution does not increase its 
concentration further [21]. Solubility can be given as concentration, molality, 
molar ratio and other units but is for simplicity reasons usually stated as 
concentration of solute in solvent [21]. Classification into high and moderate 
(>60µm/mL and 10-60µg/mL respectively) solubility provides a categorization of 
different drugs [20]. USP (US Pharmacopeia) and BP (British Pharmacopeia) 
classify solubility regardless of solvent only based on following criteria: 
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Description Parts of solvent per part of solute 
Very soluble < 1 
Freely soluble 1-10 
Soluble 10-30 
Sparingly soluble 30-100 
Slightly soluble 100-1000 
Very slightly soluble 1000-10000 
Practically insoluble ≥ 10000 
Tab. 1:  Solubility classification according USP and BP 
LogP: 
The water-octanol partition coefficient logP measures the differential solubility of 
a substance in a hydrophilic solvent (water) and a hydrophobic solvent (octanol). 
The logarithm of those two values is used for ranking substances according their 
hydrophilicity/hydrophobicity [21] with higher logP values indicating rising 
hydrophobicity and resulting better membrane permeating properties [22]. 
pKa: 
The acid/base dissociation constant, or more exactly its negative decadic 
logarithm pKa, is a physicochemical key parameter with an enormous impact on 
the biopharmaceutical properties of a drug. It defines the tendency of a drug to be 
present in dissociated (ionized, polar) or undissociated form at a basic or acidic 
pH. With respect to the fact that most drugs are either weak acids or weak bases 
[23] it is crucial to know or at least estimate which ionic form a molecule will take 
at different pH values. A pH matching the pKa of a drug means that the drug in 
this condition is present equally in dissociated and undissociated form [22]. In 
physiological systems the ionization state of a drug influences its ability to diffuse 
through membranes and overcome the various biological barriers inside the body 
[23]. The ionized form makes the drug more water soluble (=hydrophilic) while 
the unionized form provides more lipophilicity, thus enables the drug to pass the 
nonpolar membranes more easily. Acidic drugs with a pKa < 7 are present in 
ionized form in basic environments (pH > 7, such as e.g. blood, small intestine). 
On the other hand, basic drugs with a pKa >7 are ionized in acidic environments 
(pH < 7, e.g. stomach). Sometimes a basic drug, e.g. morphine with a pKa of 7.9 
20   II. Literature review 
which is just partially dissociated in plasma (pH 7.4) arrives in an acidic 
environment like the stomach (pH around 2), becomes highly ionized there and 
furthermore cannot diffuse through the gastric lining, unable to leave the stomach. 
This can have clinical consequences and is referred to as ion-trapping [22]  
With the Henderson-Hasselbalch equation the extent of ionization of a drug at a 
certain pH can be calculated, where A- is the ionized drug and HA the unionized 
drug [24]. 
pH=pKa + log10 
[A−]
[HA]
     Eq. 2 
Molecular weight: 
Among other criteria, the molecular weight of a drug determines its absorption 
and permeation properties. Small molecules, i.e. molecules with low molecular 
weight, are more likely to diffuse passively through cell membranes than bigger 
ones. A molecule is considered as small until reaching a mass of around 500 
Dalton (Da)  to 1000 Da [25]. In the so-called “rule of five”, set by Lipinsky et al. 
for the determination of “drug likeness” of pharmaceutical drug candidates, the 
preferable molecular mass is set to 500 Da or less. According to them, a drug 
candidate should fulfill at least three of the following criteria: 
 LogP < 5 
 Molecular weight < 500 Da 
 Hydrogen donor groups < 5 
 Hydrogen acceptor groups < 10 
It should be mentioned, that adherance to those criteria does not definitely make a 
molecule drug-like; on the other hand, a non-adherance is not necessarily a 
disqualification [26]. 
Protein binding: 
While a high lipophilicity, i.e. LogP, increases the ability of a drug to overcome 
biological barriers, it also increases the drug’s tendency to bind to different 
proteins, especially to albumin and glycoproteins. This protein bound fraction of 
the drug is hence unavailable. Protein binding of drugs also leads to an elevated 
risk of toxicity as for clearance the drug needs to dissociate from the protein [20]. 
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Half-life 
The terminal half-life t 1 2⁄  of a drug is the time needed to reduce the drug 
concentration to 50 % of the initial concentration. Within different compartments 
(s. drug distribution) a drug may display a different half-life depending on the 
elimination. The terminal half-life however is defined as the time until half of the 
drug has left the body. It can be viewed in terms of both clearance and distribution 
volume (s. there). A long half-life might be due to a low clearance or a high 
distribution volume or both [27, 28]. 
1.2. The (L)ADME Processes 
LADME is an easy-to-memorize acronym for the processes a drug undergoes 
between being administered and finally excreted. It stands for the following: 
 L Liberation (only applicable for certain dosage forms/formulation) 
 A Absorption 
 D Distribution 
 M Metabolism 
 E Excretion 
 
1.2.1. Liberation 
The first step liberation describes the release of a drug out of its dosage form and 
is applicable for all solid, semisolid and liquid dosage forms except the liquids in 
which the API is already available in molecular disperse solution [29]. 
 
1.2.2. Absorption 
Absorption defines the process of drug entry from the site of application into the 
systemic circulation via different application routes [30]. Influencing factors are 
the physicochemical properties of the drug, administration route, blood flow to the 
absorption site, available surface area for absorption, contact time to mentioned 
surface and affinity of the drug to certain tissues [31-33]. To which extent a drug 
is absorbed depends largely on its bioavailability [34] which is derived from 
administration route and drug properties. 
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Determining bioavailability 
The bioavailability of a substance defines the fraction of a dose reaching the 
general circulatory system unchanged. General circulation is usually defined by 
the experimental sampling site, mostly a peripheral blood vessel. Following oral 
administration, the drug is transported down the gastrointestinal tract, where only 
part of the dose might be absorbed due to chemical degradation, physically 
inactivation by binding or complexation, microbial biotransformation, etc. From 
the actually absorbed part at a time point x, some amount can be metabolised 
during transit through the gastrointestinal epithelia, some other amount may be 
metabolised by the liver by way of biotransformation or biliary excretion. Further 
elimination is possible between the hepatic vein and the periphery circulation 
system. So the bioavailability F' (of an orally applied dose) is composed of the 
different fractions that are not eliminated on the way to the sampling site [34]. 
F' = FX FG FH FS     Eq. 3 
FX is the fraction absorbed, FG is the fraction that “survives” a single passage 
through the gastrointestinal epithelium, FH is the fraction that is not metabolised 
by the liver in the first passage and FS finally the fraction that escapes any post 
hepatic elimination. Therefore, the quantity of non-absorbed and intestinally 
eliminated drug is (1-FX). 
By Eq. 3 oral bioavailability and its components are formally defined, while exact 
determination of FS is rarely needed in practice. The more common definition of 
oral bioavailability, F, is as following: 
F = FX FG FH      Eq. 4 
The main difference to Eq. 3 lies in the definition of “general circulation”. Where 
F' describes the fraction of an oral dose reaching the sampling site unchanged, F is 
effectively a means of measure for drug availability to the hepatic venous 
circulation [34] and ranges between 0 and 1[27]. 
Clinical assessment of bioavailability is calculated by comparison of integrated 
i.v. drug concentration to extravascular drug concentration 
F = 
AUC e.v.
AUC i.v.
  100 %    Eq. 5 
where F is bioavailability, AUC e.v. is the area under the curve (plasma 
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concentration) after extravascular administration and AUC i.v. the area under the 
curve after i.v. application [35]. 
 
Kinetics of absorption (elimination) 
Drug absorption as well as drug elimination (see chapter 1.2.5) can be described 
by certain pharmacokinetic models. The rate of absorption/elimination is usually 
either expressed by a half-life  t 1 2⁄  ( required time for absorption/elimination of 
50 % of the drug) [36], or by a rate constant k (the fraction absorbed/eliminated 
per time unit), while k is termed ka or ke corresponding to an absorption or 
elimination process. 
The relationship between them is [37]: 
k =
ln2
t1/2
  or t1/2 = 
ln2
k
    Eq. 6 
Kinetics of absorption/elimination follow either a first order (exponential) or zero 
order process. 
First order kinetics: A constant fraction of the drug is absorbed or eliminated in 
a unit of time; the process is therefore directly proportional to drug concentration 
and applies to the majority of administered drugs.  
Zero order kinetics: A constant amount of the drug is absorbed or eliminated in a 
unit of time, this process is independent of drug concentration. This process 
usually applies only when the drug concentration is high enough to saturate the 
absorption or elimination mechanisms. A constant rate i.v. infusion is an example 
for zero order kinetics as well as the elimination of ethanol [38, 39]. 
Fig. 1: Comparison of first- and zero order kinetics.  
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Plateau effect or steady state: If a drug is repeatedly administered in a certain 
time interval and elimination is a first order process, the plasma concentration 
[40] will approach a plateau value, also termed as steady state condition. The 
same applies for constant i.v. infusion (zero order process) with first order 
elimination [41]. While approaching the steady state there will be fluctuations in 
plasma concentration with a peak at each dose. If the half-life is shorter than the 
dosage intervals, high fluctuations of plasma concentration are the result. The 
shorter the time interval and the smaller the dose, the less fluctuations occur and 
the easier the maintenance of a constant level, which is crucial for some 
medications [38]. 
 
Fig. 2: Comparison of dosage intervals with high and small fluctuations 
1.2.3. Distribution 
After the drug has been absorbed (or just administered in case of i.v. application) 
it will be distributed throughout the body. Depending on administration route and 
drug properties such as lipophilicity, protein binding etc. the drug will either stay 
in the vascular compartment or be more or less widely distributed to the different 
tissues; the tendency of a drug for the former or latter can be evaluated by 
calculating its distribution volume [42].  
 
Distribution volumes 
In general terms, the volume of distribution is defined by the ratio of the drug 
amount in the body at a certain time and the plasma concentration at the same 
time. 
 
Vd=
amount of drug present in body at given time t
Cplasma at given time t
  Eq. 7 
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As defined, Vd is just regarded as proportionality constant between the plasma 
concentration of a drug and its total amount in the body, i.e. to which extent the 
drug stays in the circulatory system vs. the amount which is distributed to the 
organs and tissues. As this proportionality constant has volume as dimension, Vd 
is named as volume of distribution [27]. It should be mentioned that due to the 
most diverse binding properties to tissue and proteins and the compartmental 
differences in distribution pattern of each drug, the volume of distribution cannot 
be regarded as a real volume but rather as an apparent volume, that provides the 
mathematical means of measure and an estimation of drug distribution in the body 
[42].  
Drug distribution and volume of distribution are related but not the same, 
especially as several volumes of distribution can be calculated: Depending on 
measurement conditions, three distribution volumes can be differentiated: Directly 
after i.v. administration (volume of the central compartment VC, see below), at 
equilibrium (steady-state) and at pseudo-equilibrium, from which the ones at 
equilibrium and pseudo-equilibrium are the most relevant ones for practical use. 
These different Vd are necessary, as the ratio between plasma drug concentration 
and drug amount in the body, yields different values for Vd in different states of 
drug distribution [27].  
Also the compartmental drug distribution is important. If a drug stays in the 
plasma and does not partition into any tissues, a so-called one compartment model 
is enough to calculate Vd. This is rarely the case. The vast majority of drugs does 
partition into different tissues. Therefore, the intravascular space can be described 
as central compartment (including well perfused organs like heart, liver and 
kidneys) and the tissues as peripheral compartments. The extracellular space and 
intracellular space can be defined as compartments as well as certain tissues (e.g. 
fat) or organs [43, 44]. Also special compartments such as the CNS with restricted 
access by the blood brain barrier (BBB) [20] and the placenta are defined. Some 
drugs accumulate in certain compartments which can lead to toxicity [56]. The 
tendency of the drug of partitioning to some or all the tissues, the extent and 
velocity of doing so, binding to tissues or proteins and the “preference” of a 
certain compartment, all influences the volume of distribution of those drugs [40].  
Directly after i.v. administration, plasma concentration of a drug is at its 
maximum (C0) and before the start of all drug distribution and elimination, the 
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amount of drug in the body is defined as equal to the administered dose, so the 
initial distribution volume (VC) is as following: 
Vc=
dose
C0
    Eq. 8 
After the drug administration, the distribution and elimination start right away. If 
the drug distribution begins instantly afterwards, the body can be regarded as one 
homogenous compartment and VC is the same as Vd. In most cases however this 
approach is not possible because of a delayed distribution where the plasma 
concentration of drug decreases faster than the total amount in the body; due to 
distribution of the drug throughout the body but not elimination. Referring to the 
definition of a distribution volume (s. eq. 7), Vd increases until the pseudo-
equilibrium of distribution is reached, which is characterised by a balance 
between plasma (central compartment) and tissues (peripheral compartments). 
The only decrease of plasma concentration is now a result of irrevocable 
elimination, proportional to the total body clearance. In this situation the 
distribution volume reaches an asymptotic value, named Varea. So, during the 
distribution phase Vd can be seen as a time-dependent variable with a range 
starting from VC and stretching until Varea.  
Varea=
amount of drug in body during terminal phase
plasma concentration during terminal phase
   Eq. 9 
As Varea can be only seen in relation to total body clearance, it is not the right 
distribution volume in the cases where clearance is zero/apparently zero, e.g. 
during i.v. infusion after achieving steady-state conditions. Here, the drug intake 
is equal to the loss through clearance, therefore as if no clearance occurred. In this 
situation the right distribution volume is the so-called VSS, see equation below: 
Vss=
amount of drug in body at equilibrium
steady-state plasma concentrations (Css)
   Eq. 10 
All these distribution volumes are used to compute the drug amounts and loading 
dose. VC and VSS are often used for the prediction and prevention of critical doses. 
VC itself can be used to calculate the initial maximum concentration of e.g. i.v. 
anesthesia or the estimation of the plasma volume of substances which do not 
leave the central compartment. VSS can determine loading doses while Varea gives 
information about the residual amount of drug in the body during elimination 
phase. It should be noted, that for parenteral drug administration the 
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bioavailability factor F should be implemented in all the calculations. If F is 
unknown, the estimation of drug distribution becomes rather difficult and less 
exact [27]. 
 
1.2.4. Metabolisation 
Metabolisation is a process happening to any drug applied to the body that reaches 
the circulatory system. First the drug is resorbed, which means that the 
concentration in the blood increases and the drug starts its effect. The last step is 
the elimination, where the drug is modified in a way that it can leave the body. 
Sometimes this process is already considered while designing a drug, so an 
inactive pre-drug can be applied that the body transforms to its active form [45]. 
Other times, the metabolisation multiplies the efficacy of a drug to such an extent, 
that it is toxic [46]. In every case, however, metabolisation is meant to serve the 
inactivation and excretion of the drug  [45].  
Metabolisation of drugs mainly occurs via the liver, gastrointestinal epithelia and 
kidney [45]. The liver is the first site, where all toxic substances (and all the drugs 
can be considered as such from the body’s point of view) are collected and 
modified in a process which is called biotransformation. One feature of many 
drugs is that they are relatively unpolar (weak acid/weak base) and highly 
lipophilic, i.e. hydrophobic and poorly water soluble [21]. Therefore, in phase I of 
the biotransformation the substances will be polarized by reduction or oxidation. 
In phase II they will be conjugated with i.e. glucuronic acid and glutathion, or 
acetyl-, sulfate- or methyl groups are added. In this way, the substances are 
transformed from lipophilic to hydrophilic molecules, which is urgently necessary 
to enable the kidneys to excrete them along with the urine or the liver via bile 
[45]. 
First pass effect  
For oral drug administration, the so-called first-pass effect is crucial in 
determining the bioavailability of a drug. The applied drug, absorbed in stomach 
or intestine, will be collected in the corresponding veins which meet in order to 
form the portal vein (V. portae). All the blood from this vessel flows directly to 
the liver before it is introduced to the systemic circulation [45]. 
This means that before reaching the target side, the drug passes the liver, where it 
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is partially metabolized, before it can develop any of the desired effects. 
Depending on the pharmacologic properties of the drug and individual enzymatic 
activity, this effect can reduce the drug’s concentration by about 70 % or more 
[47]. Moreover, this effect is not just limited to the liver, but there is also a 
gastrointestinal first pass effect due to enzymatic metabolic activity of the gut 
walls [45, 48, 49]. The intensity of the mentioned effects not only strongly differ 
from individual to individual, but is also species-dependent, which can cause 
difficulty in predicting the behavior of drugs based on existing data [3, 4]. 
Enterohepatic recycling 
Substances absorbed in the duodenum are transported through the portal vein 
firstly to the liver, as already mentioned. Part of the portal blood will be “used” 
for the secretion of bile back to the duodenum. Some substances are extracted 
from the portal blood by the liver, secreted into bile and again reabsorbed in the 
duodenum for up to 12 times or more [45]. These substances circulating between 
small intestine and liver are subject to enterohepatic recycling. This process is 
important for bile salts, bilirubin and different vitamins but also certain drugs can 
undergo enterohepatic recycling as e.g. antibiotics, NSAIDs and hormones [45, 
50]. Factors determining whether and to which extent a drug will be recycled in 
such a way are among others drug characteristics, transport, biotransformation and 
intestinal absorption as well as genetic variations of the individual and health 
status [51]. Enterohepatic recirculation can prolong the pharmacologic effects of 
these drugs and drug metabolites [51] by increasing the toxicity if the substance 
remains active during circulation [46].  
 
1.2.5. Elimination/Excretion 
Excretion is the last step of the LADME processes, by which the drug is removed 
from the body. Effective excretion is only possible for hydrophilic molecules. 
Accordingly, either the drug itself is hydrophilic enough and can be excreted 
directly without undergoing metabolism (fraction unchanged) or (if it is more 
lipophilic) the drug is altered to a hydrophilic molecule during biotransformation. 
The water-soluble drugs and drug metabolites can now be excreted via the 
kidneys, but also via bile (and consecutively via feces), sweat, lungs and other 
routes. Renal drug excretion, however, is the main route for the majority of drugs. 
Renal excretion includes glomerular filtration, active tubular secretion and passive 
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tubular reabsorption [22]. 
Glomerular filtration: The kidneys filter a huge amount of blood per day which 
makes filtration an effective excretion route, but as the glomerular barrier blocks 
the passage of plasma proteins and generally large molecules, the drug fraction 
bound to any of these blood constituents cannot be filtered. Factors affecting the 
filtration of free drug in plasma are the renal blood flow as well as the glomerular 
filtration rate (GFR) [22].  
Tubular secretion: In this renal excretion pathway substances in the plasma are 
actively transported into the tubular lumen by two transporter groups: OAT 
(organic anion transporter) and OCT (organic cation transporter). Drugs that are 
highly plasma protein bound can be excreted by tubular secretion [22]. 
Tubular reabsorption: As for other substances and body minerals (Na, Ka, Cl 
etc.), some (unionized) drugs are (passively) reabsorbed in the distal tubule and 
Henle loop and will be excreted in a following cycle [22, 52]. 
Summing up all three renal excretion processes, the total renal clearance (CLR) 
can be calculated as following: 
CLR=fu(GFR+CLS)×(1-FR)     Eq. 11 
where fu is the fraction unbound (free drug), GFR the glomerular filtration rate, 
CLS the drug fraction secreted into the tubule and FR the fraction reabsorbed in the 
Henle loop [40]. 
Further pharmacokinetic parameters corresponding to drug elimination and 
excretion are total drug clearance (Cl) and the biological or terminal half-life [52]. 
They can be defined as following: 
 
 Cl=drug elimination rate constant (K) x Vd   Eq. 12 
t 1 2= (
0.693
clearance
∗) Varea⁄     Eq. 13 
     * valid for first order elimination drugs [28] 
The influence of drug distribution on elimination is caused by the availability of 
the drug for the eliminating organs liver and kidneys which only have access to 
intravascular residing drugs. Therefore, the larger the distribution volume, the 
lower is the drug fraction inside the vascular system and consequently the 
elimination over time, resulting in a long half-life [27].  
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1.2.6. Limits of oral and parenteral drug delivery 
In the previous few chapters some aspects of pharmacokinetics and 
pharmacodynamics referring mainly to general drug metabolism and 
metabolisation following oral administration were described.  The goal was to 
provide not only overall understanding but also some important information why, 
although widely used, oral drug administration and its resulting systemic effects 
on the organism, are associated with several downsides such as e.g. low 
bioavailability of the drug resulting in inefficient treatment and potential toxic 
effects [53]. Some disadvantages of the oral route can be avoided with parenteral 
drug administration, but this method also has some critical drawbacks such as the 
invasive nature of parenteral (usually intravenous) drug administration. Also 
patient acceptance may be low due to pain associated with the injection procedure, 
and there is a risk of infection. To administer the drug parenterally, trained 
personal is required [53].  
 
1.2.7.  Advantages of transdermal drug delivery 
Depending on the purpose of treatment, transdermal drug administration can offer 
a variety of advantages. It is painless, non-invasive, with a large surface easily 
accessible, increased bioavailability in the case of drugs undergoing extensive 
gastrointestinal metabolisation, and a rather stable pharmacologic profile with 
fewer peaks compared to other routes [1, 53]. To be able to consider transdermal 
drug delivery as an option and to get a deeper insight into the underlying 
mechanisms, a profound knowledge of the skin’s anatomy, histology and 
physiology is needed. 
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2. Skin  
2.1. Structure and physiological function 
The skin is the largest organ in mammals. It is the most external layer of the body 
and its contact interface to the environment. The major task of skin is to separate 
the inside from the outside but also to enable controlled interactions with the 
outside world. It acts as a barrier against mechanical, chemical, biological, 
radiological and thermal influences, it keeps the homeostatic milieu of the body 
(regulation of water, mineral and vitamin household, maintaining body 
temperature etc.), it is surface for communication, receptor for 
pressure/strain/stress, pain, heat and cold, and it forms the first defense line of the 
immune system [54-57]. 
Its condition is directly linked to physical and mental health. The overall health 
status and many diseases can be recognized from the skin [54]. At the same time, 
skin problems also have a high impact on the general wellbeing of humans and 
animals [58, 59]. 
The skin can be differentiated in 
 Subcutis (also known as hypodermis) 
 Cutis (skin as such) with skin appendages and hair 
 Skin modifications like nail, claw, hoof and horn 
2.1.1. Subcutis 
The subcutis or hypodermis [57] lies directly under the skin and is made from 
loose connective tissue, containing more or less large amounts of adipose tissue. It 
serves as isolator against cold, as energy storage, padding and also as a flexibly 
movable layer between skin and muscle. The continuous fat layers in the subcutis 
of pig and cattle are known as lard and tallow. Strands of tight connective tissue 
run through the subcutis to fix it to the underlying fascia and muscular tissue [54, 
55]. The main cell type, the adipocytes are large (up to 100 µm) roundish cells 
with a lipid filled cytoplasm that pushes the nucleus against the cell membrane 
[60]. 
2.1.2. Cutis 
The cutis defines the outer border of higher organisms which transitions to 
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mucosa at the natural body openings. It can be divided in 
 Dermis and 
 Epidermis 
2.1.2.1. Dermis 
The dermis is the base of the actual skin. It is the thickest layer of the skin. 
Variations in skin thickness result mainly from varying dermal thickness. Total 
human skin thickness including epidermis ranges from 0,05 mm at the eyelids to 
1,5 mm at the palms and soles [55]. It is composed of a dense network of 
collagenous and elastic fibers, different cells and vessels. These are enclosed by 
the gel-like so-called ground substance, consisting of water binding 
mucopolysaccharids, also named proteoglycans. They belong to a group of 
glycosaminoglycans with their major representative being hyaluronic acid. In 
humans, two layers of the dermis can be structurally differentiated [54, 55]. 
 Stratum reticulare 
 Stratum papillare 
The thicker stratum reticulare, adjacent to the subcutis, is made of dense, tight 
connective tissue and is rich in collagen and elastic fibers. They provide flexibility 
and firmness to the skin, making it resilient to mechanic stress. A network of 
lymphatic capillaries is located in the deeper part of the stratum reticulare as well 
as epidermal appendages like hair roots, sweat glands and sebaceous glands [54, 
55, 61]. Pacini corpuscles, registering pressure, can be found in the deeper parts of 
dermis as well as in the subcutaneous tissue [55]. 
The thinner stratum papillare, directly connected to the epidermis, comprises a 
high amount of cells, capillaries and lymph vessels. The main cell types of both 
stratum reticulare and papillare are fibroblasts. They produce and secrete 
procollagen and elastin which are transformed to the aforementioned fibrous 
networks. Collagen fibers provide especially tensile strength and resistance to 
shear stress while elastic fibers help resisting deformation and returning the skin 
to its normal shape [54, 61]. The other important cells are mast cells. They play a 
crucial role in the mechanism of chemotaxis in allergic and inflammatory 
reactions. Their granules release cytokines and other pro-inflammatory mediators 
upon activation by surface antigen binding [62]. They also influence cell 
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proliferation, the production and remodeling of collagen and the formation of scar 
tissue after injury [63]. 
 
Fig. 3:  Connective tissue: a) regular and b) irregular dense connective tissue  
With permission from: OpenStax, Anatomy and Physiology. OpenStax CNX. 12. Feb. 
2019 http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@15.1.  
The border between the stratum papillare and the epidermis is referred to as 
dermoepidermal junction and characterized by an undulating basement membrane 
[55]. In humans, the contact surface to the epidermis is hereby highly expanded 
by the formation of numerous fingerlike projections of the dermis, the papillae, 
which are interdigitated with surrounding papillae from the epidermal side, also 
referred to as “rete ridges”, see fig 4 [54, 57]. This strengthens the connection 
between both layers, by also increasing the surface area for exchange of oxygen, 
nutrients and waste materials by facilitated diffusion from the vascularized dermis 
toward the avascular epidermis and the reverse. Sebaceous glands can be found 
here as well as in the stratum reticulare [54]. Meissner corpuscles are also 
numerously located here, responsible for the detection of light touch [55]. 
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Fig. 4:Histologic section of dermoepidermal junction and papillae, stained with H.E. 
With friendly permission of Kai Emrich, Institut für Pathologie Saarbrücken-Rastpfuhl 
2.1.2.2. Epidermis: 
 The epidermis is a multi-layered keratinising squamous epithelium. It is 
made from several different layers in which the skin cells, the 
keratinocytes are built, multiplied and differentiated. From the deepest 
layer they get pushed toward the outer layers by new cells coming after 
them and are shed after ca. 29 days [54, 55, 60, 61]. The average thickness 
of the human epidermis is around 100 µm [60] with similar values for 
porcine epidermis [64]. Canine epidermis, however, ranges from 
approximately 25 to 45 µm (depending on breed and body region), thus 
being  significantly thinner [65]. As the epidermis is avascular, nutrients 
and oxygen reach only the bottom layers which leads to cell death in the 
upper epidermal regions [54, 55, 61]. Following layers can be generally 
differentiated although differences between species and body region are 
observed [64]: 
 Stratum basale 
 Stratum spinosum 
 Stratum granulosum 
 Stratum lucidum  
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 Stratum corneum 
 
Fig. 5:  Schematic diagram of the different  layers of the epidermis 
With permission from: OpenStax, Anatomy and Physiology. OpenStax CNX. 12. Feb. 
2019 http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@15.1.  
 
Stratum Basale (Basal cell layer) 
The stratum basale, together with the stratum spinosum and the stratum 
granulomatosum also known as Stratum germinativum (meaning living, 
proliferating layer, equal to the term “viable epidermis”), is the deepest layer of 
the epidermis. It is directly superficial to the stratum papillare of the dermis and 
part of the dermoepidermal junction. From this single to triple layer of cubic cells 
(6 to10 µm diameter), anchored to the basement membrane by hemidesmosomes, 
new skin cells are built. These cells, called keratinocytes, migrate by 
differentiating gradually towards the stratum corneum. The basal cell layer is the 
location of melanocytes, which produce the pigment melanin that gives the skin 
its color and helps protecting the skin against UV radiation [54, 55, 61]. 
Stratum spinosum (Prickle layer) 
This layer is characterized by several (5 to 15) layers of polyhedral, larger 
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keratinocytes (10 to 15 µm diameter), connected by glycoprotein structures called 
desmosomes [57, 60]. The cells develop a flattened appearance while they are 
filled with lamellar granules and keratohyalin masses. The mitochondria and 
nuclei start showing signs of degradation [57]. 
Stratum granulosum (granular layer) 
In the stratum granulosum, shortened as SG, the flattened keratinocytes (ca. 
25 µm diameter) are further differentiating into corneocytes. The key 
transformation to form the final SC takes place here. The name of the SG is 
derived from the granules that appear in this just a few cell layers (1 to 3) thick 
sheet [56, 60]. Two kinds of granules are produced by the cells; keratohyalin 
granules containing keratin precursors and lamellar bodies (also known as Odland 
bodies) containing lipids. In the course of the transformation, the cytoplasm 
vanishes, the nucleus is digested and the keratin filaments start forming 
microfibrils. The cell membrane is superseded by a so-called “cell envelope” 
made from cross-linked protein. The lipids of the lamellar bodies are thus released 
into the intercellular space [56]. Keratin belongs to the protein family of 
intermediate filaments which are part of the cytoskeleton of nucleic cells. This 
tough fibrous protein is a crucial structural compound of skin, nail and hair. 
Keratin type I is acidic while a second type is neutral to basic. This enables the 
two helical proteins to interact with each other to form a so-called “coiled coil” 
structure and aggregate to microfibrils which lie parallel to the skin surface and 
strengthening the corneocytes [56]. The desmosomes of the stratum corneum are 
modified by addition of another protein and also called corneosomes [56, 57].  
Stratum lucidum (clear layer) 
The Stratum lucidum has its name from the light breaking properties of young 
differentiating keratinocytes. It only occurs at the fingertips, palms and soles of 
human or at the footpads and nose of members of dog and cat family and 
comprises three to five layers of squamous keratinocytes, devoid of nuclei [54]. 
Stratum corneum (horny layer) 
The Stratum corneum, shortened as SC, is the top, outermost layer of the 
epidermis and the primary barrier against any outside influence. It comprises, 
depending on species and body site, ca. 9-50, in average (human) 12-16 layers of 
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non-viable, squamous, hexa-or pentagonal keratinocytes or corneocytes with a 
diameter of 29 to 40 µm [56, 60]. They are constantly shed and replaced by 
keratinocytes coming up from the deeper sections. MCM (membrane coating 
material), as intercellular matrix, and desmosomes keep the corneocytes together 
[54, 56]. In this way, the SC is often referred to as a conceptual model of a wall of 
bricks with mortar in between them, the “bricks and mortar model” [56]: 
According to this model the keratinocytes are symbolized as bricks and the MCM 
as mortar. The latter contains epidermal lipids such as ceramides, cholesterol, 
cholesterol esters and fatty acids. This lipid intercellular matrix forms a 
semipermeable water barrier, keeping needed skin moisture inside, an absolute 
necessity for land living creatures [54-56]. Lipophilic substances on the other 
hand penetrate the epidermis easily. Its function is essential for an intact skin 
barrier. The healthy SC can protect the organism against invading 
microorganisms, irritating chemicals and allergens [56]. A morphological 
subdivision of the SC into the deep stratum compactum with densely packed 
keratinocytes and the superficial stratum disjunctum where the cells are being 
shed is possible [60]. 
Epidermal cells 
The cells in the epidermis are 85% keratinocytes. The other 15% are melanocytes, 
Langerhans cells and Merkel cells, situated in the viable epidermis. While 
melanocytes protect against UV radiation as mentioned above, Langerhans cells, 
originating from the bone marrow, belong to the MPS (mononuclear phagocytosis 
system) of the cellular immune system and get activated by viral infections, skin 
tumors and contact allergies [55]. By ingesting the antigens and breaking them 
down to small peptide fragments, the Langerhans cells bind the remains of the 
antigen to major histocompatibility complexes (MHC) to be recognized by 
lymphocytes (T-cells) in order to activate the immune response [55, 60]. Merkel 
cells are tactile receptors that transfer information about touch to the intra-
epithelial nerve ends [54, 55]. Free epithelial nerve ends in the basal layer 
transmit pain while Krause bulbs recognize cold and Ruffini corpuscles detect 
heat, both are located in the superficial epidermis [6]. 
2.1.2.3. Epidermal Appendages 
Epidermal appendages are epithelial structures located inside the dermis, lined 
38   II. Literature review 
with epithelial cells which are able to divide and differentiate. These cells are a 
crucial reserve of epithelial cells for re-epithelialization after damage or 
destruction of the overlying epidermis [54, 55]: 
 Sebaceous glands 
 Sweat glands 
 Hair follicles 
Sebaceous glands 
Sebaceous or holocrine glands are spread over almost the whole body. They are 
always connected to one or several hairs [54]. Being most concentrated and 
largest in size in the face and scalp of humans and the chin of cats, they are the 
site of origin of acne. The secretion of sebaceous glands, the sebum, is a mixture 
of complex oils including triglycerides, wax esters, cholesterol and its esters, 
squalene and more [55]. It gets mixed with the secretion of apocrine glands and 
serves the purpose of forming a protective lipid layer on the skin to keep hair and 
the stratum corneum smooth, healthy and more impervious to moisture [54]. 
Sweat glands 
Two types of sweat glands can be differentiated, which secrete either apocrine or 
eccrine. Apocrine sweat glands are associated with sebaceous glands and release a 
slightly alkaline liquid which is responsible for the individual smell of any human 
or animal [54]. The mammary gland is considered as a modified and highly 
specialized apocrine gland [55]. Eccrine sweat glands are especially frequent in 
higher primates and secrete a relatively acidic watery liquor, the sweat [54]. By 
evaporation, sweat has a cooling function on the body and prevents overheating 
due to environment temperature, sun exposure and effort. Its release is triggered 
by exceeding the set body core temperature [55]. Thermoregulation in most 
mammals other than horses and primates does normally not involve sweating, 
therefore they do not have eccrine sweat glands [66]. Sweating in species such as 
human and horse can be also induced by catecholamine release (e.g. adrenalin, 
noradrenalin), as a result of elevated stress levels [67-69].  
Hair follicles 
The intradermal hair root or hair bulb is a part of  the hair follicle which is built by 
an epithelial and a fibrous layer derived from both epidermis and dermis, which 
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are also known as hair root sheath [54]. They are ubiquitously spread over the 
body. Sebaceous and also sweat glands often open into the hair follicles instead of 
directly toward the skin’s surface. The entity of glands and hair is named a 
pilosebaceous unit [55]. While humans, horses and cattle have hair follicles 
surrounding one single hair [66], dogs and cats have compound hair follicles, 
meaning that their hair grows in bundles. For the dog it is usually one primary and 
up to 14 secondary hairs (see next section “hair”) in one follicle whereas cats have 
single primary follicles with up to five surrounding compound follicles with 
around three primary and up to 12 secondary hairs in each of them. The density of 
hair follicles can vary from around 40 to 60 follicles per cm2 (human and pig) 
over 900 follicles/cm2 (cattle) to amounts of 10,000 follicles/cm2 in merino sheep, 
again with considerable variation between body regions [64]. 
Hair 
Hairs are long, thin and elastic filaments made from epidermal keratin. They are 
exclusively characteristic for mammals and cover their bodies in various length 
and thickness. They protect against cold, humidity and can prevent or minimize 
injury. While in normal condition the hair follicles are oriented inclined to the 
skin surface, they can be raised vertically by a strand of smooth muscle, the M. 
arrector pili, which connects the follicle to the superficial dermis (causing e.g. 
goosebumps) [55]. Hair color is determined by granules of melanin within the hair 
[54].There are three main kinds of hair: Vellus hair, intermediate hair and terminal 
hair. The gentle, almost transparent vellus or “wool” hair is spread all over the 
human body, excluding areas like palms, soles and lips (so-called glabrous skin) 
[70] and has for humans an average diameter of 16-18 µm [56]. Terminal hair on 
the other hand is stronger pigmented and thicker; between 57-68 µm in diameter 
[56, 70]. Scalp hair, eye brows, eye lashes, axillary and pubic hair are examples of 
terminal hair. Hair of arms and legs lies in between in thickness and color and is 
therefore categorized as intermediate hair, with a thickness of 28-42 µm diameter 
[56, 70]. This very same differentiation applies to all mammals but with the 
difference that many of them have a higher density of vellus hair in total, covered 
by another layer of terminal or primary hair [54].  
The hair root is only completely developed during the anagen or growing phase 
(see below). The follicular epithelium is surrounded by the root sheath and at its 
bottom is thickened to form the hair bulb enclosing the hair papilla [54]. The 
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continuation of the hair bulb is the hair shaft. The hair shaft separates from the 
hair follicle and its outside part protrudes from the skin surface. The keratinized 
hair can be differentiated into three segments; namely the hair cuticle covering the 
inner layers with flat cells, overlapping each other similar to the scales of a fish, 
then the hair cortex, containing bundles of keratin and structural lipids and on the 
inside of the hair fiber the medulla, an open area at the center [54, 71, 72]. Again 
this structure is similar for all mammals but shows enough morphologic 
differences to distinguish human hair from animal hair by analyzing the scale 
pattern of the cuticle and the ratio of medullary width to diameter of the hair [72]. 
Hair growth is a cyclical process with three repeating stadiums. The anagen phase 
is characterized by growing hair. The catagen phase is the transition time from 
anagen phase to telogen phase. In the following telogen phase, the hair follicle is 
resting. The duration of the anagen phase is directly proportional to the length of 
the created hair. At every place of hair covered human body, all three phases are 
visible next to each other. They can differ in duration depending on anatomic 
location, genetics and individual health status [55] Animals (mammals) often 
exhibit a seasonal hairgrowth, induced by factors such as the length of daylight or 
temperature [73]. 
 
Fig. 6:  Schematic drawing of the different sections of a hair in situ  
With permission from: OpenStax, Anatomy and Physiology. OpenStax CNX. 12. Feb. 
2019 http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@15.1.   
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2.1.2.4. Skin modifications 
Besides the already mentioned skin modification of skin-associated glands and 
hairs (epidermal appendages), also other structures are considered part of the skin. 
 Footpads (mostly animal) 
 Nails/claws/hooves (human and animal) 
 Horns (obviously animal) 
Each of them is an adaptation of epidermal, dermal and hypodermal structures to 
meet the needs of different species. While footpads are characterized by an 
especially strong upholstery of subcutaneous fat, nail/claw/hoof and horn are 
formed by highly specialized keratinocytes [54]. 
Embryologically, subcutis and dermis are of mesodermal origin while the 
epidermis and its appendages/modifications are derived of ectodermal origin [60]. 
2.1.2.5. Skin barrier and acid mantle  
As explained before, the skin barrier is mainly formed by the SC, consisting of 
keratin and lipids, describable with the aforementioned bricks and mortar model. 
The lipids are hereby not homogenously dispersed in the extracellular space of the 
SC but organized into multiple sequestered lamellar membrane bilayers. The 
degradation of corneodesmosomes leaves spaces in these lamellar lipids. This 
way, in a healthy SC under normal conditions, a discontinuous system of tunnel-
like structures, the so-called lacunae, is formed. Subjected to certain treatments 
(e.g. occlusion, iontophoresis, sonophoresis, and prolonged hydration) these 
lacunae can temporarily extend and enlarge and create a continuous and 
permeable system, like pores, an effect that is exploited in transdermal drug 
delivery (see chapter 3). A further feature of the SC is its function as a very 
precise biosensor; already a small change of air humidity can up- or down-
regulate the synthesis of epidermal lipids, filaggrin (main component of the 
cornified envelope of SC cells) and DNA, and also promote inflammation. This is 
possible via connections down to the viable cells of the epidermis [74].  
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Fig. 7: Visualization of bricks and mortar model and lacunar system model 
Another aspect that accounts to the SC barrier is the so-called acid mantle [56]. 
The mortar lipids are made up of three main types: Ceramides, cholesterol and 
free fatty acids, in the ratio 1:1:1. Their very composition and distribution 
provides the high hydrophobicity and the acidic pH of the SC, which usually 
varies between 4 and 5.5 (human). This pH acts as an additional protection against 
bacterial colonization of the skin. Disruption in the ratio of these lipids leads to an 
impaired barrier function due to alteration in the membranes [56, 74].  
 
2.2. Unphysiological condition 
The skin, especially the stratum corneum, can only fulfill its natural protective 
tasks as long as the homeostasis of the skin and skin associated milieu remains 
undisturbed. If due to any internal or external influences the sensitive equilibrium 
is impaired, the skin barrier becomes leaky and leaves the organism vulnerable to 
the hostile outside world.  
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2.2.1. Damaged skin barrier 
Whatever the underlying causes for an affected skin barrier are, they can 
frequently be broken down to three complex conditions which are to a high extent 
mutually dependent. These are: 
 Dryness 
 Irritation due to chemicals/radiation 
 Inflammation 
2.2.1.1. Chemical irritation and dryness 
Chemical irritation of the skin is usually associated with dryness, as the damaged 
skin barrier cannot keep moisture inside anymore. One common example for skin 
irritants are surfactants as ubiquitous components of most washing and cleansing 
products, i.e. soaps, lotions, shampoos etc. They are surface-active molecules 
comprised of a hydrophilic head group and a hydrophobic tail portion 
(amphiphilic molecule). Their mode of action however can cause serious damage 
to both the bricks and mortar of the SC barrier. Surfactants bind to proteins by 
changing their structure and have been proved to also bind to the SC and cause 
swelling.  Surfactant effects on the lipid mortar include removal of lipids as well 
as alteration of their composition by disordering their lamellar structure. Further 
effects focus on the protective acid mantle of the skin: The natural SC pH of 4.0 
to 5.5 is raised by washing with soap to 7.5. While washing once in a while does 
not cause any further harm and the skin is repaired in short time, repeated washing 
can exceed the buffering and repairing ability of the skin, i.e. between the washing 
cycles the pH does not return to its normal value. The damaged SC barrier causes 
loss of water. Therefore, the skin gets dry and dry skin is not flexible and pliable 
anymore but stiff and brittle. This leads to cracking (fissuring) of the skin which is 
now open and permeable for other chemicals, harmful bacteria etc. which further 
challenge the disrupted skin. Low hydration status of the SC disturbs also the 
normal desquamation, resulting in shedding large flakes instead of normal cells, 
thus increasing the surface area for bacterial colonization. Surfactants can also 
trigger the liberation of pro-inflammatory cytokines by interacting with the 
keratinocytes in the viable layers of the epidermis. This can cause an 
overstimulation that leads to hyperproliferation of the skin which does not leave 
enough time for the complex processes necessary for the formation of a fully 
functional SC [56]. Organic solvents such as ethanol damage the SC barrier in a 
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similar way to the surfactants; by delipidization. Acids and alkali (bases) cause a 
conformational alteration of skin protein and damage the epithelium of the sweat 
gland ducts, thus increasing the porosity of the skin. The result can be an immense 
water loss of up to 350 % following NaOH and Na2PO4 application, both pH 12, 
[75] as well as vesicles and inflammation. UV irradiation is another irritant to the 
skin, inducing epidermal hyperplasia, alteration in lipids, erythema and 
inflammation [75]. 
2.2.1.2. Inflammation  
Skin inflammation can be induced by many factors. UV irradiation is one of the 
main sources of skin inflammation in humans, along with skin injury, microbial 
invasion and allergies. In contrast, UV damage is only seen in sparsely haired and 
nonpigmented skin such as the eyelids, ear tips or the nose in animals. In many 
inflammatory skin disorders, the process may start with pruritus. Upon scratching, 
the skin is subjected to mechanical trauma and barrier disruption and reacts with 
inflammation which, in turns, enhances the itching, thus creating a vicious circle 
which is the harder to break the longer the situation exists (see figure 9). 
 
Fig. 8: Acute vs chronic skin inflammation. 
Redrawn based on [76], with friendly permission of the publisher (spandidos publishing) 
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One example of such an amplification cascade is atopy-like/atopic dermatitis. 
Genetic factors and/or environmental influences lead to an increased inflammation 
with production of allergen-specific IgE, a preponderance of T helper 2 cells with 
release of cytokines such as IL-4, IL-5, IL13 and IL-31. The subsequent pruritus 
leads to scratching. By scratching the itching skin, primary proinflammatory 
cytokines such as IL-1α, IL-1β, TNF- α and chemokines are produced which 
together with adhesion molecules direct the chemotactic recruitment of leukocytes 
to the skin, including dendritic cells. These prompt mast cells to release histamine 
via antigen-specific IgE complexes. The disturbed skin barrier opens way for 
bacterial colonization of the inflamed skin, releasing more inflammatory 
mediators, e.g. staphylococcal enterotoxins, which summons further immune cells 
to the site (memory T-cells, possible involvement of eosinophils) which sustain 
the inflammatory cycle [77]. This activation of both the innate and the adaptive 
immune system triggers mass production of reactive oxygen species (ROS) as a 
result of phagocytosis. These free radicals usually serve defensive purposes but if 
they are produced in excess, so that the cellular scavenging system cannot cope 
with their amount, a radical chain reaction may be started, leading to considerable 
damage of host cell membranes. Due to the high amount of polyunsaturated fatty 
acids (PUFAs) and continuous exposure to UV light, which both contribute to the 
forming of ROS, the skin is especially susceptible to damage by free radicals, 
further promoting inflammation and inflammatory diseases [78]. 
Inflammation is macroscopically defined by five major or “cardinal” signs, 
namely: calor (heat), rubor (redness), dolor (pain), tumor (swelling) and functio 
laesa (loss of function), all of which are also present in skin inflammation. 
 
Skin diseases  
For the interested reader are some examples of infectious/inflammatory cutaneous 
diseases such as Acne vulgaris or Canine atopic dermatitis described in the 
Appendix. 
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3. TDD (Transdermal drug delivery) 
Transdermal drug delivery is, as such, not a new concept as it has been carried out 
for thousands of years in the form of creams and ointments placed on skin [1]. 
However, the purpose typically was to treat the skin or underlying tissue. It was 
less commonly used to administer drugs for treatment of systemic diseases. 
Compared to other ways of drug administration, delivery via skin has numerous 
advantages. As largest organ of the body, the skin offers a vast surface that can be 
employed for percutaneous absorption. Drug administration is non-invasive, 
painless and does not require medical personnel in contrast to e.g. injections. It 
can be applied repeatedly to the same region without considerable irritation and is 
thus suitable for long-term treatment [2]. Transdermal delivery avoids side effects 
and also drug metabolism in the gastrointestinal tract (s. first-pass effect) [83, 88]. 
In many instances, lower dosages are needed than with oral intake, contributing to 
the lower incidence of adverse effects. By circumventing gastrointestinal 
metabolism, a more sustained and controlled drug release with stable plasma 
levels is possible [2], a feature which is generally not provided by both oral and 
parenteral administration, but may be vital for some patients. In many cases, the 
corresponding products and procedures are inexpensive in contrast to their 
counterparts for other administration routes [1]. However, the physiologic 
function of the skin, namely of the SC, to keep exogenous substances outside, is 
so well designed that the epidermis was considered an impregnable barrier to 
TDD for a long time. 
It took until 1979, when the first transdermal patch was approved by the FDA, 
delivering scopolamine for the treatment of motion sickness. Approximately ten 
years later, with the introduction of nicotine patches for people wanting to quit 
smoking, TDD gained more attention and popularity and was finally recognized 
as a profitable research area. Other patches for various diseases entered the market 
during the following years. They can be described as first-generation transdermal 
delivery systems which are based on diffusion [82,83]. Testosterone patches 
against hypogonadism (1993), fentanyl against chronic pain (1990) or 
estradiol/norethidrone against menopausal symptoms (1998) can be listed as 
examples [1]. However, the substances employed for these first-generation 
systems were strongly limited due to constraints based on their physicochemical 
properties. To overcome the skin barrier without further enhancement, a 
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molecular weight below 400-500 Da, small particle size, high lipophilicity with a 
corresponding logP value and therapeutic efficacy at low doses (5-10 mg/d) [89] 
are required [1, 2]. 
The second generation of transdermal delivery systems can be characterized by 
employing permeation enhancers to expand the scope of drug candidates. 
Increasing delivery into and through the skin had to be balanced against injury to 
the tissue [1]. Permeability enhancement can be achieved by chemical enhancers 
as the most conventional method but also by other techniques like iontophoresis 
and ultrasound. 
In the third generation, combinations of chemical enhancers as well as 
biochemical enhancers were tested (e.g. peptides). With electroporation and 
microneedles, the SC barrier could be evaded while with thermal ablation or 
microdermabrasion it was completely removed [1] 
A fourth generation combining wearable devices and drug delivering patches 
connected over a feedback loop, opening the way for personalized therapy, is 
currently under research [2]. 
 
3.1. Percutaneous absorption  
The term percutaneous absorption refers to the permeation of a substance through 
the SC and epidermis into the viable layers of the dermis and from there into the 
circulation (local clearance), hence describes an in vivo process. Permeation is the 
first part of this process, the diffusion across the skin [79]. Penetration can be 
viewed as a part of permeation where a substance does not pass through a layer 
but enters it and gets stuck inside. These two latter terms can describe in vitro 
processes and will be used in this context. As, in vivo, permeation is the rate 
controlling factor and not clearance, determination of permeability in vitro is 
thought to reflect in vivo conditions well enough to predict the bioavailability of 
drugs via this method [79]. 
3.1.1. Skin permeation  
When testing a drug candidate or formulation intended for percutaneous 
application, usually an in vitro permeation study will be conducted during the 
process [80]. The substance is screened for its permeation properties and how it 
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can be modified.  
3.1.1.1. Selection of (skin) membrane  
For in vitro permeation studies, different membranes can be used. Employment of 
human skin is preferred for human application but also substitutes from animal 
skin, artificial skin tissue or reconstructions can be taken. Choice of skin and skin 
preparation strongly depend on intended application and tissue availability [15] . 
Generally, following possibilities exist, which will be described in detail in 
chapter 4 In vitro skin models: 
 freshly excised skin from surgery or cadaver skin 
 stored (frozen/thawed) skin 
 full-thickness (FT) skin 
 split skin which will be dermatomed to the desired thickness 
 skin with removed SC layers by tape stripping 
 heat separated epidermis (HSE) 
 trypsin isolated SC 
 artificial skin 
 reconstructed epidermis 
 animal skin from pig, rat, mouse, guinea pig, snake and other species 
 
3.1.1.2. Diffusion cells  
For measuring the skin permeability, the selected skin membrane will then be 
placed in a diffusion cell. Although a variety of diffusion cells exists for this 
purpose, the principle is always the same. They are made of stable and inert 
materials such as glass or steel [79] and consist of two chambers, the donor and 
the receptor compartment. The membrane is placed between the two 
compartments with the SC facing towards the donor compartment where the API 
is applied. The other compartment is filled with receptor solution. Over a defined 
time, the API will permeate through the membrane and can be quantified in the 
receptor solution. 
From all different models of diffusion cells, two designs are most common. One is 
the side-by-side diffusion cell, a design employed by Wurster et al. [81], Flynn 
and Smith [82], Southwell and Barry [83] and many others [80]. More common is 
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the diffusion with vertical compartments with the donor compartment on the top 
cell mimicking in vivo conditions. This design is more suitable to variation of the 
donor vehicle, enables finite and infinite dose experiments and offers better 
control of atmospheric conditions [80]. The Franz diffusion cell is a very popular 
example of a vertical diffusion cell (s. figure 9). Different types of Franz diffusion 
cells offer a diffusion area of 0.1 to 39 cm2. The volume of the receptor chamber 
is generally defined whereas the volume of the donor can be varied [84]. The 
membrane is fixed between both compartments using clamps. The temperature of 
the tissue and the receptor fluid should usually be maintained at 32 ± 1°C which 
can be achieved with a water bath system [79]. 
 
Fig. 9:  Depiction of a regular Franz diffusion cell  
 
3.1.1.3. Receptor fluid  
As receptor fluid generally an isotonic buffer solution with a pH of 7.4 is chosen, 
e.g. PBS or KRB. Its solubility and stability regarding the corresponding 
experimental conditions has to be ensured. It must be assured that it does not 
compromise the integrity and permeability of the skin [84]. The thermodynamic 
activity of the drug in the receptor solution must not be higher than 10 % of its 
activity in the donor liquid that the permeation proceeds in the desired direction 
[79]. It is inevitable to constantly stir the receptor fluid in order to distribute the 
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API homogenously inside and avoid local concentration peaks. Agitation of the 
receptor fluid reduces static diffusion boundary layers and thus increases 
permeation rates. The aim is to maintain so-called infinite sink conditions 
throughout the complete experiment [80]. While for hydrophilic drugs aqueous 
receptor fluids such as the aforementioned buffers are preferred, the addition of 
solubilizers, i.e. BSA or isopropyl myristate, might be required for lipophilic 
compounds [79, 80].  
3.1.1.4. Donor solution 
Occlusion vs. Open application: Depending on the product to be tested, the 
permeation experiment can be conducted under occlusion or as open application. 
Occlusion is achieved by the coverage of the donor compartment with a moisture-
impermeable membrane which can prevent evaporation of the drug 
formulation/solution or hydrate the SC for the experiment [79].  
Finite vs. infinite dose: The API can be applied as finite or infinite dose. Infinite 
dose is defined as an amount of more than 10 µL drug solution per cm2 skin while 
for a finite dose the amount of drug solution per cm2 skin is less than 10 µL. By 
infinite dosing, the velocity of permeation can be measured as so-called 
permeation coefficient. By finite dosing, the focus lies on the evaluation of the 
distribution of the drug within the skin and also the receptor fluid.  
3.1.1.5. Experimental procedure 
It is important to assess the skin membrane for its integrity before the study. Next 
to macroscopic examination this can be done by conducting a separate 
permeability experiment with a validated quality marker, e.g. caffeine. Usually, 
the number of required specimens is excised from the used membrane directly 
before the experiment, generally circular pieces of variable diameter according to 
the employed diffusion cell. They are fixed between donor and receptor 
compartment with a clamp, receptor fluid and API are added subsequently. The 
whole set up can then be placed in a water bath and magnetically stirred. A typical 
permeation experiment has a preset duration of 24 or 48h with defined sampling 
time points where a small amount of receptor fluid is sampled via the arm of the 
diffusion cell and then analyzed qualitatively and quantitatively by e.g. HPLC 
(High Pressure Liquid Chromatography), scintillation counting or any other 
suitable method [84].  
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3.1.1.6. Permeability analysis 
Generally, the transport of molecules across any barrier can be quantified by flux 
which quantifies the amount of moving particles as a function of time as described 
in Fick’s first law: 
J=
m
At
     Eq. 14 
with J being the flux (usually as mg or mol/cm2/s) of a mass or amount m of a 
compound over an area A during a time t. If within the compartments of the 
diffusion cell there is no other concentration gradient than that through the barrier, 
i.e. skin membrane, then Fick’s law can be modified as  
J=P (Cdonor - Creceptor)    Eq.15  
where P is the permeation coefficient, C the concentration in the donor and 
receptor compartment and J the flux from donor to receptor compartment. P is 
often described as Papp as it is an apparent coefficient due to simplifications and 
dependending on the experimental conditions. Assuming that the transport across 
the membrane and the concentration in the donor chamber is constant and the 
concentration in the receptor chamber is so much smaller than in the donor that it 
can be considered practically zero, then the equation can be further simplified as 
follows: 
J=Papp Cdonor    Eq. 16 
and transformed to: 
Papp=
J
Cdonor
     Eq. 17 
 
With this equation, the permeability of a drug substance through a certain barrier 
can be calculated. Several substances can be compared with each other and 
categorized in permeability classes [85] (BCS guideline). It should be taken into 
account that permeation as a form of diffusion is driven by a concentration 
gradient, thus the system is not in a state of equilibrium at the beginning of the 
experiment when the drug is applied. The drug may diffuse slowly or even stop 
due to interactions, e.g. protein binding inside the skin membrane for a while 
(non-steady state conditions). This is the so-called lag time (s. figure 10), where 
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still no drug can be found in the receptor solution. When this time period is passed 
which may be different and specific for various compounds, an equilibrium is 
reached and the diffusion (flux) is strictly proportional to the concentration 
gradient (steady state) [85, 86].  
Evaluation of the results of such a permeation study includes besides the Papp 
value and steady state flux (slope) the total mass balance of the tested compound 
for which the drug residues in the donor, the acceptor and inside the skin have to 
be quantified [79]. 
Fig. 10:schematic presentation of a typical permeation curve. tL=lag time 
 
3.1.2. Penetration/Extraction 
If the goal of a study is not the evaluation of a drug’s permeation through a 
membrane (skin) but to see if it is able to penetrate the SC, to which extent if at 
all, and determine the fractional distribution in the skin layers, a penetration 
experiment will be conducted. Usually, full thickness skin is either placed in a 
diffusion cell (as described for skin permeation) in case of a drug solution or in a 
Petri dish for a semisolid formulation or a patch. The skin specimens are 
incubated for a defined time at 32 ± 1°C and remaining drug is removed with 
cotton balls afterwards. The SC is segmentally removed by tape-stripping. The 
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remaining skin layers will be segmented as cryo-cuts with a cryomicrotome. The 
cotton balls, strips and cryo-cuts of each skin specimen are then collected in a 
specific vessel and filled up with a defined amount of extraction medium which is 
selected according to the solubility of the used drug and again incubated for a 
defined time (usually at least 60 min). Afterwards the samples can be analyzed.  
Evaluation can focus on recovery (total mass balance) of the drug in the skin 
fractions, amount of API per skin area of SC and deeper layers or API content in 
relation to skin volume [84].  
3.1.3. Routes of drug delivery through skin 
When applied to the skin surface, a drug has three possible ways of penetration: 
 Directly across the SC 
 Through the sweat ducts 
 Through the appendageal route (via hair follicles and sebaceous glands) 
 
Fig. 11:schematic depiction of skin penetration routes: 1) sweat ducts; 2) across the 
SC; 3) hair follicles  
Under creative commons license from: OpenStax, Anatomy and Physiology. OpenStax 
CNX. 12. Feb. 2019 http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-
3ef2482e3e22@15.1.  
It is a general consensus that with a fraction of 0.1 % of the steady state flux the 
appendageal route contributes only negligibly to permeation although it may have 
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some involvement in the pre-steady state permeation of large and polar molecules 
[87, 88]. In fact, the most important route is the diffusion across the SC. Two 
microroutes can be differentiated here, the intercellular and the transcellular route. 
 
Fig. 12: Schematic depiction of the intercellular and transcellular penetration routes  
As previously described, the SC with its “brick and mortar” structure is the main 
barrier of the skin. Its multiple lipid bilayers formed by long hydrocarbon chains 
(ceramides, fatty acids etc.) are arranged in lamellar gel, lamellar liquid crystalline 
and semicrystalline domains with different properties. While it was thought that 
hydrophilic compounds may favor the transcellular and hydrophobic compounds 
the intercellular route, this view could not be confirmed and today the intercellular 
route is regarded as main permeation pathway. Consequently, most methods for 
enhancing permeation target manipulation or disruption of the intact SC [87, 88]. 
3.1.4. Enhancement of penetration and permeation 
While the first generation of TDD systems mainly concentrated on choice of 
suitable compounds, different ways of enabling and increasing permeation of a 
larger variety of APIs were discovered with the second generation. 
3.1.4.1. Enhancement based on drug and vehicle properties 
Many substances can act as penetration enhances, e.g. water, sulphoxides, fatty 
acids, esters, alcohols, terpenes, essential oils, azone, epidermal enzymes, 
polymers and others. Several mechanisms of enhancement can be described which 
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in many cases are specific for a group of similar drugs. 
 
Disruption of SC lipids  
A phase separation of the SC lipid bilayers is induced by lipid disruption which 
creates transient permeable “pores” in the skin through which the drug can reach 
the deeper skin layers. Fatty acids, specifically oleic acid, employ this mode of 
action as well as different terpenes, Dimethyl sulfoxide (DMSO), azone and some 
essential oils [89, 90]. Extracting lipids from the SC is another mechanism, 
observed in ethanol and DMSO, hereby creating channels inside the skin [88, 89]. 
Raising drug solubility 
An increase of drug solubility in the skin can be seen with ethanol and propylene 
glycol (PG)  as well as a change of solubility of the SC in the direction towards 
the employed drug as proven for estradiol, ibuprofen and metronidazole 
additionally to an unspecific solvent drag effect [89].   
Increase in drug partitioning 
Ethanol, PG and DMSO also facilitate the partitioning of drugs into the SC. By 
aforementioned actions, i.e. disorganization of SC lipids, the free volume and the 
bilayer available for partitioning can be increased and the chemical environment 
inside the SC is altered [88]. 
Increase in drug saturation 
Higher drug saturation can be obtained by an increase of the drug concentration or 
its solubility in the vehicle. This results in a higher thermodynamic activity of the 
drug and so in an increased permeation. It is possible to transiently supersaturate a 
drug solution to obtain even better permeability but this state is very instable and 
should be created directly before/during the experiment, e.g by evaporation of a 
volatile component. Addition of stabilizing agents might be possible [87, 89]. 
Prodrug 
Here, the strategy is to increase the permeation by adding a functional group to 
the drug which makes its partition coefficient more favorable for skin penetration. 
After the viable epidermis is reached, the added group is removed by epidermal 
esterases and the actual “parent” drug is released [87]. 
Ion-pairs 
A modification of the prodrug approach is the usage of ion-pairs. Usually, charged 
molecules do not easily permeate through skin. By adding an oppositely charged 
molecule, both charges neutralize each other and the drug can permeate through 
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the SC. In the aqueous milieu of the viable epidermis the components dissociate 
and the parent drug is released again [87]. 
3.1.4.1.1. Nanocarriers 
Different structures can be called as nanocarriers, including nanoparticles, 
liposomes, ethosomes, niosomes, dendrimers and many others, ranging between 1 
and 500 nm in scale and thus being small enough to evade the immune system.  
 
Transdermal 
nanocarrier type 
Applications 
Liposomes Can encapsulate both lpophilic and hydrophilic drugs. Positively charged 
liposomes are used for NDA delivery in gene therapy, antifungal and 
anticancer applications. 
Drug examples delivered via liposome TDD: melatonin, ketoprofen, 
estradiol, indinavir, amphotericin B, methotrexate, lignocaine 
Transfersomes Have been reported to improve in vitro skin delivery of various drugs, 
penetrate intact skin in vivo and transfer therapeutic amounts of drugs 
efficiently. 
Examples: diclofenac, insulin, tetanus toxoid, corticosteroids, DNA, 
ketoprofen, superoxide dismutase, interleukin-2 
Ethosomes Treatment of atopic dermatitis, Parkinsonian syndrome and dystonia 
therapy. 
Examples: tacrolimus, clotrimazole, ketoprofen, testosterone, 
trihexyphenidyl HCL 
Niosomes Especial potential for cutaneous drug targeting, e.g. feasible cargo carrier 
for topical minoxidil delivery in hair loss patients. Topical application 
increases residence time of drugs in SC and epidermis, reducing systemic 
absorption. 
Examples: minoxidil, ellagic acid 
Dendrimers Diverse applications such as gene therapy, controlled drug delivery, 
delivery of contrast agents, catalysts, chemical sensors, cross-linking and 
light-harvesting agents, also vaccines, antiviral and anticancer therapy. 
Further act as solubility enhancers, used for biocompatibility and toxicity 
assessment. 
Examples: indomethacin, ketoprofen, diflunisal, 5-fluorouracil, peptides 
Nanoparticles Treatment of cancer, diabetes; in case of polymeric nanoparticles also bone 
healing and vaccination. 
Examples: minoxidil, triptoide, DNA, dexamethasone phosphate, 
cyclosporine A, testosterone, caffeine, 5-fluorouracil, chlorhexidine, insulin, 
celecoxib, coenzyme Q, tricloan, triamcinolone acetonide acetate, 
flufenamic acid 
Fig. 13: summary of nanocarrier applications in TDD, based on [91]. 
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They can greatly vary in structure and chemical composition and be employed for 
gene therapy, vaccination, antiviral, antifungal and anticancer-treatment as well as 
for diabetes or atopic dermatitis, see figure 13 [91]. Nanocarriers can improve 
drug solubility, permeability, stability and bioavailability by influencing cellular 
uptake based on their shape, size, rigidity and surface charge [91]. 
Liposomes  
Liposomes are the artificial equivalent to naturally occurring vesicles. They are 
colloidal particles consisting of phospholipids and cholesterol, arranged in 
concentric layers, encapsulating a drug. They seem to accumulate on the skin 
surface or in the upper SC layers and fuse there with the endogenous lipids while 
releasing the drug, an effect that seems to be most significant if the composition 
of the liposome is similar to those of the skin lipids. Drug delivery was described 
to be 4 to 5 times higher compared to a simple ointment with the same drug and 
concentration [87].  
Transfersomes 
Transfersomes are a specific kind of liposome with phospholipids as their main 
constituent with added 10-25 % surfactant and 3-10 % ethanol. The function of 
the surfactant molecules is to act as so-called “edge activators”, making the 
transfersome ultra-deformable, reportedly 105 times more than an ordinary 
liposome [87, 88]. It is postulated that they can permeate through pores of less 
than one tenth of their size. Applying the transfersome containing drug solution 
on the skin under non-occluded conditions, evaporation will cause dehydration of 
the transfersomes which, in order to maintain their hydration level, will be 
prompted to follow the hydration gradient from the dry SC to the aqueous viable 
layers underneath [87, 88]. It was claimed that after 30 min over 50 % of a topical 
dose of e.g. insulin was delivered by using transfersomes in vivo [87]. 
Ethosomes 
Ethosomes are further specialized liposomes, i.e. transfersomes, which can 
disorganize the SC lipids due to their high ethanol content, hence reaching deeper 
skin layers and the systematic circulation [87, 88]. They seem to be safe to use 
and an efficient drug delivery system, especially for lipophilic drugs such as 
testosterone or propranolol [91]. 
Niosomes 
Another specialized liposome is the niosome, composed of lipids, e.g. cholesterol 
and nonionic surfactants [87-89]. The aim for niosomes as for ethosomes and 
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transfersomes was to create liposomes which are less rigid. The addition of 
surfactant increases their stability. Niosomes are frequently used in cosmetic 
products, e.g. delivering anti-aging substances but also have therapeutic potential 
as carrier of antifungal drugs [91]. 
Dendrimers 
Dendrimers are made up of many small molecules, commonly from 
(poly)amidoamine. They can be fabricated in relatively uniform shape and size 
and are used to encapsulate instable and hydrophobic components, delivering 
antiviral, anticancer, antifungal and gene therapies. A disadvantage is their poor 
biodegradation resulting in cytotoxicity [91]. 
Nanoparticles 
Nanoparticles are another heterogeneous group of nanocarriers. They can be 
composed of polymers, polysaccharides, lipids, metals and various combinations 
thereof [92]. They are prepared using techniques such as in situ polymerization, 
emulsification-polymerization, inverse salting out etc. Next to categorization 
according to the used material, they can be divided into nanospheres with a solid 
core and nanocapsules with a hollow core [91]. 
Polymeric nanoparticles can be tailor-made from degradable or non-degradable 
polymers, in various sizes and with different surface modifications enhancing 
their penetration properties. Both they and polysaccharide nanoparticles are 
especially suitable for TDD [91].  The most common natural polymer for this 
application is chitosan, a cationic, biodegradable polysaccharide from crustacean 
shells. Synthetic polymers such as poly-lactic acid (PLA) and poly-glycolic acid 
(PGA) and their co-polymers are alternatives, all of which are naturally 
biodegradable [92].  
Silver and gold nanoparticles are two examples for metal nanoparticles. While for 
silver, the active agent seems to be the breakdown product of the particle itself, 
gold nanoparticles affect drug uptake indirectly via co-delivery. Here, an 
interaction between the skin barrier and the gold nanoparticle increases skin 
permeation and facilitates the absorption of the simultaneously administered 
(protein) drug. Hence, the drug does not need to undergo the complicated loading 
process into the nanoparticulate system, increasing simplicity and cost-
effectiveness [91]. Magnetic nanoparticles are made from iron derivatives and 
with around 10 nm smaller in size than most other nanoparticles which makes 
them useful for applications such as cell targeting. They have been proven to 
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passively diffuse through the SC lipids and hair follicles [92]. Titanium dioxide 
(TiO2) and zinc oxide (ZnO) nanoparticles do not penetrate into the SC but form a 
layer on the skin surface where they reflect and scatter UV rays which accounts 
for their usage in sunscreens [92]. 
Solid lipid nanoparticles (SLNs) and nanostructure lipid carriers (NLCs) are also 
used for TDD [91]. They both act by adhesion, occlusion and skin hydration on 
the skin barrier, improving drug penetration [92]. 
Although generally the appendageal route of skin penetration is neglected, 
nanoparticles have a strong tendency to accumulate in hair follicles. Thus, the 
penetration of the encapsulated drug can be considerably increased. Moreover, it 
seems that the drug-loaded particles are stored within the hair follicle while the 
hair shaft acts as a pump and drives the particles deeper into the follicle reservoir, 
gradually releasing them into the deeper layers. On the other hand, this 
mechanism can be also exploited to block the hair follicles with nanoparticles in 
order to stop or prevent drug uptake via the follicular route [92]. 
3.1.4.2. Enhancement based on SC modifications 
Hydration 
Utilization of water is the most common and safest method of enhancing 
permeability for most substances, whether hydro- or lipophilic. Increasing the 
water content of the SC can alter the solubility of the drug and thus increase its 
permeability, in addition the SC structure swells, prompting the lacunae to form a 
continuous pathway [87]. This increased hydration can be achieved by occlusion 
of the skin surface with impermeable films (e.g. parafilm), oils, waxes, paraffins 
and oil/water emulsions. Although not always effective and not for all 
compounds, a tenfold increase of the diffusion components of alcohols compared 
to dry skin was observed by Scheuplein and Blank [87]. 
 
3.1.4.2.1. Removal of the stratum corneum  
As constituent of the main permeation barrier, removing the SC can be an 
opportunity. This can be achieved by chemical peels, microdermabrasion and 
laser ablation, but all methods cause damage to the skin and are therefore not 
suitable for many applications, in addition to high costs in the case of e.g. laser 
ablation. Tape stripping, however, is occasionally used to remove SC layers 
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before drug application [88]. 
Fig. 14: Schematic drawing of stratum corneum tape stripping, based on [93]. 
 
3.1.4.2.2. Bypassing of the stratum corneum 
Follicular delivery 
The intact SC can be bypassed by using the appendageal route for drug delivery. 
Offering a higher permeability than the rest of the SC (human skin), a drug can 
enter the sebaceous glands, the associated hair follicle (s. pilosebaceous unit) or 
the follicular sheath and directly pass from there through to the dermis. Although 
the area for diffusion is small, absorption is facilitated by rich blood supply. 
Sometimes also liposomes target this route. Follicular delivery is especially 
relevant for large molecules such as DNA which is employed for gene therapy 
[88]. Due to the higher density of hair follicles compared to human and also 
porcine skin, in other animal skin, e.g. dogs, this follicular route may be of higher 
importance than for humans, although the differences in follicular epithelium have 
to be considered. Follicular delivery offers another advantage for lipophilic drugs 
as they are dissolved by sebum, thus “trapping” them within the follicular shaft 
and also providing protection against mechanical removal of the drug. This 
mechanism is employed by some topical drugs such as fipronil (prevents flea 
infestation in dogs and cats) [64] [neu].  
Microneedles 
An array of microneedles is another tool for bypassing the SC barrier. The needles 
of micron size punch holes into the SC which are large enough for the drug 
molecules to permeate through but also small enough to circumvent pain or 
serious damage [94, 95]. The feeling was described as similar to a cat’s tongue in 
a human study [88]. Several trials reported increased permeability by orders of 
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magnitude even for large molecules [88, 94]. This makes microneedles especially 
interesting for cutaneous vaccination (often protein and DNA or parts hereof), 
targeting Langerhans cells, and gene therapy [94, 95]. Various  kinds of 
microneedles have been developed so far. Solid microneedles from metal or 
silicon can be used to form holes inside the skin as a pre-treatment before 
applying the drug in another step. The needles may be also coated with drug to be 
released when punched inside the skin, or hollow needles may be used to flow the 
drug into the skin. Dissolvable needles are made from water soluble and 
biocompatible polymers with the drug embedded inside. When reaching the viable 
skin layers, the remains of the needle dissolve or degrade in the fluids and release 
the drug [2]. This approach can be used for a controlled drug release over seconds 
to several months. Although this technique is very promising, some challenges are 
still associated with it. The quantity of deliverable drug is rather low for coated 
microneedles, for hollow needles a drug reservoir attached to it and a pump 
driving the drug through is required, causing cost and inconvenience. The curing 
process of the polymers employed for dissolvable microneedles might denaturate 
the drug prior to application [2, 88, 94]. 
3.1.4.2.3. Electric and acoustical methods 
Iontophoresis 
Iontophoresis is another way to increase transdermal transport for both charged 
and uncharged molecules [94]. A small current (around 0.5 mA/cm2) is applied to 
the skin via a drug containing electrode directly in contact with the skin with a 
second electrode placed on another body region to complete the circuit [88]. 
Permeation is enhanced by three mechanisms. Firstly, an electrophoretic driving 
force, repulsing charged molecules from the electrode and driving them into the 
skin. Secondly, electro-osmosis, dragging uncharged and large molecules with the 
induced solvent flow and thirdly permeabilization of the skin through the electric 
current which seems to act on the follicular pathway at lower voltages and to 
disrupt the SC lipids at higher voltages [88, 94]. The effect greatly depends on 
molecular mass, charge, polarity and the formulation and is mostly used for 
delivery of anti-inflammatory and topical treatment. Concern about possibly 
irreversible damage to skin and growing hair (induction of follicular route) and 
difficulties in handling of the apparatus are some considerable disadvantages of 
this method [88, 94]. 
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Fig. 15: schematic depiction of iontophoresis. 
 
Electroporation 
By electroporation, transient pores in the SC lipids are created by application of 
short, high voltage pulses (micro to milliseconds, up to 1000 V/cm). In this way, 
drugs can permeate directly to the viable epidermis. The mechanism employs the 
aforementioned concepts of iontophoresis, elecro-osmosis and the decrease of 
skin resistance for several orders of magnitude [88, 94].  
 
Fig. 16: schematic depiction of electroporation process. 
Redrawn based on Neoelegance.co.uk, with friendly permission 
 
 
Sonophoresis (ultrasound) 
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Originally used in the context of physiotherapy, sonophoresis has been also 
discovered for transdermal transport enhancement. The important difference to 
therapeutic ultrasound is the low frequency (around 20 kHz), which directly 
targets the skin surface instead of deeper muscular tissues. Low frequency 
sonophoresis has been proven to increase transdermal transport in vitro for 
various big molecules such as insulin, erythropoietin and interferon. The main 
mechanism of sonophoresis as permeability enhancer is the disruption of SC lipid 
packing structure by cavitation. Bubbles are created inside the SC. When they 
collapse, a shock wave is emitted, leaving free space for the drug to penetrate. 
Additional mechanisms may involve a heat effect by ultrasound absorption and 
oscillation of fluids. The effect usually lasts several hours in which the drug may 
be applied [88, 94]. 
  
64   II. Literature review 
4. In vitro skin models 
In order to be able to develop and optimize drug formulations for TDD, both for 
systemically and topically applied drugs, appropriate skin models are required. 
Depending on the specific purposes of investigation, a variety of in vitro skin 
models exist up to date. However, most of them represent an isolated stand-alone 
approach rather than a comparable, standardized and validated procedure that 
could be widely accepted [14, 15]. Moreover, each of the following skin models is 
associated with some inherent advantages and disadvantages, making it difficult 
to define what the ideal skin model should be like. A high similarity to in vivo 
conditions may provide increased predictive potential and reliability but requires 
more biological complexity with resulting challenges in handling, analytics and 
costs. However, a lower degree of in vitro-in vivo correlation may – possibly, not 
necessarily – decrease the scientific significance but may constitute the only 
feasible solution, considering practicability and business economics [14]. 
4.1. Different state of the art approaches 
4.1.1. Artificial in vitro skin models 
Complementary to in vitro skin models based on natural tissues, artificial skin 
models were designed mostly for initial drug screening. With this approach the 
selection of drug and formulation candidates could be narrowed down to a few 
suitable formulations to be further investigated with one of the natural models. 
This approach aimed to increase the efficiency of formulation optimization as the 
artificial models had an advantage in simplicity and reproducibility over the 
natural ones in this early state of drug development [15]. 
4.1.1.1. Poly(dimethylsiloxane), Silicone 
Silicone (PDMS) membranes can be a useful tool for vehicle screening and 
analysis of their effect on drug transport as the acquired data show a good 
correlation to in vivo data in the literature [15]. Several potential vehicles such as 
mineral oil, oleic acid, ethanol, glycerin, octanol etc. were studied regarding their 
effects on the permeation of caffeine and salicylic acid. The model has been 
improved with PEG 6000 copolymer but is still of limited use for the development 
of formulations as it has been only tested for drugs in aqueous solution [15]. 
II. Literature review    65 
 
4.1.1.2. PAMPA 
The PAMPA (parallel artificial membrane permeability assay) was developed in 
1998 as a high throughput screening assay for the evaluation of transcellular 
intestinal permeability. A hydrophobic filter coated with phosphatidylcholine 
served as membrane barrier. This assay was modified in 2009 as skin-PAMPA by 
introducing a lipid system more closely modeled after in vivo conditions. The 
synthetic certramides (sic) were used as replacement for the natural ceramides as 
they are cheaper and more suitable for longtime storage. The permeability of 
several drugs tested with the skin-PAMPA was correlated with human skin data 
which resulted in a good correlation of skin-PAMPA and FT skin [15]. 
4.1.2. Reconstructed human skin equivalents 
4.1.2.1. RHE (reconstructed human epidermis) 
Different RHE models were introduced since the validation of the two pioneer 
RHE models EpiSkin® and EpiDerm™ by the ECVAM (European Centre for the 
Validation of Alternative Methods) in 1998. In 2008, the modified Epiderm™ SIT 
and the SkinEthic® Reconstructed Human Epidermis were accepted. These 
models were mainly designed for the assessment of skin corrosion and skin 
irritancy or for hazard prediction in the case of the Japanese LabCyte EPI-
MODEL 24. However, they were also used for permeation and penetration studies 
and fast screening of the behavior of nanoparticles [14, 15]. Contrary to the high 
variation in permeability of human skin, one would expect a significantly higher 
reproducibility of these RHE models. Although the results of a validation study 
with different permeation substances showed a decreased variability of the data 
compared to excised skin, the expectations were still not met [14]. In addition, the 
barrier properties of the RHE models did not meet the requirements as all of them 
were significantly more permeable than excised human or porcine skin (10-fold 
and up to 800-fold increased permeation). Although the absolute permeability was 
not comparable, the permeation ranking of different substances through the RHE 
models showed high correlation with human and porcine excised skin, reflecting 
relative permeation rather well [14, 15]. 
4.1.2.2. Human skin equivalents 
Full thickness reconstructed skin models, so-called human skin equivalents (HSE) 
are made of a matrix equivalent, usually collagen I, with human fibroblasts for the 
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dermal part and keratinocytes seeded on top for the epidermal part. To allow 
epidermal differentiation, they are cultivated at the air liquid interface. 
Supplements and serum are required for organotypic structuring and survival of 
fibroblasts [14]. Examples for such HSE models are the GraftSkin®, EpidermFT® 
and Pheninon® models as well as the fibroblast-derived matrix model (FDM), the 
full-thickness collagen model (FTM), the Leiden epidermal model (LEM) and the 
full-thickness outgrowth model (FTO) [14, 15]. The barrier properties of these 
HSEs were more similar to human skin with only a 3-fold to 4-fold higher 
permeability than excised skin, compared to RHE models (regarding permeation 
of caffeine, hydrocortisone and tamoxifen). The lipid composition and packing 
was different to in vivo skin, partially due to the relative humidity during 
cultivation. Although the HSEs were already able to mimic several features of 
natural human skin, the differences in barrier function and lipid composition limit 
their suitability for drug development [14]. 
4.1.2.3. Additional cells 
The aforementioned reconstructed skin models are of course a very simplified 
approach to imitate in vivo skin, as many components and cell types still are 
missing. 
Melanocytes: For the investigation of diseases like vitiligo, where melanocytes 
and skin pigmentation are involved, the establishment of a pigmentation model 
such as the 3D pigmentation model from Duval et al. was necessary to study 
pathogenesis and response to appropriate drug development. 
Langerhans cells: The epithelial dendritic Langerhans cells are one of the most 
important immune cells of the skin. As such, there were various attempts to 
incorporate them into HSE models. These models serve to predict allergic 
reactions, e.g. contact dermatitis. 
Endothelial cells and adipocytes: To achieve higher biological complexity and 
predictive potential, the expansion of HSE models with added blood vessels and 
subcutis was a logical step. Seeding of human umbilical vein endothelial cells 
(HUVEC) and fibroblasts onto a scaffold resulted in rudimentary vascularization 
while for the adipose tissue even a preliminary metabolism could be detected 
[106]. 
Hair follicles: While the interfollicular epidermis is an effective barrier for 
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hydrophilic substances, the hair follicles open a pathway for these drugs. 
Therefore, the penetration and permeation profile of a HSE model including this 
pathway may be more close to in vivo skin. 
Tissue stem cells: Adult mesenchymal stem cells (MSCs) from human bone 
marrow and adipose-derived MSCs were added to a human 3D skin equivalent. 
They both promoted the development of a stratified epidermis similar to native 
skin while the latter ones increased epidermal healing upon laser injury [14]. 
4.1.3. Ex vivo/explant models 
Skin for explant models can be taken from healthy donors or donors with a certain 
disease, depending on the study purpose. They may be used as full-thickness or 
split-thickness skin, long- or short-term cultivation, with or without serum 
supplementation and in viable or non-viable conditions, fresh or thawed after 
freezing [14]. 
4.1.3.1. Human skin 
For the investigation of TDD for human, human skin is obviously the most 
suitable model. It is usually obtained from surgery or as cadaver skin. Sampling 
sites are the abdomen, breast, back and leg, rarely also the face [14, 15]. Due to 
the natural origin of the tissue, the in vivo - in vitro correlation is generally higher 
than for other systems. With their complexity, these models can be employed for 
the study of various biological processes, influences of endogenous and 
exogenous factors, disease formation and healing attempts, co-cultivation of 
specific cell types and pharmacological modulation, next to the assessment of 
penetration and permeation of drugs. For example, full thickness human skin 
models have been used for the measurement of epithelial outgrowth (keratinocyte 
migration) and study of populations of dendritic cells. They can also be used for 
compound screening and, in short-time culture, for skin barrier function 
reconstruction, the assessment of skin inflammation or as co-culture models with 
heterologous cell types [14]. Many topical formulations have been tested on 
human full skin, such as nanoparticles in hydrofluoroalkane foam for the delivery 
of tocopheryl acetate or the evaluation of celecoxib delivery via ethosomes, 
liposomes and transfersomes [15]. In addition to its use for drug screening, split-
thickness human skin (epidermis) has been used for the study of the transition 
from the non-proliferative to the proliferative phase during epithelial outgrowth 
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[14]. In addition to the utilization of healthy skin to study general processes, 
disease models are also possible, mainly intended for development of topical 
drugs which should prove their efficacy on skin displaying the typical alterations. 
The focus here can be on inflammation (psoriasis, atopic dermatitis, vitiligo), 
trauma (wounds, burns) or neoplastic cells (melanoma, squamous cell carcinoma) 
[14]. However, in spite of its advantages, human skin comes with certain 
limitations. Additional to the inherent loss of vascularization and nervous system 
like other 3D cultures, the high variation of skin permeability between different 
donors is a problem. The lipid content and composition, skin thickness, hydration 
etc. are influenced by anatomical site of the explant, sex, age and ethnicity, 
resulting in variations of up to 45% in vivo and up to 66% in vitro [15]. Further 
obstacles are the restricted availability of skin specimens and biological 
limitations [14, 15]. 
4.1.3.2. Animal skin 
Porcine: After human skin as the “gold standard”, domestic pig skin counts as the 
second most suitable model [16]. Porcine skin is similar to human skin regarding 
features such as epidermal thickness, hair follicle density, ratio of dermis to 
epidermis, SC lipid content, and dermal collagen and elastin fibers. In contrast to 
human skin, it does not contract after removal, rendering especially porcine ear 
skin a better model for topical drug delivery via hair follicles than even human 
skin itself. Skin from other body regions can also be used. A good correlation to 
human skin could be gained especially for lipophilic substances [15]. Full-
thickness porcine ear skin has been employed to study the penetration of 
resveratrol via ethosomes and transfersomes [96], for the optimization of 
nanocarriers with minoxidil [97] and for the evaluation of epidermal accumulation 
of clobetasol from nanoparticles [98], to mention just a few examples. Numerous 
creams, ointments, emulsions and microparticles were tested using porcine skin. 
Another model with abdominal porcine skin was used for a delivery system with 
semisolid vesicles. With split-thickness porcine dorsal skin a microemulsion 
formulation of testosterone was optimized [99] while newborn pig skin is 
increasingly considered for topical drug formulations [100]. Porcine ear HSE was 
employed for the screening of polyamide nanocapsules containing sunscreen 
filters [101]. Porcine skin shows lower inter-individual variation than human skin 
and is freely available from local slaughterhouses, without ethical concerns and 
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almost no cost (ca. 1€/kg skin). 
Rodent: In contrast to porcine skin, rodent skin is restricted and its acquisition 
needs ethical permission. Advantages of rodent skin are their size, easy handling 
and low costs. However, with their fur coat and resulting density of hair follicles 
they need to be shaved before usage of skin which may damage the SC barrier. 
Several nude species are available, such as hairless mice, rats and guinea pigs. 
Generally, looking at skin morphology, lipid composition, hair follicle density, 
thickness of SC and water content, rodent skin is more permeable than human 
skin and not completely suitable as a surrogate. Especially rats and mice yield 
considerably higher permeation rates. Guinea pigs seem to be the most suitable 
rodent species. Hairless species may show better result than furry ones.  
Others: Other less conventional attempts included primate skin which is not 
feasible due to ethical restrictions, the perfused bovine udder model (BUS) and 
shed snake skin. The BUS is very well-correlated and can be used for the 
comparison of permeation, metabolism and absorption. The udders have to be 
isolated directly after slaughter and continuously perfused via the pudendal 
external arteries. The practicability is therefore rather low and the model rather 
unique and not widely accepted. Another approach is the snake skin model. Shed 
snake skin has been confirmed to have similarities with the human SC regarding 
structure, composition, lipid content and water permeability. Moreover, a snake 
sheds periodically, thus providing a high amount of shed skin of the same 
individual, eliminating unfavorable variability. Furthermore, the snake does not 
suffer injury or death to obtain the tissue, no pre-treatment of the shed is 
necessary and the sheds can be stored at ambient temperature. However, snake 
skin lacks hair follicles which may influence permeability and makes it unsuitable 
for drugs penetration via hair follicles. Also there seems to be a high variation 
between different snake species so that some studies present promising results 
while others do not. Of course, this list (see figure 17) is by no means complete 
and further species may be selected [15]. 
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Fig. 17: List of different skin models, based on [15] and [14] 
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Fig. 18: List of different skin models, based on [15] and [14]
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4.1.4. Skin preparation, handling and storage 
Depending on the special purpose, different experimental setups are used. While 
rodent skin is often used fresh, porcine skin as well as human skin for permeation 
experiments is mostly stored frozen at -20 °C for six months or more. Although it 
was long general consensus that permeation of hydrophilic substances does not 
significantly differ in frozen and fresh human or porcine skin, some studies from 
2014 proved the frozen skin to be more permeable than the fresh one. Skin for 
permeation studies can be prepared as FT skin (often rodents, pig ear or newborn 
pig which have very thin skin), split thickness skin (human, dermatomed to 200-
400µm and pig, dermatomed to 400-700µm), trypsin-isolated SC and HSE. HSE 
is created by peeling of the epidermis after placing the skin specimen in 60°C hot 
water for a minimum one minute and is rather unsuitable for hairy skin due to 
holes from the hair shafts remaining in the dermis. Trypsin isolated SC is 
produced by leaving the skin in trypsin buffered solution for 24 hours. Both HSE 
and trypsin-isolated SC were reported to be equivalent in permeation rates [15]. 
4.1.5. Data correlation 
One of the most important points about in biopharmaceutical research is data 
correlation. As by now, it is mostly not feasible to abstain from in vitro models 
during drug development, it is crucial that data obtained from ex vivo studies are 
correctly correlated to data from in vivo studies to allow reasonable comparison. 
Only then, any significance can be given to in vitro results. Another challenge is 
the huge number of animal species used and different models described in the 
literature which makes comparisons almost impossible. Slight variations in 
experimental procedures with the exact same skin model such as the type of 
diffusion cell, skin temperature, acceptor media, application dose, diffusion area, 
culture conditions etc. can tremendously affect data [102]. These facts might be 
some of the reasons why many of all these models are stand-alone approaches 
rather than defined procedures [14, 15]. As a result, literature data may not be as 
reliable as they could be, urging researchers to conduct their own studies to 
answer the same questions already asked before, contributing to the vastness of 
the field and squandering valuable resources. Therefore, methods to correlate data 
and validate and standardize experimental procedures are urgently required [102]. 
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4.2. Skin viability 
While for permeation and penetration studies generally non-viable skin is used 
and often no difference is made between fresh and previously frozen skin, this 
approach is not possible for all applications as for some of them, viable skin is 
crucial, e.g. epithelial migration, skin inflammation, disease models etc. The 
necessity for usage of viable skin models imposes a set of difficulties and 
challenges that non-viable skin does not have. Still, usage of viable skin may have 
to be considered even for permeation experiments, as several studies have 
demonstrated the impact of viability and skin metabolism on the results [14, 103, 
104]. Kao et al. [103] found metabolic viability of the skin to be a determining 
factor in skin permeation. In the non-viable skin samples only unchanged parental 
drug was found in the receptor fluid, whereas with the viable samples parental 
drugs and a spectrum of metabolites could be detected. Most drugs proved to be 
inducer, substrate or inhibitor of the involved enzymes of cutaneous metabolism 
[104]. Inducement by topical benzo[a]pyrene, e.g., led to a two to threefold 
increase of the permeation of the drug [103].  The conception of skin as a merely 
passive barrier is hence untenable. Therefore, representative in vitro studies 
should consider both diffusional and metabolic processes to achieve meaningful 
conclusions [14, 104]. 
 
4.2.1. Skin metabolism 
Skin metabolism is largely due to enzymes of the cytochrome P450 (CYP) family. 
They are involved in several homeostatic processes as well as in the metabolism 
of xenobiotics and can be induced by numerous allergens, toxins and carcinogens 
to which the skin is exposed. CYP enzymes are located in the endoplasmic 
reticulum and mitochondria and perform a two-phase oxidative biotransformation, 
similar to the hepatic biotransformation. A substance may be subjected to 
degradation or activation, possibly resulting in skin sensitization or 
carcinogenesis. Normal healthy skin shows expression of CYP1A1, CYP1B1, 
CYP2B6, CYP2E1 and CYP3A, which could also be detected in organotypic skin 
models [104]. Upregulation is often associated with (skin) disease and 
inflammation. CYP are involved in the metabolisation of retinoic acid, which is 
used as drug against psoriasis and several types of acne. CYP enzymes also 
control the transformation of vitamin D into its active form (1,25-
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dihydroxycholecalciferol), its degradation and turnover. Vitamin D is handled as 
another anti-psoriatic agent. Furthermore, CYP contribute to the biosynthesis of 
proinflammatory agents which are elevated in patients with psoriasis and other 
skin diseases. CYP inhibitors such as ketoconazole, clotrimazole, itraconazole etc. 
are widely successful in dermatophyte therapy. With such an immense 
involvement in various skin related biochemical processes, this potent enzyme 
family should not be neglected in drug development [104].  
 
4.2.2. Bridge 
When considering the two previous chapters about transdermal drug delivery and 
in vitro skin models, up to 100% of the whole research focuses on human health. 
Drugs are formulated and optimized for human treatment and skin models of 
various origins are evaluated based on their ability to mimic in vivo human skin. It 
has been proven that animals suffer from similar or even the same ailments than 
humans do. Therefore, this thesis is meant to initiate a new approach to the field: 
The establishment of skin models specifically for the intention of investigating 
and treating skin diseases of the animal, with particular regard of companion and 
farm animals.  
Prior to that, of course, a lot of basic research has to be conducted to develop a 
solid foundation, including the establishment of basic models under simple 
conditions and their validation in terms of accuracy, stability and reproducibility.  
On this base, further attempts can be built and the models may be adapted, 
optimized and expanded according to various requirements. 
In the following three publications, the establishment of a viable in vitro human 
skin model including the modification of viability measurement procedures, their 
validation and stability analysis and the transfer and expansion of the human 
model to a comparative animal model will be elucidated. 
The overall aim hereby is, to contribute to the establishment of data sets and 
validated standards for the veterinary field which are comparable to human 
medicine and equally qualified. 
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Abstract 
Transdermal drug delivery avoids first-pass metabolism and provides decreased 
toxicity risk and higher patient compliance compared to gastrointestinal drug 
administration. Drug development may be significantly shortened by transfer from 
in vivo to in vitro testing. The aim of this pilot study was to obtain a viable in vitro 
human skin model, employable for drug development of new formulations for the 
treatment of cutaneous diseases. Herefore several skin specimens were cultivated 
under simplest conditions serum-free over 14 days in unsupplemented Dulbecco's 
modified Eagle's medium at 37 °C/5% CO2 with the stratum corneum at the air 
liquid interface. Skin viability was determined with the lactate dehydrogenase 
(LDH) release assay which is generally designed for cell culture systems. The 
second aim of this study was therefore the modification of a commercial LDH 
assay for tissue application. The results of skin cultivation demonstrate, that the 
skin specimens could be kept at a viability level of ≥60% for the first seven 
cultivation days, followed by a sharp decrease afterwards, being comparable to 
studies with more complex cultivation conditions. The LDH measurement method 
was validated, hence it was concluded that the modified assay can be a reliable 
and useful tool for the viability evaluation of skin tissues. 
 
Keywords: In vitro, LDH assay, skin model, skin viability, dermatology 
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1. Introduction 
Chronic inflammatory and infectious skin diseases such as acne vulgaris are a 
continuous problem [1], [2], [3]. Antibiotic treatment of those disorders is 
increasingly questioned in the time of rising bacterial resistance [4], [5], [6], [7], 
[8]. Therefore, new therapeutic options are urgently required. To facilitate and 
abbreviate the development of new pharmaceuticals and use resources efficiently, 
in vitro models are becoming increasingly popular [9], [10], [11], [12]. 
Furthermore, in recent years, acceptance for animal testing has markedly 
decreased [13], [14], [15] and consequently, legislation has issued several rules 
and guidelines regarding animal testing. The 3R-principle [16], first set up by 
William Russell and Rex Burch in “Principles of humane experimental 
technique”, 1959, requests researchers to Replace animal testing where possible 
with another method, Reduce the number of animals and/or Refine the testing 
process in such a way that pain and suffering will be decreased to the absolute 
minimum [16]. With the introduction of new legislation (EU) such as the 
Directive 2010/63/EU, the establishment of the European Center for the 
Validation of Alternative Methods (ECVAM) in 1991 and the adoption of the 
“Declaration of Bologna” in 1999 as well as the proposal of Registration, 
Evaluation and Authorization of Chemicals (REACH) by the European 
commission (and similar approaches in the US), in vitro research is promoted to 
be a future standard [16]. Hence, the focus of this study was the development and 
validation of a novel viable skin model with its main intended application acne 
vulgaris but also suitable for a wide variety of skin disorders, e.g. also by 
cutaneous gene therapy [17] and even useful for cosmetic purposes [18], [19], 
[20]. The use of viable skin is rather challenging compared to non-viable skin, as 
it has to be obtained directly from surgery, immediately cooled down, transported 
and prepared for the experiment on the same day and afterwards kept in viable 
condition for a prolonged period of time [18,21]. Yet, for the investigation of skin 
disease and as the absorption properties of skin not only depend on the stratum 
corneum (SC) as the main barrier, but also on the metabolic activity of various 
cutaneous enzymes and factors [22], a viable skin model has a better predictive 
potential for in vivo conditions. To monitor the skin viability over time, the usage 
of an appropriate marker is essential. As the viability measurements are repeated 
several times with the same skin, a non-destructive test method is needed, which 
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excludes tests such as MTT and WST assay [23,24]. The LDH (lactate 
dehydrogenase) test is a straightforward alternative although it has to be adapted 
for the application on tissue instead of cell culture systems [25]. LDH is a 
ubiquitous soluble intracellular enzyme found in humans and almost every other 
species [26,27]. It catalyzes the reversible reduction of pyruvate to lactate through 
conversion of the co-factor NADH to NAD+ and reverse while the interconversion 
of NADH and NAD+ is equimolar to that of pyruvate and lactate [25]. This 
enzyme can be used as a viability marker as it is only found inside the cells as 
long as they have an intact cell membrane. If the cells begin to die, LDH is 
released into the extracellular space, i.e. the culture medium. The amount of LDH 
in the medium can then be quantified by photometry [25,28,29]. This test could 
potentially be used also for tissue in the original form, but proper results may not 
be assured in this way. 
Therefore, the main focus of this particular study was on one hand the 
modification of the LDH release assay for tissue usage including a validation in 
terms of measurement range and reproducibility and on the other hand the 
establishment of a viable in vitro full-thickness human skin model, cultured 
serum-free under simple conditions in a basic, unsupplemented cultivation 
medium over 14 days, monitored with the adapted LDH assay. 
2. Materials and methods 
2.1. Adaptation of LDH release test for tissue 
As an ordinary commercial kit (Cytotoxicity Detection Kit PLUS from Roche 
Diagnostics GmbH, Mannheim, Germany) was used for determining LDH release, 
which is designed for cell culture [30] and not applicable for tissues, the test 
protocol had to be modified for this purpose. All the measurements were 
conducted in triplicate. 
Sample to reaction mix ratio: With a higher cell density than in monolayer cell 
cultures, higher LHD values were expected from tissue. In order to determine the 
needed quantity of each solution for usage on tissue, nicotinamide adenine 
dinucleotide (NADH) from VWR International GmbH, Darmstadt, Germany was 
selected as a reference compound. In a first experiment six concentrations of 
NADH in solution were prepared as calibration standards (named as KLP1 to 6), 
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ranging from 35.64 μg/mL to 213.87 μg/mL and 50 and 100 μl respectively were 
pipetted (using piston-stroke pipettes from Eppendorf GmbH, Wesseling, 
Germany) into a generic 96-well plate (here Nunclon Delta Surface, Thermo 
Fisher Scientific, Karlsruhe, Germany). After addition of a reaction mixture 
containing a so-called catalyst and sodium lactate [25], the plate was incubated for 
15 min on a horizontal shaker at 150 rpm and either no stop solution, 50 μL of 
stop solution, or 75 μL of stop solution were added respectively. With different 
ratios of test solutions in six test runs, the aim was to determine the exact amount 
needed for each of the components according to the cell abundance in tissue. As 
the ratio of NADH in the first experiment, called test 1, is twice the amount of the 
second experiment (test 2), the measured signal after blank subtraction should 
represent this ratio and be ≤ 0.5. 
Reproducibility: With different tests performed under the same conditions, the 
reproducibility of the method was assessed. 
Stop solution: The necessary amount of stop solution and when it should be 
added was assessed to ensure, that with the addition of stop solution the reaction 
is stopped completely but without oversaturation of the reaction. Improper 
amounts or wrong timing may lead to either under- or overestimated LDH levels 
and therefore incorrect results. Herefore, a positive control was taken, 50 μL and 
75 μL of stop solution added each after 14, 46 and 54 min and measured 
photometrically with the plate reader. 
Establishment of controls: To identify the highest possible LDH release from 
one skin, a positive control had to be defined for which the skin was mechanically 
destroyed with an immersion blender. As a comparison, a piece of both fresh skin 
and of skin stored at −20 °C for 3 years was tested. The skins were submerged in a 
specific amount of DMEM, 12.82 mL/1 g fresh skin and 6.41 mL/1 g frozen skin. 
After skin destruction the suspension was filtered through a nylon net, the filtrate 
was centrifuged and the supernatant was aliquoted and stored at 4 °C and −20 °C 
for measurement. Positive controls for cultivated skins were obtained by the same 
procedure. As a negative control, all LDH in the skin was denaturized by heating 
an aliquot of positive control up to 65 °C for 30 min [31]. The negative controls 
could then be used as blank sample for positive controls, i.e. the measured 
absorption of the negative control was subtracted from the absorption of positive 
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controls to remove the influence of turbidity of the medium due to skin matrix. 
Measurement result of the positive control sample will be considered as 100% of 
the total LDH amount of this skin specimen. 
2.2. Human skin cultivation and viability determination 
Several fresh human abdominal skin specimens were obtained from aesthetic 
surgery (Cabinet Dr. Pierre Sibille, Luxembourg, Luxemburg) from healthy 
donors with no skin diseases of the same age group. They were processed directly 
on the day of arrival. The subcutaneous fat was carefully removed with a scalpel 
and the skin surface rinsed with water. From each skin four full skin punches of 
13 mm ø were taken and weighed. The punches were quickly cleaned with 70% 
ethanol (Waldeck GmbH & Co KG, Münster, Germany) and phosphate buffered 
saline (PBS) solution (Merck Millipore, Darmstadt, Germany) under sterile 
conditions (sterile bench laminar airflow, Heto-Holten GmbH, Wettenberg, 
Germany). Afterwards the punches were placed dermal side down into a 12-well 
plate (Costar 3513 12-well plates from Corning Life Sciences, Kaiserslautern, 
Germany) and immersed in 0.7 mL Dulbecco's modified Eagles medium (Sigma 
Aldrich Chemie GmbH, Taufkirchen, Germany) solution per each well, 
containing 3.7 g/L sodium bicarbonate (Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany), glucose (VWR International GmbH, Darmstadt, 
Germany) and 2.5% gentamycin sulfate (Merck Millipore, Darmstadt, Germany). 
The SC remained uncovered with medium at the air-liquid interface. The skin 
specimens were cultivated for 14 days in a sterile incubator (Heracell Incubator, 
Heraeus, Hanau, Germany) at 37 °C in 5% CO2/air to keep the pH of the medium 
at 7.4 [32] which is not only important for the cultured skin but also for the 
enzymatic reaction employed for measurement [33]. The medium was changed 
daily, except on weekends. The received medium samples were then measured for 
the quantification of LDH release into the medium by photometric measurement 
(microplate reader Wallac 1420 Victor 2) using an absorbance wavelength of 
450 nm. Photographs of the skin were taken every working day to monitor the 
skin's appearance and medium levels. For photometric measurement, the samples 
were diluted with DMEM solution into the linear range of the LDH calibration 
curve. Measurements of LDH release were conducted on cultivation days 3, 7, 10 
and 14. The resulting amount of LDH inversely correlates with tissue viability. 
From each fresh skin prepared for cultivation a positive control was made to 
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compare the measured LDH to the maximum release. For sampling, tubes from 
Eppendorf and Corning were used. 
3. Results 
3.1. Adaptation 
Sample to reaction mix ratio: In order to determine the required amount of the 
different components of the LDH assay kit, several pre-tests under different 
conditions were conducted. In order to evaluate the limiting factor of the reaction, 
two experiments with NADH concentrations 2:1 were compared (test 1 and test 
2). As for all the standard solutions (KLPs) the ratio of test 2/test 1 was <0.5 
(Table 1), it was assumed that both reactions were run in excess of reaction mix 
and 100 μL of sample + 100 μL reaction mix were set as amounts for following 
experiments. 
Table 1. Measurement of the absorption of the NADH calibration standards of test 
1/2/3 (n = 3). 
Sample 
Test 1 
absorbance 
w/o blank 
subtraction 
[AU] 
Test 2 
absorbance 
w/o blank 
subtraction 
[AU] 
Test 1 
absorbance 
with blank 
subtraction 
[AU] 
Test 2 
absorbance 
with blank 
subtraction 
[AU] 
Ratio of absorbance with 
blank subtraction [AU] test 
2 divided by test 1 
KPL1 0.726 0.381 0.671 0.329 0.49 
KPL2 0.629 0.319 0.574 0.267 0.46 
KLP3 0.531 0.260 0.477 0.208 0.44 
KLP4 0.376 0.191 0.322 0.139 0.43 
KLP5 0.243 0.130 0.188 0.078 0.42 
KLP6 0.125 0.075 0.070 0.023 0.33 
Sample 
Test 2 
absorbance 
w/o blank 
subtraction 
[AU] 
Test 3 
absorbance 
w/o blank 
subtraction 
[AU] 
Test 2 
Calculated 
NADH 
concentration 
[μg mL−1] 
Test 3 
Calculated 
NADH 
concentration 
[μg mL−1] 
Calculated 
NADH 
concentration 
[μg mL−1] 
Mean ± SD 
Calculated 
NADH 
concentration 
RSD [%] 
KPL1 0.381 0.374 53.5 53.8 53.6 ± 0.2 0.39 
KPL2 0.319 0.307 44.6 44.0 44.3 ± 0.4 0.88 
KLP3 0.260 0.256 36.1 36.4 36.2 ± 0.2 0.51 
KLP4 0.191 0.187 26.2 26.3 26.2 ± 0.1 0.29 
KLP5 0.130 0.125 17.4 17.1 17.2 ± 0.2 1.19 
KLP6 0.075 0.073 9.4 9.6 9.5 ± 0.1 1.29 
KLP=Calibration standard, AU = Absorbance unit. 
Reproducibility: By comparison of test 2 and an additional test 3, both run under 
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the same conditions, the reproducibility of the developed test method was 
assessed. The relative standard deviation was <2% for all the calibration 
standards. 
Stop solution: The evaluation of stop solution efficacy demonstrated a plateau in 
NADH concentration following the addition of 75 μL stop solution after 54 min of 
incubation (Fig. 1) rendering that amount sufficient to completely stop the 
reaction in the tested skin specimen. Thus, 75 μL stop solution were used for the 
following measurements. Based on the slope of increasing NADH concentration 
the reaction was not oversaturated. 
 
Fig. 1. Measurement of NADH concentrations before and after addition of 75 mL stop 
solution (after 54 min) over 90 min of incubation (n = 3). 
Controls: In the positive control of a skin specimen previously stored at −20 °C 
for 3 years, the mean LDH activity was 22156 ± 842 U/g skin. Fresh skin 
destroyed directly after excision gave a mean LDH activity of 32862 ± 1723 U/g 
skin. The detected LDH activity in the stored skin demonstrated that LDH was 
partly preserved in the skin during a storage time of 3 years at −20 °C but showed 
too much loss compared to the fresh skin positive control, to be used for 
determining tissue viability. The employed destruction method allows 
differentiating LDH release from skin specimens of different storage times and is 
suitable to be used to prepare positive controls for this study (see Fig. 2). 
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Fig. 2. Comparison of the LDH levels (n = 3) of fresh skin and frozen skin to be used for 
positive control. 
3.2. LDH release profile 
The two skins displayed an LDH release profile similar to each other (Fig. 3). For 
both of them, a first peak within 48 h was observed, followed by a plateau phase, 
a second peak on day 7 and a sharp decrease over the course of the second week. 
Skin A exhibited its first peak already on day 1 with 10.44 ± 0.39% LDH release 
while skin B reached the maximum later, on day 2, with 9.66 ± 2.39% release. The 
subsequent plateau phase was clearly shown for skin B but not as demonstrable 
for skin A. However, in both cases an interim phase between two peaks could be 
recognized. The second peak on day 7 was with 6.83 ± 1.61% release for skin A 
and 8.16 ± 1.94% for skin B lower than the first one. 
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Fig. 3. Course of LDH release in percent of the two 13 mm ø full thickness skin punches (skin 
A and skin B) over the complete cultivation time of 14 days at 37 °C with DMEM as 
cultivation medium (n = 3). 
3.3. Skin viability 
To calculate the viability of the skin tissue from its LDH release, the positive 
control obtained from the same (fresh) skin was taken as reference. This control 
displayed a LDH release of 32862 ± 1723 U/g skin. This value represents 100% 
LDH release of this skin specimen and therefore is equal to 0% skin viability. 
The trend of LDH release of two human skin specimens obtained from aesthetic 
surgery, referred to as skin A and skin B, was monitored over a cultivation time of 
14 days. Based on the measurements of LDH activity in AU (Absorbance units), 
the percentage of LDH release of each skin specimen on every cultivation day was 
calculated. From the sum of the LDH release percentage of the previous 
cultivation days, the cumulated LDH release could be calculated (Table 2). From 
this value, the viability of this skin specimen was calculated (positive control in 
percent minus cumulated LDH release in percent = skin viability in percent). As 
after eight days of cultivation 44 ± 3% LDH (skin A) and 42 ± 5% (skin B) were 
released, a residual viability range of 53%–63% (maximum LDH release both A 
and B 47%, minimum release 37% skin B) for both skin specimens was concluded 
(Table 2). In this way, it was possible to monitor the gradually decreasing 
viability of the skin samples over the cultivation time. Both skin specimens were 
successfully maintained viable for eight days of cultivation under simple 
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conditions. Starting from day 9, the skin was considered non-vital when ≥50% of 
LDH were released, indicating a skin viability ≤50%. 
Table 2. Mean LDH activity (n = 3) as cumulative release for skin A and B over 8 
cultivation days. 
Sampling 
time point 
T0 T1 T2 T3 T4 T5 T6 
Cultivation 
time [days] 
0 0.7 2 3 4 7 8 
Skin A 
LDH activity 
[U/g 
skin] ± SD 
744 ± 128 4175 ± 128 6971 ± 128 9425 ± 128 11029 ± 366 13274 ± 528 14595 ± 964 
LDH release 
[%] ± SD [%] 
2 ± 0.4 13 ± 0.4 21 ± 0.4 29 ± 0.4 34 ± 1 40 ± 2 44 ± 3 
Skin B 
LDH activity 
[U/g 
skin] ± SD 
649 ± 109 2900 ± 666 6074 ± 785 7877 ± 785 9649 ± 1051 12331 ± 1294 13706 ± 1663 
LDH release 
[%] ± SD [%] 
2 ± 0.3 9 ± 2 18 ± 2 24 ± 2 29 ± 3 38 ± 4 42 ± 5 
Course of cumulative LDH release over 8 days of cultivation, comparing two different skin 
specimens (skin A and B). On day 8, skin A has released 44 ± 3% of its total LDH content and 
skin B has released 42 ± 5% of its total LDH, referring to the positive control. A remaining 
viability of 56 ± 3% for skin A and 58 ± 5% for skin B (positive control minus LDH release of 
the corresponding skin specimen) was calculated. With a viability ≥50% for both skin 
specimens (range from 53 to 63%), both of them were considered still viable on day 8. So 
both skin specimens were successfully maintained viable for eight days of cultivation. 
4. Discussion 
In this study, a traditional LDH release assay was adapted for tissue usage by 
evaluating the sample to reagent ratio, the reproducibility of the method and the 
efficacy of stop solution. NADH was selected as reference compound. By linkage 
of this reaction to the reduction of a yellow tetrazolium salt (INT) to a red 
formazan salt, corresponding to formation of NADH and pyruvate and hence 
LDH activity, the red formazan salt can be quantified by photometry. The more 
cells of the tissue are dead or in process of dying, the more LDH is released 
through damaged cell membranes and the more formazan salt is detected [25]. For 
the evaluation of the sample to reagent ratio it was crucial to always ensure in-
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excess availability of reaction mixture because otherwise with one of its 
constituents, e.g. catalyst or lactate (substrate) being the limiting factor of the 
reaction, a correct evaluation of LDH would be impossible. To obtain the best 
efficacy of stop solution, different amounts and application times were 
investigated as too early application might interrupt the reaction and lead to 
underestimated LDH results, late application to an overestimation or improper 
readings, as the reaction continues as long as enough of the needed reagents are 
available, causing an oversaturation and making measurements unreliable. The 
LDH release profile of both investigated skin specimen over the cultivation time 
of two weeks, displayed the characteristic shape described in relevant literature 
[34,35] where two distinct peaks separated by a plateau were observed. However, 
in the described former studies the culture medium and conditions were more 
complex than in the current study where the aim was to keep the conditions as 
simple and cost efficient as possible. Human abdominal skin tissue was cultivated 
with 10% serum and hormonal supplementation for up to 216 h at 32 °C by Reus 
[35] while in the present study a serum-free culture of abdominal skin in basic 
DMEM without supplementation at 37 °C was conducted. Human scalp skin was 
cultivated under serum-free conditions with hormonal supplementation over 22 
days at 37 °C by Lu [34] with the main distinction to the current study being the 
use of scalp skin in order to investigate hair follicle growth, different cultivation 
medium, treatment of the skin and significantly smaller size of skin specimens 
(2 mm biopsy). 
In both studies the first peak was observed after 24 h, while in the present study 
one skin's first peak was consistent with these findings and the other skin 
displayed the first peak on day 2. The second peak was described on day 8 by 
Reus [35] and on day 16 by Lu [34], respectively. Under the culture conditions of 
the current study the second peak was reached on day 7. Therefore, culture 
conditions are the main factor influencing the skin viability. The addition of 
selected media supplements may increase the lifetime of the tissue in culture. 
The first peak generally originates from cell stress and cell death [29], mainly 
direct necrosis, corresponding to a cellular-trauma induced by a physical factor as 
the excision of the tissue, but also due to environmental changes (culture 
conditions). Afterwards the tissue gets adapted to its new environment and less 
LDH is released. The second peak may be linked to the time point of maximum 
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apoptosis rate. After this peak, the LDH release dropped down rapidly along with 
the skin's viability, altering the correlation pattern between low LDH release and 
high tissue viability. As many skin cell membranes were already opened and the 
cells dead or in process of dying, most of the contained LDH was already released 
before, so no more LDH was left to be released further on. The course of skin 
viability over the two weeks of cultivation was regularly assessed with the LDH 
release assay, which demonstrates a very close correlation between LDH release 
and cell death [29]. A cumulative LDH release of approximately 45% until day 8 
was observed, from which a residual skin viability of around 55% was concluded, 
followed by a sharp decrease thereafter. As the viability limit was set to 50% prior 
to the study, the skin was considered non-vital from day 8 which was further 
supported by visual signs of degradation, in accordance with the literature [36]. 
5. Conclusion 
The establishment of this viable skin model is a first important step towards a 
more modern method of drug screening and testing in vitro, and evaluating human 
and animal disease. In order to improve the dermatological health of humans, 
companion and livestock animals, this may lead to new insights about the 
underlying disease processes of various skin disorders, helping to find new 
therapeutic solutions. 
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Abstract 
In view of increasing numbers of dermatological disorders, transdermal drug 
delivery along with in vitro research is becoming increasingly popular. Herefore, 
qualified in vitro skin models are required. The objective of this study was the 
optimization and validation of a modified lactate dehydrogenase (LDH) release 
assay during the establishment of an in vitro viable human skin model, 
employable for a variety of skin associated disorders. Firstly, the most suitable 
LDH isoform for the study was determined. Subsequently, a stability study was 
conducted to investigate the best storage conditions of the LDH enzyme. Finally, 
the test system was validated in terms of linear range, range limits and system 
suitability. The results indicate LDH-5 as most suitable isoform due to its 
predominance in skin. The stability samples stored at −20 °C in the presence of 
polyethylene glycol (PEG) as cryoprotector displayed the targeted recovery of 
100% ± 15 % until the end of the four-week study in contrast to other investigated 
conditions. A six-point calibration without PEG and a seven-point calibration with 
PEG including evaluation of system suitability and quantification limits were 
established with both correlation coefficients r2 above 0.99 and all deviations 
below 15%. Concluding from those results, this method can be considered valid 
and useful for its employment in viability determination of viable in vitro skin 
models.
Keywords: Biochemistry; Biotechnology 
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1. Introduction 
Dermal health is one of the greatest concerns in both the human and the veterinary 
field, as skin related disorders, especially allergies, but also infections are rising 
worldwide [1, 2, 3]. Increasing resistances can make conventional therapy very 
time consuming and often ineffective [4, 5, 6]. Therefore, new therapeutic options 
are required. 
Because of the complicated and expensive pharmacological development process, 
in vitro research became more and more popular over the last years [7, 8]. In vitro 
research also addresses the controversial issue of animal testing. Social acceptance 
of animal experimentation declined over the last years due to ethical reasons [9, 
10] and resulted in new scientific principles [11] as well as international 
legislation strengthening animal rights (e.g. Declaration of Bologna in 1999 etc.). 
Furthermore, the outcome of these tests may, in many cases, not be transferable to 
humans [12, 13]. Thus, in vitro research was gradually becoming more important, 
as it can be a solution to many of those problems, leading to the development of 
different skin models. The main aim of this research was the establishment of an 
in vitro viable skin model for the investigation of cutaneous diseases and as basis 
for the development of new drug formulations [14]. It may also be suitable for 
other applications, e.g. gene therapy [15]. While for most of those possible 
applications, the evaluation of percutaneous absorption with non-viable skin may 
be sufficient, for the investigation of skin diseases and inflammatory processes, a 
more complex approach is necessary. Usage of viable skin can be challenging, as 
it has to be maintained viable for a certain time [14]. However, considerable 
metabolic activity was shown in viable skin [16]. This metabolic enzymes 
strongly influence the uptake and efficacy of drugs and lead to a better simulation 
of in vivo conditions [16]. 
Therefore, an in vitro human skin model was established. Herefore, human (or 
animal) full skin is freshly obtained from cosmetic surgery. The still viable tissue 
is cleaned and cut into several specimen. These are cultivated at 37 °C/5% CO2 
with the stratum corneum at the air-liquid-interface for two weeks. Every day, the 
cultivation medium is changed and samples taken which are then analysed with a 
viability marker. In this way, as first step, the development of skin viability under 
different conditions can be monitored and optimized. A second step could involve 
III. Publications   95 
 
the application of different (e.g. anti-inflammatory) nanoformulations and the 
evaluation of their effects on the tissue. 
For the determination of skin viability, a suitable method had to be chosen. 
Measurement of TEWL (transepidermal water loss) showed a low correlation to 
skin barrier integrity in vitro and was described as unreliable in the literature [17]. 
As the viability of the same skin tissue had to be assessed continuously at 
different time points, a non-destructive method was required which excludes the 
popular WST or MTT tests acting destructive on tissue [18, 19]. Hence, the non-
destructive LDH release assay was selected as viability marker (Roche, 2016). 
This assay was previously modified for tissue usage instead of cell culture 
systems. It is also simple to use, provides fast results and does not need expensive 
equipment. In order to be able to use this assay in the above-mentioned way, and 
to ensure reliable results, this test method has to be validated. Therefore, one aim 
of this particular study was to conduct a partial validation, including the following 
parameters: Linear range, range limits and system suitability. A stability trial was 
another part of this study, as the issue of LDH stability in various conditions is 
controversially discussed in the literature [20, 21, 22, 23] and no conclusion could 
be drawn. A literature review about nomenclature and specific properties of LDH 
isotypes was also included in this study. 
2. Materials & methods 
2.1. Basic research on LDH nomenclature and isotype distribution 
In order to be able to perform any study with an enzyme, information about its 
specific properties has to be collected, i.e. temperature and pH optimum [24], 
substrates, storage conditions etc. The potential existence of several serotypes 
should be clarified as well as their major differences in catalytic activity. 
Therefore, intensive literature research was conducted about LDH isoenzymes and 
their features. 
2.2. Determination of LDH stability in different storage conditions 
For this experiment, recombinant LDH from rabbit muscle with a specific activity 
of 844 U/mg protein was diluted in Dulbecco's modified Eagle's medium 
(DMEM) solution (Sigma Aldrich Chemie GmbH, Taufkirchen, Germany). 
Sodium bicarbonate (Sigma Aldrich Chemie GmbH, Taufkirchen, Germany), 
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glucose (VWR International GmbH, Darmstadt, Germany) and gentamycin sulfate 
(Merck Millipore, Darmstadt, Germany) were added to the solution. PEG 400 
(VWR International GmbH, Darmstadt, Germany) was selected as cryoprotector 
[25]. For LDH measurement, the Cytotoxicity Detection Kit PLUS (Roche 
Diagnostics GmbH, Mannheim, Germany) was used. LDH catalyzes the 
conversion of pyruvate to lactate and reverse by reducing/oxidizing the co-factor 
NADH/NAD+. This enzymatic reaction indirectly produces a red formazan salt, 
which can be quantified by photometry [26]. 
The stability study was conducted over four weeks with measurement time points 
directly after preparation (T0) and on days 1, 3, 6, 8, 10, 14, 20 and 27 (Table 1) 
with a high (0.438 U/mL), medium (0.135 U/mL) and low (0.034 U/mL) 
concentration. Each of them were measured in six-fold determination, with PEG 
and without, and stored at 4 °C and −20 °C. Two stock solutions were prepared, 
from which the samples were diluted to the corresponding concentration levels. 
Fifteen percent of PEG were added to one of the stock solutions. The same 
amount of DMEM was added to the stock solution without PEG to exclude any 
measurement interferences due to concentration and volume. Blank samples (only 
medium) were carried with and without PEG to evaluate the influence of PEG on 
the absorbance. For the measurement, 100 μL of sample per well were pipetted 
into a generic 96-well plate (Nunclon Delta Surface from Thermo Fisher 
Scientific, Karlsruhe, Germany), using piston-stroke pipettes (Eppendorf GmbH, 
Wesseling, Germany). 100 μL of reaction mixture (kit) were added and the plate 
incubated for 30 min. at 150 rpm on a horizontal shaker. After adding 75 μL stop 
solution (normally the enzymatic reaction would continue as long as substrate is 
available. To ensure that each plate is incubated exactly 30 min, the reaction is 
terminated with the stop solution), the plate was gently shaken by hand for ca. 10 
seconds and then measured by photometry in a plate reader (Microplate reader 
Wallac 1420 Victor 2). All the numerical results (expressed as LDH activity in 
absorbance units) were divided by 2.75 during evaluation. This dilution factor is 
caused by the addition of reaction mix and stop solution (100 μL sample + 100 μL 
reaction mix + 75 μL stop solution = 275 μL. Hence, the sample is diluted in the 
ratio 1:2.75 which has to be considered in the evaluation, in order not to 
underestimate the measured activity). Tubes from Eppendorf and Corning 
(Corning Life Sciences, Kaiserslautern, Germany) were used for sampling and 
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measurement. All the measurements were performed in triplicate. 
Table 1. Timetable and conditions for stability study. 
Stability Week 1 Week 2 Week 3 Week 4 
TP/timeline 
T0/day
0 
T1/day
1 
T2/day
3 
T3/day
6 
T4/day
8 
T5/day1
0 
T6/day1
4 
T7/day2
0 
T8/day2
7 
Refrigerato
r + PEG 
RT 4 °C 4 °C 4 °C 4 °C 4 °C 4 °C 4 °C 4 °C 
Freezer + 
PEG 
RT −20 °C −20 °C −20 °C −20 °C −20 °C −20 °C −20 °C −20 °C 
Refrigerato
r – PEG 
RT 4 °C 4 °C 4 °C 4 °C 4 °C 4 °C 4 °C 4 °C 
Freezer – 
PEG 
RT −20 °C −20 °C −20 °C −20 °C −20 °C −20 °C −20 °C −20 °C 
TP = time point, RT = room temperature (22–25 °C). 
2.3. Method validation 
To ensure the accuracy and reproducibility of the developed test method, the 
modified LDH release test was subjected to a partial validation including linearity 
(calibration curve), system suitability test (SST) and measurement range limits 
(ULOQ = upper limit of quantification, LLOQ = lower limit of quantification), 
with acceptance criteria loosely based on some of the Food and Drug 
Administration guideline for bio-analytics [27]. 
The establishment of calibration curves for enzyme assays can be challenging, 
therefore a three-step approach was carried out as following. For the first 
preliminary experiments a four-point (partial) linearity was sufficient while in 
another step for the planned main study a six-point (full) linearity was targeted. 
As in the course of the stability study the usage of PEG was evaluated, a third 
linearity containing PEG was needed, targeting seven points. For all of them the 
preparation principle was the same, only for the last one 15 % of PEG were added 
to the stock solution. 
Known concentrations of the re-suspended LDH enzyme were prepared as 
calibration standards and measured according to the same method described in the 
stability section. For each measurement series an array of six blanks was carried, 
and mean blank absorbance subtracted from the received absorbance values of the 
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standards. The LLOQ was calculated based on the mean blank absorbance plus 
standard deviation of the blanks multiplied by 3 in accordance with the guideline. 
The highest standard was defined as ULOQ. The SST was performed using an 
LDH activity level in a medium-high range of the calibration in six fold 
determination. Based on the guideline, ≤15 % RSD (relative standard deviation) 
for the calculated activity of LDH was set as acceptance criterion for each 
validation parameter except LLOQ, where ≤20 % marked the limit of acceptance. 
All the measurements were performed in triplicate. The mean of the three values 
was reported. 
Data evaluation: The obtained absorbance values with blank subtraction were 
plotted against the corresponding theoretical concentrations. The coefficient of 
correlation (r2) and the back-calculated calibration standard activities were 
reported. 
3. Results 
3.1. Basic research on LDH nomenclature and isotype distribution 
The different isoforms of LDH enzyme are listed in Table 2. Five naming systems 
are used in parallel. One refers to the different isotypes as LDH-1/2/3/4/5. The 
others depend on the prevalence and distribution of LDH subunits H and M with 
A = M and B=H. H4/H3M/H2M2/M4 corresponds to B4/B3A/B2A2/BA3/A4, 
while each of them can be also written as HHHH, HHHM, HHMM, or BBBB, 
BBBA etc. 
Table 2. Description and comparison of LDH nomenclature. 
LDH Isotypes Isotype 1 Isotype 2 Isotype 3 Isotype 4 Isotype 5 
Synonym names 
LDH-1 LDH-2 LDH-3 LDH-4 LDH-5 
H4 H3M H2M2 HM3 M4 
HHHH HHHM HHMM HMMM MMMM 
B4 B3A B2A2 BA3 A4 
BBBB BBBA BBAA BAAA AAAA 
 
There are five main isotypes of the LDH enzyme, composed of two tetramere 
subunits (Fig. 1) and commonly named as LDH-1 to LDH-5. They differ in 
catalytic activity, mostly depending on the amount of each subunit. There are two 
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“pure” forms, HHHH (H4) and MMMM (M4) and three hybrids HHHM (H3M), 
HHMM (H2M2), HMMM (HM3). M-rich isoforms have a higher activity in the 
presence of high pyruvate concentration, hence being predominant in tissues with 
considerable anaerobic metabolism, e.g. skeletal muscle or liver (reduction of 
pyruvate). The activity of H-rich isoforms is inhibited by high pyruvate 
concentrations and they are predominant in tissues with aerobic metabolism, e.g. 
heart (oxidation of pyruvate) [28, 29]. Following the same principle, H units can 
also be termed B units and M units as A [30]. 
 
Fig. 1. LDH tetramers and isotype distribution in the human body.  
From Bettelheim/Brown/Campbell/Farrell. Introduction to Organic and Biochemistry, 7E. © 
2010 Brooks/Cole, a part of Cengage, Inc.  
Reproduced by permission. www.cengage.com/permissions 
 
The predominant LDH form in skin is LDH-5, followed by LDH-4 [30, 31] and 
LDH-3. Isotypes LDH-1 and LDH-2 cannot be found in the epidermis and the 
percentage of subunit M and the ratio of LDH-5 to LDH-4 is significantly higher 
than in the dermis, where all five isoenzymes can be detected [32]. It was essential 
to compare the main LDH isoform of the tested LDH enzyme with the main 
isoform of the used tissue, as, if they do not match, the obtained results would not 
be representative. LDH-5 is the main LDH type in the skin. In the recombinant 
enzyme LDH-5 was also the main isotype, in a similar ratio (based on the 
information obtained from supplier). Therefore, the results of all the experiments 
with the recombinant LDH, especially concerning storage conditions, can be 
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regarded as comparable to skin and therefore valid. 
3.2. Stability of LDH 
The outcome of the stability test is summarized in Figs. 2 and 3. Fig. 2 shows for 
all three concentrations that only storage with PEG at −20 °C kept the recovery 
above 85% until the end of the four weeks. The samples without PEG at both 
temperatures (4 °C, −20 °C) show a sharp drop of recovery to around 50% (low 
samples) or 20% (medium and high samples) on the second measurement time 
point after 24 h of storage. From there, the recovery either decreased further to 
around 7 % (high samples) or stayed in this range (low and medium samples). The 
samples with PEG stored at 4 °C also exhibited a marked decrease, ranging from 
approx. 25% recovery (low samples) to 12% (high samples). This decrease was 
less pronounced than for no-PEG samples and their level was reached after 6 days 
of storage on the fourth sampling time point. 
 
 
A 
B 
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Fig. 2. Display of LDH recovery [%] over the course of 27 days. A: low concentration (0.034 
U/mL), B: medium concentration (0.135 U/mL), C: high concentration (0.438 U/mL). All 
samples measured once directly after preparation (=T0), and on day 1/3/6/8/10/14/20/27 
(n=3). 
 
Fig. 3. Plot of measurement results on day 27 for all the 12 investigated storage conditions, 
showing the difference between PEG samples and no-PEG samples as well as the difference 
between 4 °C and −20 °C and the concentration levels low, medium and high (n = 3). 
C 
102   III. Publications 
The twelve possible conditions resulting from the experimental setting were then 
plotted into one graph to facilitate the evaluation of the different influences and 
detect potential codependencies of certain factors, as seen in Fig. 3 where the 
stability of LDH at the end point of the study (day 27) is shown. There, the 
samples with low concentration and without PEG displayed a recovery of 48.95% 
± 0.001 % (4 °C) and 50.04% ± 0.001 % (−20 °C). The medium samples without 
PEG maintained a recovery of 22.67% ± 0.02 % (4 °C) and 17.29% ± 0.01 % 
(−20 °C) while the high samples showed recoveries of 6.99% ± 0.02 % (4 °C) and 
8.01% ± 0.001 % (−20 °C). 
All the samples with PEG showed more differences between storage 
temperatures. At 4 °C the PEG samples range from 5.76% ± 0.002 % (high) to 
8.66% ± 0.001 % (medium) and 24.6% ± 0.001 % (low). At −20 °C the recovery 
of PEG samples for all three concentration levels was finally within the favorable 
recovery range of 100% ± 15 % (85.1% ± 0.02 % low, 102.97% ± 0.03 % 
medium, 98.70% ± 0.22 % high concentration). 
Residual standard deviation (RSD) of all the stability results was <15%. 
3.3. Method validation 
For the 6-point calibration without PEG (Table 3) a linear range from 0.020 U/mL 
to 0.409 U/mL (concentration in tubes, before dilution for measurement) was 
established with six calibration standards, each measured in triplicate. The 
determination coefficient r2 was 0.9983 and hence higher than the acceptance 
value of ≥0.99 and the deviations (RSD) ranging from 8.19 % to - 14.92 % within 
the acceptance limits of FDA-guideline (deviations ≤15%, for LLOQ ≤20%). The 
ULOQ was set to 0.974 AU which corresponds to 0.409 U/mL and the LLOQ was 
set to 0.029 AU, corresponding to 0.020 U/mL accordingly. The values for AU 
(absorbance units) are all given after mean blank subtraction of 0.058 AU. 
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Table 3. 6-point and 7-point linearity with/without PEG including deviations and 
r2 (n = 3). 
Linearity 
samples 
Theoretical 
concentration 
[μg/mL] 
Absorbance 
[AU] w/o 
blank 
subtraction 
mean ± SD 
Absorbance 
[AU] with 
blank 
subtraction 
Calculated 
LDH 
concentration 
[μg/mL] 
Calculated 
LDH 
concentration 
RSD [%] 
KPL1 no 
PEG 
0.149 1.033 ± 0.04 0.974 0.147 −1.08 
KPL2 no 
PEG 
0.074 0.560 ± 0.01 0.502 0.078 4.14 
KLP3 no 
PEG 
0.041 0.324 ± 0.01 0.265 0.043 4.16 
KLP4 no 
PEG 
0.018 0.140 ± 0.005 0.082 0.016 -14.92 
KLP5 no 
PEG 
0.012 0.110 ± 0.002 0.051 0.011 -7.48 
KLP6 no 
PEG 
0.007 0.087 ± 0.001 0.029 0.008 8.19 
r2 0.9983 
KPL1 
PEG high 
0.148 1.619 ± 0.03 1.568 0.148 -0.24 
KPL2 
PEG high 
0.114 1.391 ± 0.04 1.340 0.110 -3.40 
KLP3 
PEG high 
0.074 1.231 ± 0.03 1.180 0.084 13.04 
KLP4 
PEG high 
0.041 0.938 ± 0.04 0.887 0.035 -13.32 
r2 0.9963 
KLP4 
PEG low 
0.041 0.938 ± 0.04 0.887 0.041 -0.57 
KLP5 
PEG low 
0.018 0.480 ± 0.01 0.429 0.019 2.42 
KLP6 
PEG low 
0.012 0.348 ± 0.02 0.297 0.013 5.00 
KLP7 
PEG low 
0.007 0.218 ± 0.01 0.168 0.006 −11.29 
r2 0.9981 
PEG = polyethylene glycol, KLP = common name for calibration standards, AU = absorbance 
units, RSD = residual standard deviation, r2 = correlation coefficient. 
From the linearity with PEG (Table 3) all seven points fulfilled the specifications 
in a split linearity (the linear range is divided in a higher and lower division, 
which must intersect at one point). The linear range expanded again from 0.020 
U/mL to 0.409 U/mL, with 0.113 U/mL (KLP4, corresponding to 0.938 AU) as 
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common point. The determination coefficient of both high/low was with 0.9963 
and 0.9981 higher than the acceptance value of ≥0.99. The deviations (RSD) 
ranging from 13.04% to -13.32% were within the acceptance limits of ≤15%. 
1,568 AU was set as ULOQ, the LLOQ reached 0.168 AU. The system suitability 
test (SST) was carried out in six-fold determination (also n = 3) with a 
concentration of 0.077 μg/mL and resulted in a mean absorbance of 1.315 ± 0.08 
AU. The deviation was with 5.94% within the acceptance limit of ≤15%. The 
corresponding calibration curves and plot of residues are shown in Fig. 4. 
 
Fig. 4. Calibration curves and plot of residues. Left: 6 point calibration without PEG; middle: 
7 point calibration with PEG, low part of the split linearity; right: 7 point calibration with 
PEG, high part of the split linearity (n = 3). 
4. Discussion 
In this study an LDH stability trial under different conditions was conducted and 
the LDH release test system was validated under bioanalytical aspects. In 
addition, a literatur review about nomenclature and specific properties of LDH 
isotypes was carried out. 
After the clarification of LDH nomenclature in the literature, the research about 
specific features of LDH isotypes was considerably facilitated. Based on the 
studies of Lewis and Uitto [29, 30], LDH-5 is the main isoform in skin, followed 
by LDH-4. From the supplier of the recombinant LDH enzyme used in this study, 
the confirmation was obtained that also in this product, LDH-5 was the 
predominant isoform. This information is on one hand based on literature as the 
enzyme is derived from rabbit muscle, and LDH-5 is generally predominant in 
muscular tissue [28, 29]. On the other hand, an internal assay has also been 
conducted by the supplier but no more information was given due to 
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confidentiality reasons. As the claim of LDH-5 being predominant in muscle 
tissue could be supported during the first part of this study, the obtained 
information was considered as reliable. 
Conflicting recommendations exist regarding stability of total LDH and especially 
isotypes LDH-4 and LDH-5. According to Collins et al. and de la Peña et al. [20, 
22], LDH displays cryo-sensitivity and loses part of its activity after freezing, 
especially if subjected to repeated freeze-thaw cycles [20]. De la Peña identified 4 
°C as preferable storage temperature for salivary LDH [22]. The predominant 
isoforms in saliva are LDH-4 and LDH-5, identical to cutaneous LDH isoforms 
[22, 30, 31]. In another study with salivary LDH [21], LDH was least stable at 4 
°C, with room temperature obtaining a better recovery and the best results with 
storage at −20 °C. Services described activity loss of LDH-4 and LDH-5 with 
storage at 4 °C and −20 °C but reported longer preservation in frozen samples 
compared to refrigerated ones or those stored at room temperature [33]. Shain 
et al. did not find any instability/loss of activity of LDH-4 and LDH-5 after six 
weeks of storage, neither at 4 °C nor frozen at −20 °C [23]. Rohaya et al. 
investigated LDH stability at room temperature, 4 °C and −20 °C in presence of 
three different protectors [25]. The addition of PEG prevented degradation for two 
weeks at all three temperatures with a recovery of ≥98 %, while glycerol seemed 
to be suitable only for frozen samples and ethylenediaminetetraacetic acid 
(EDTA) only for room temperature. Due to those contrasting results, an own 
stability study was conducted. As from Rohaya's study, PEG provided better 
results than glycerol and EDTA [25], PEG was chosen as protective agent as 
described. In this study, a low recovery for samples without PEG at 4 °C and −20 
°C was obtained, with only slight variation between those two conditions, but 
differences between the concentrations. Storage at 4 °C in presence of PEG 
delayed the stability decrease for up to 2 days, being most visible in the high 
concentrated sample and partially supporting the finding of Rohaya et al. [25]. 
This PEG-derived preservation decreased, and from day 6 the recovery dropped 
down to the levels of storage without PEG. Storage of LDH at −20 °C in the 
presence of PEG displayed the highest recovery for the complete four week 
period. The results indicate, that the individual effects of concentration, 
temperature and cryoprotector are negligible while the combination of high 
concentration, low temperature and cryoprotection had a significant and 
106   III. Publications 
synergistic effect on the results. The best stability of LDH is therefore given at 
−20 °C in presence of PEG with a higher concentration while for the other 
conditions a marked instability was observed. These findings are in accordance 
with some researchers [21] but contrasting to others [20, 22, 23]. Some of these 
inconsistencies may stem from variation in sample handling, preparation and 
measurement due to different study protocols or enzyme composition, as already 
discussed by De la Peña [22]. Accordingly, as various recombinant LDH enzymes 
are available which differ in activity and isotype composition, their properties 
regarding stability and preferrable storage temperature may differ as well, 
partially explaining the controversial results. Variation in laboratory procedures 
such as thawing of the enzyme before usage (thawing time, using heat or passive 
thawing at RT), incubation time (strongly depends on enzyme activity, usual 
variation from 5 min to 30 min), measurement wavelenght, amount of 
cryoprotector, and equipment related restrictions may be another contributing 
factor. 
The modified LDH assay used in this study was subjected to a partial validation to 
ensure sufficient accuracy and reproducibility. To be considered as valid, the 
correlation coefficient r2 and deviations had to fulfill the corresponding 
acceptance criteria of the FDA bioanalytic guideline. Hereby, the focus was set on 
establishing a linear range, evaluating if a good correlation could be achieved and 
if the measurement system is suitable for the intended application. If these 
requirements were met, the investigation of further parameters was deemed 
unnecessary for this study. As with six, respectively seven points a full calibration 
curve was achieved, all the deviations for the linearity and SST were below 15 % 
and the r2 was above 0.99 as specified in the guideline, it was concluded that the 
test system is validated for the application on in vitro viable skin models with 
which new insights about dermatological disease processes can be gained. This 
may improve therapeutic possibilities and the wellbeing of humans and animals. 
Compared to several other methods of viability determination, the LDH release 
assay is non-destructive. A skin cultivation study over two weeks with regular 
measurements of the same skin specimen would not be possible with e.g. the 
MTT or WST test, for which the cell layers/tissue generally have to be damaged. 
The LDH release assay is also easy to use, non-expensive and fast. It is 
traditionally designed for cell culture systems and often used without being 
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validated first. With the adaption of the test system to tissue usage and partial 
validation, a higher degree of comparability and standardization is reached, 
providing an advantage over other methods. 
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Abstract 
Transdermal drug delivery provides several advantages over conventional drug 
administration, such as the avoidance of first-pass metabolism and better patient 
compliance. In vitro research can abbreviate and facilitate the pharmaceutical 
development considerably compared to in vivo research as drug screening and 
clinical studies can be reduced. These advantages have led to the development of 
corresponding skin models. Viable in vitro cultured skin models are more useful 
than non-viable ones, due to the influence of skin metabolism on the results. 
While most in vitro studies concentrate on evaluating human-based models, the 
current study is designed for the investigation of both human and animal diseases. 
So far, there is little information available in the literature about viable animal 
skin cultures which are in fact intended for application in the veterinary and not 
the human field. Hence, the current study aims at filling this gap. For this in vitro 
viable cultured skin model, specimens of human, porcine and canine skin were 
cultured over two weeks under serum-free conditions. To evaluate the influence of 
medium supplementation on skin viability, two different supplement mixtures 
were compared with basic medium. The skin specimens were maintained at a 
viability-level >50% until the end of the study. From the tested supplements, the 
addition of bovine pituitary extract and epidermal growth factor increased skin 
viability whereas hydrocortisone and insulin induced a decrease. This in vitro 
viable cultured skin model may be a useful tool for the investigation of skin 
diseases, especially for the veterinary field. 
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1. Introduction 
Transdermal drug delivery (TDD), compared to oral and parenteral drug 
administration, offers several advantages such as a decreased risk for toxicity and 
adverse effects, avoidance of first-pass metabolism and better patient compliance 
[2, 94]. In order to facilitate and abbreviate the pharmaceutical development 
process, an increasing trend to the transfer from in vivo to in vitro research  has 
been observed during the last few decades [105, 106]. Simultaneously, the social 
acceptance for animal testing has remarkably decreased [10, 11, 107], resulting in 
corresponding changes in legislation. Examples include the 3R-principle  in 1959, 
the European Centre for the Validation of Alternative Methods (ECVAM) 
established in 1991, the “Declaration of Bologna” in 1999 and the enactment of 
Registration, Evaluation and Authorization of Chemicals (REACH) in 2007 [12]. 
Consequently, in vitro research is being promoted as future standard, requiring the 
establishment of suitable models. The evaluation of percutaneous absorption (skin 
permeation) is essential in the design and development of various drug 
formulations. Only if a drug is able to overcome the outermost layer of the skin, 
the stratum corneum (SC), which constitutes the major part of skin barrier, can the 
drug be considered as a promising candidate for TDD. Whereas the SC poses a 
stronger barrier for hydrophilic substances, the permeation of lipophilic 
substances is limited by viable epidermis and dermis [108, 109]. However, the 
assessment of permeation is just one aspect of TDD and mainly useful for 
substance screening and defining rank orders to categorize drugs in different 
permeability classes. For the investigation of complex issues such as skin 
inflammation and disease, a more comprehensive approach has to be chosen. With 
chronic inflammatory and infectious skin diseases being a continuous problem [5-
7] and decreasing efficacy of antibiotic treatment due to bacterial resistances [8, 9, 
110, 111], new therapeutic options are imperative. The popular view of the SC as 
the only factor influencing skin absorption is not tenable anymore due to the 
detection of considerable metabolic  capabilities of living skin [104, 112, 113]. 
Hence, viable skin is preferable for studying complex skin conditions [14]. One 
factor among others, affecting transdermal drug delivery, is skin resistance. A 
higher level of skin resistance is associated with skin integrity and an intact 
barrier [114], influencing methods such as iontophoresis [115]. This method 
employs a non-invasive electric current at low voltages for the delivery of 
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ionisable drugs into the skin [116]  
Further skin properties need to be considered for TDD. Skin thickness varies 
considerably between different body regions [15, 56, 60, 117]. Human skin, e.g., 
is especially thin at the eyelids or directly behind the ears while on palms and 
soles it is very thick [56, 60]. Intensity of blood flow (in vivo or perfused models) 
to different skin locations proved to be an important parameter as well as 
functional properties, i.e. resistance toward stress or strain and the amount of 
elastic fibers [60, 118-120]. General metabolic activity of the skin and amounts of 
metabolic enzymes are also variable but tend to increase along with blood supply 
[121]. Fluctuations of the density of hair follicles between body regions  but even 
more between different species (e.g. human vs. sheep) have to be taken into 
account as well as variations in lipid content and composition [15, 64]. All the 
aforementioned skin properties are also subject to considerable variation between 
human individuals depending on sex, body weight, age and ethnicity with 
variations up to 66 % [15, 117]. For this study, viable skin was chosen due to 
better predictability of in vivo conditions [117] and potential  metabolic activity 
although no exact determination of the metabolic capacities was intended. If the 
skin has to be maintained viable over a prolonged time, the usage of an 
appropriate viability marker is crucial.  
However, most of them are designed for cell culture and not for tissue, such as the 
standard assays MTT (3-(4,5-dimethylthiazol-2(yl)-2,5-diphenyltetrazolium 
bromide) and WST (water soluble tetrazolium salts). Furthermore, they are 
destructive to the tissue and often very time-consuming. [122, 123] The finally 
selected LDH (lactate dehydrogenase) release assay, however, is shorter, easy to 
use and non-destructive. Therefore it can be used for repeated measurements with 
the same skin specimen which is crucial for this study [124]. As this assay is also 
in principle designed for cell culture, a modified version, adapted to tissue [125] 
and validated according FDA (Food and Drug Administration, USA) guidelines 
[126], was used in the current study.  
In most, if not all studies involving in vitro skin models, the focus has been on 
human research, with animal skin models as mere approximations of the 
properties of human skin, e.g. such as the pig ear model [14-16]. Therefore, 
although human skin was employed as well, this study aims to benefit the 
veterinary field by adding valuable information about in vitro cultured skin 
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models with viable animal skin which can scarcely be found in the literature 
[127].  
Hence, a long-term cultured in vitro viable skin model from human, porcine and 
canine skin was established under simplest and serum-free conditions. Here, the 
aim was not human research but to fill the empty space in the literature regarding 
ex vivo cultured animal skin models and bridge the gap between human centered 
and animal centered research and medicine. Due to availability restrictions, the 
planned number of species for this study (including feline, equine and bovine 
skin) was not achieved. Therefore, porcine skin was not only selected for 
comparison to human skin, but also to represent the group of livestock animals. 
Canine skin represented the group of companion animals but was also chosen 
because of a known predisposition of dogs for skin diseases [5]. Several criteria 
for selection of the particular skin donors applied (same sex and age group, 
normal body weight). Only full-thickness trunk skin was considered. The selected 
body regions were determined by the human skin donor since only abdominal skin 
was available. Abdominal skin, however, was avoided for the canine donor due to 
mammary complexes and scar tissue following mastectomy. Back skin was also 
avoided due to pigmentation and higher amount of hair follicles. Therefore, skin 
from the flank/lateral abdominal region was taken. Back skin was chosen for the 
porcine skin specimen based on the results of Khiao et al. [128] who compared 
histological and functional properties of porcine skin from different anatomical 
regions with human abdominal skin. According to these results, both back and 
flank skin are most similar to human abdominal skin. However, due to skin 
injuries in the flank region of the pig, back skin was deemed as better option in 
this case.  
The absence of nutrients provided by serum had to be compensated by adding 
other supplements to achieve better viability results. Therefore, the influence of 
supplementation with insulin, hydrocortisone, human epidermal growth factor 
(hEGF) and bovine pituitary extract (BPE) was evaluated. These four supplements 
were selected as they are known to have beneficial effects on skin and skin cells 
[129-133] which is why they are included in media for keratinocyte growth and 
proliferation (e.g Keratinocyte growth medium 2 from Promocell). The selection 
of these supplements was hence based on findings in the literature where their 
effects were described separately and in combination [132, 134]. Based on the 
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literature findings and due to practical reasons, insulin and hydrocortisone were 
evaluated as one supplement mixture and EGF plus BPE as another. 
 
4. Materials & Methods 
4.1. Skin preparation and cultivation 
Human abdominal human skin (53 y/o, female, Caucasian) was obtained after 
informed consent of the patient according to the Declaration of Helsinki from 
esthetic surgery (Cabinet Dr. Pierre Sibille, Luxembourg, Luxemburg), porcine 
back skin (ca. 6 months old, female, Deutsche Landrasse) from a slaughterhouse 
(Schwamm und Cie, Saarbrücken) and canine flank/lateral abdominal skin (11 
y/o, female, middle-sized mongrel) from a local veterinary practitioner (Dr. 
Norbert Paulus, Saarbrücken) after the dog's euthanasia with informed owner 
consent. All skin specimens were freshly excised and stored/transported for less 
than 2 hours at 4°C and high humidity to maintain their viability as high as 
possible. The subcutaneous fat was carefully removed with a scalpel, the tissue 
surface was rinsed with water and then gently dried. From each of the three skin 
specimens, nine full skin punches of 13 mm diameter were taken and weighed. 
They were cleaned under sterile conditions (sterile bench laminar airflow, Heto-
Holten GmbH, Wettenberg, Germany) with a mixture of phosphate buffered 
saline (PBS) solution (Merck Millipore, Darmstadt, Germany) and 70% ethanol 
(Waldeck GmbH & Co KG, Münster, Germany) and placed dermal side down in 
12-well plates (Costar 3513 12-well plates from Corning Life Sciences, 
Kaiserslautern, Germany). From the nine punches per species, three skin punches 
were placed together in one plate. Three plates per species were cultivated using 
three different media, so that in total 27 skin punches have been cultivated as 
shown in figure 1. 
One plate from each species was filled up to 0.7 mL per well with Dulbecco’s 
modified Eagle’s medium solution (Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany), containing 3.7 g/L sodium bicarbonate (Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany) and glucose (VWR International GmbH, Darmstadt, 
Germany). 75.5 mg/L gentamycin sulfate (Merck Millipore, Darmstadt, Germany) 
were added from a stock solution of 15 g/L gentamycin sulfateThis solution is 
further referred to as basic medium. Another plate was filled up with the same 
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DMEM solution, but with an added supplementation of insulin and 
hydrocortisone, each 2 mL/L of DMEM (KGM single quots, Lonza, Walkersville, 
USA), further referred to as supplement mixture 1. The third plate was filled up 
with DMEM solution and supplementation of bovine pituitary extract (BPE) 8 
mL/L and human epidermal growth factor (hEGF) (KGM single quots, Lonza, 
Walkersville, USA), 2 mL/L of DMEM, further referred to as supplement mixture 
2 (see figure 1). 
 
Graphical illustration of the sample distribution for cultivation 
 
Figure 1: From the human skin specimen, 9 skin punches were made. These 9 punches were 
then distributed into three 12-well plates, three punches per plate. Each of the three plates was 
filled up with either basic medium, supplement mixture 1 or supplement mixture 2. The 
porcine and canine skin explants were treated accordingly. 
The supplements were originally designed for keratinocyte growth medium. For 
the cultured skin model, a higher need of nutrients for full skin compared to cell 
monolayers was assumed, hence the recommended concentrations for cell culture 
were doubled, based on some ranges given in the literature [132, 134]. These 
concentrations may be optimized for receiving best results in future experiments 
but serve as working standard in this study. The exact concentration of the 
supplements themselves could not be determined as no further information was 
provided by the supplier (KGM single quots: CC-4002E BPE, CC-4015E hEGF, 
CC-4021E insulin, CC-4031E hydrocortisone). 
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The SC (stratum corneum) of every skin punch remained uncovered with medium 
at the air-liquid interface. The skin explants were then cultivated over 14 days 
with daily sampling and medium change in a sterile incubator (Heracell Incubator, 
Heraeus, Hanau, Germany) at 37°C in 5 % CO2/air to keep the pH of the medium 
at 7.4 [135] which is not only important for the cultured skin but also for the 
enzymatic reaction employed for measurement [136]. Photographs of the plates 
were taken every other day to monitor the medium levels and changes in the 
skin’s appearance (see figure 2). 
105 µL polyethylene glycol (PEG) 400 were added to the daily collected samples 
from medium supernatant containing LDH before storage at -20 °C for up to 4 
weeks until measurement. These conditions were chosen according to the results 
of a previous stability study [126]. 
 
4.2. Controls 
In order to quantify the highest possible LDH release from the skin of each 
species, a positive control was established for which a piece of skin was weighed, 
added to a defined amount of DMEM and mechanically destroyed with an 
immersion blender. After skin destruction, the suspension was filtered through a 
nylon net, the filtrate was centrifuged and the supernatant was aliquoted and 
stored at -20 °C for measurement. Measurement result of every positive control 
sample was considered as 100 % of the total LDH amount of this skin specimen. 
A negative control was obtained by heating one aliquot of positive control to 65 
°C for 30 minutes [136] to denaturize all the contained LDH. The negative 
controls serve as blank sample for positive controls, i.e. the measured absorption 
of the negative control was subtracted from the absorption of positive controls to 
remove the influence of turbidity of the medium due to skin matrix. From the 
absorbance values of the positive control, the LDH activity per gram skin relative 
to those of the control was determined in order to calculate the viability of the 
skin in percent. 50% were set as limit, lower values were considered as indicators 
of a non-viable skin specimen. 
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4.3. Measurement by plate reader 
Photometric measurement of the obtained medium samples for the quantification 
of LDH release into the medium was conducted with a plate reader (microplate 
reader Wallac 1420 Victor 2) using an absorbance wavelength of 450 nm (see 
figure 2). The generally cell-based LDH release assay was modified and validated 
for its usage on tissue beforehand [126]. 
For measurement, the samples were thawed at room temperature, shaken, diluted 
with DMEM into the linear range of the LDH calibration curve and pipetted with 
piston-stroke pipettes (Eppendorf GmbH, Wesseling, Germany) into a generic 96-
well plate (here Nunclon Delta Surface, Thermo Fisher Scientific, Karlsruhe, 
Germany). Tubes from Eppendorf and Corning (Corning Life Sciences, 
Kaiserslautern, Germany) were used for sampling and measurement preparation. 
All the cultivation samples were measured in duplicate, except the control 
samples which were measured in triplicate. Reported values are mean values if 
not specified otherwise. 
All calculations were performed using Microsoft Excel 2010.  
 
4.4. Data analysis 
Statistical evaluation was conducted using statistics software OriginPro 9.0 
(Additive GmbH, Friedrichsdorf, Germany). Non-parametric analysis such as 
Kruskal-Wallis ANOVA (KWA), NPH k independent samples test (NPH) 
combining Kruskal-Wallis ANOVA and Mood’s Median Test (MM) has been 
employed. A p-value of < 0.05 was considered significant. The exact p-value and 
degrees of freedom (DF) are reported.  
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Illustration of skin cultivation samples and LDH measurement 
 
Figure 2: (A) porcine skin punch on cultivation day 7, well 4. (B) human skin punch on 
cultivation day 7, well 4. (C) canine skin punch on cultivation day 7, well 4. 
 
(D) Exemplary LDH measurement to demonstrate the difference in LDH content between two 
timepoints (T 2 and 3) which is shown in the slight color change from T2 (upper nine wells) 
to T3 (lower nine wells).(E) Exemplary LDH measurement displaying high amounts of LDH 
(dark red). (F) Exemplary LDH measurement displaying low amounts of LDH (light 
red/pink). 
The LDH measurements in panels D-F do not correlate with the skin punches in panels A-C. 
 
5. Results 
The LDH content of the positive control samples showed considerable variation 
between species. The human control reached 163.1 U/g skin, porcine control 
124.8 U/g skin and canine control 57.3 U/g skin. The total LDH release over the 
whole cultivation time reflected the differences seen in control samples. With 
76.19 ± 0.03 U/g skin, LDH release of human skin was the highest in comparison 
to the other species (Fig. 3) with significant differences between the three species 
(NPH: KWA p=0.02732 DF 2, MM p=0.04285 DF 2). Relative to the positive 
control, however, human skin was with 46.72% release in the middle, slightly 
lower than porcine skin. The total release of porcine skin was 60.66 ± 0.09 U/g 
skin while the relative release was the highest one with 48.60%. Canine skin 
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displayed a total release of 19.17 ± 0.3 U/g skin, considerably lower than the other 
ones. Also the relative release of canine skin was 33.47%, and thus lower than 
human and porcine samples with significant differences between the three species 
(NPH: KWA p=0.00179 DF 2, MM p=0.02732 DF 2). 
Comparison of the total released LDH of each species at the end of the study with 
the relative LDH release as percentage of the positive control of each species 
 
Figure 3: (A) Total amount of LDH released by all the human, porcine and canine skin 
samples in catalytic units per gram skin until end of cultivation (day 14). The columns are 
calculated from the cumulated sum (e.g. sum of LDH release of all human samples at 
timepoint d0+d1+d2+...d14; same for porcine and canine samples) of all the means from each 
species, respectively. (B) Amount of LDH released by all the human, porcine and canine skin 
samples as percentage of the corresponding positive control. Same principle for calculation 
applies as for panel A. 
 
In the viability trend (Fig. 4 and Fig.5), the mean percentage of viability of the 
three investigated species already ranged from 83.26% (canine) over 73.76% 
(human) to 67.46% (porcine) on the first measurement time point, displaying an 
order that was maintained until day 7 (67,70% canine, 54.18% human, 52,13% 
porcine) and throughout the whole cultivation time. The curves of the different 
cultivation media for one species were similar in the case of porcine and canine 
skin (Fig.5 B and C) but not for human skin where the three curves exhibited a 
different behavior and intersected on the second day of cultivation (Fig.5 A). A 
rather rapid drop in viability occurred during the first two to three cultivation 
days, followed by a gradual decrease afterwards. This decrease happened until day 
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1 in porcine skin (mean), until day 2 for canine skin and until day 3 for human 
skin with a slope being slighter in the latter than the other ones (Fig. 5). The 
difference in viability between the three species at the beginning of the cultivation 
was not significant (NPH: KWA p=0.36788 DF 2, MM p=0.22313 DF 2) while 
the difference after seven cultivation days was significant (NPH: KWA 
p=0.01832 DF 2, MM p=0.01111 DF 2). The statistical species difference in 
viability for day 14 is reported with figure 6.  
In the course of the first cultivation week (roughly until day 5 to 7) a marked 
decrease in viability was visible for each curve while afterwards either a plateau 
was reached (Fig. 4 B) or a slight further decrease could be observed (Fig.4 A and 
C). The effect of the respective cultivation medium can be seen in figure 4, where 
for all three species, supplement mixture 1 obtained the lowest (Panel B) and 
supplement mixture 2 the highest viability results (Panel C) are shown. 
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Viability trend of the skin samples in percent over 14 days of cultivation, 
comparing cultivation media 
 
Figure 4: Viability trend (measurement timepoints connected via trend-lines) in percent 
relative to the corresponding positive control for the three investigated species: human 
(yellow), pig (blue) and dog (red) in order to compare differences between cultivation media. 
All the data points are mean values from three skin punches cultivated in the same condition, 
measured n=2.(A) basic medium (B) medium with added supplement mixture 1, (C) medium 
with added supplement mixture 2. 
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Viability trend of the skin samples in percent over 14 days of cultivation, 
comparing species 
Figure 5: Viability trend (measurement timepoints connected via trend-lines) in percent 
relative to the corresponding positive control for the three investigated cultivation conditions: 
basic medium, supplement mixture 1 and supplement mixture 2 in order to compare 
differences between species. All the data points are mean values from three skin punches 
cultivated in the same condition, measured n=2. 
(A) human skin, (B) porcine skin, (C) canine skin 
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Comparison of the viability of the skin samples at the end of the study 
 
Figure 6: Remaining viability of the skin samples at the end of the study (day 14). Differences 
in viability levels between the three species: human (yellow), pig (blue) and dog (red) and 
between the three cultivation media: basic medium (plain), medium with supplement mixture 
1 (dotted) and supplement mixture 2 (striped) are compared. The values are given as mean of 
each cultivation condition (e.g. human skin in basic medium). 
 
The viability of each plate on the last day of cultivation is shown in fig. 6. Human 
skin in basic medium reached a viability of 52.16 ± 0.10 %. In supplemented 
medium it obtained a viability of 51.90 ± 0.20 % (suppl.1 = 
insulin+hydrocortisone) and 55.77 ± 0.10 % (suppl.2 = BPE+hEGF), respectively. 
Porcine skin viability ranged from 51.06 ± 0.21 % (basic medium) over 47.98 ± 
0.15 % (suppl.1) to 55.17 ± 0.12 % (suppl.2). Canine skin viability extended from 
65.43 ± 0.09 % (basic) over 64.93 ± 0.30 % (suppl.1) to 67.83 ± 0.22 %. The 
differences were significant between canine skin and human skin (KWA 
p=0.04953 DF1) and between canine and porcine skin (KWA p=0.04953 DF1), 
but not between human and porcine skin (KWA p=0.05091 DF2). The difference 
between all three conditions was again significant (MM p=0.04285 DF2). The 
absolute difference between the cultivation condition with the highest and the 
lowest viability were 2.9 % for canine, 3.78 % for human and 7.19 % for porcine 
skin. By referring to the corresponding highest value as 100 %, hence calculating 
the relative variance describing the ratio of the observed difference compared to 
the absolute values, canine skin showed 4.28 % difference, human skin 6.78 % 
and porcine skin 13.03 %. The variation within porcine skin was therefore about 
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double compared to human skin and four times higher than within canine skin.  
The effects of medium supplements on viability were significant comparing 
suppl.1 with suppl.2 (MM p=0.0455 1DF) and basic medium with suppl.2 for all 
three species (MM p=0.0455 1DF). Comparison of basic medium with suppl.1 
resulted in a significant difference only for porcine skin but not for the other two 
species (MM p=0.0455 DF1). However, these findings might have been more 
significant if a larger sample size was available. 
 
6. Discussion 
In this study, a viable in vitro model of cultured human, porcine and canine skin 
was established and cultivated for two weeks with regular viability measurements 
using a modified LDH release assay [125]. The total LDH content of each skin 
specimen and the influence of two different medium supplements on the skin 
integrity and viability were investigated. 
By now, a large variety of skin models from human skin has been established, 
closely followed by different porcine models while for canine skin very scarce 
information can be found in the literature, emphasizing the importance of this 
research. One of the most common porcine cultured skin models is the pig ear 
skin model. The skin of a pig’s ear is comparable to human skin in terms of skin 
thickness, lipids, hair follicle density and permeability [15]. Percutaneous 
absorption and skin metabolism of pig ear skin was evaluated by Jacques at 
al.[137] While the sample processing and cultivation conditions were similar to 
the current study, the skin was sectioned to a defined thickness with a dermatome 
(vs usage of full skin) and only a short-term culture of 48h was performed (vs. 14 
days). Further examples include Scoglamiglio et al. [96] and Gomes et al.[97] 
who used pig ear skin for the evaluation of deformable liposomes and ethosomes 
or nanostructured lipid carriers, respectively. Porcine abdominal skin 
(dermatomed) was employed by Nagelreiter et al. [138]. One example of a dog 
skin model is described by Serra et al.[127] who developed a canine skin 
equivalent with isolated keratinocytes and fibroblasts which differentiated into a 
multilayer epidermis starting from day 15. A cultivation method with canine skin 
was reported by Abramo et al. [139] who used full-thickness adult canine skin in 
serum-free medium. These conditions are similar to the ones employed in the 
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current study, however, the skin was only maintained until day 7 and 4 mm skin 
biopsies have been collected in contrast to skin culture over 14 days and 13 mm 
punches in this study. 
Skin specimens from the three species were cultured for two weeks. The skin 
could be maintained at minimum 50 % viability for the whole 14 days of 
cultivation which is a better result compared to other studies with a similar 
approach, such as described by Suarato et al, De Wever et al.and Castagnoli et 
al.[140-142]. De Wever investigated the NativeSkin® model where human skin 
biopsies from plastic surgery were placed in a solid nourishing matrix and were 
maintained viable for 7 days, using MTT assay and histologic characterization as 
viability markers. Castagnoli used human post-mortem allograft skin biopsies. 
Their viability was also assessed with the MTT assay. A viability level of the 
fresh skin of around 75 % was reported after 12-30h following harvesting which 
decreased to 40 % after 60h. After 6 days of cultivation, the viability further 
decreased to 0% which held also true for cryopreserved samples using 10 % 
DMSO. Storage at 4°C extended viability but did not prevent its decrease to 25 % 
after 15 days. Suarato, however, used explanted mouse skin in a 3D printed 
diffusion cell which could be maintained viable for maximum 24h, assessed again 
with the MTT assay.  
Due to the different cultivation conditions (e.g. sample size, number of samples, 
cultivation medium) and the necessity for repeated measurements to assess the 
skin viability, the LDH assay was deemed a suitable alternative. The viability 
profile of the three cultivation conditions for each species showed a notable 
difference in viability starting from the first measurement which, however did not 
prove to be statistically significant. A sharp decrease in viability from the start 
until the first (pig), second (dog) and third (human) cultivation day is typical for 
this kind of tissue culture, also the following plateau or relatively flat interim 
period. A second decrease phase is reported in the literature [143, 144] but was 
not observed here.  
The evaluation of the LDH content of human, porcine and canine skin based on 
the positive control samples revealed a rank order of LDH content as follows: 
human > porcine > canine skin. The total LDH release over the complete 
cultivation time reflected this. The relative LDH release of each skin specimen in 
relation to the positive control, however, was in the order porcine > human > 
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canine skin.  This, combined with the rather low initial viability, might be a 
contributing factor to porcine skin yielding the lowest viability results at the end 
of cultivation. The low initial viability values could be due to the longer transport 
of the pig cadaver from the slaughterhouse to the place of processing, which was 
in another city. However, the differences in the initial viability levels were not 
significant and the viability of human skin after 14 days only slightly exceeded 
that of porcine skin, so that a major influence seems improbable. Over the whole 
study, the canine skin specimen maintained the highest viability.  
Still, these results do not claim to prove a generally higher viability of canine skin 
which is not possible due to a notable amount of factors influencing skin 
properties as mentioned in the introduction. Although with human abdominal, 
canine flank skin and porcine back skin three physically adjacent regions (with 
assumed functional similarities) have been selected and the influence of sex, age 
and weight has been considered, variations in viability due to different anatomical 
and functional properties (e.g. skin thickness, lipid content and composition, 
absorption of nutrients etc.) could not be excluded. This may be especially the 
case considering canine skin, as morphological and functional analysis of porcine 
back skin showed great similarities to human abdominal skin [128]. However, 
there is little reliable information available about these properties in other animal 
skin and how and to which extent they may have affected the outcome of this 
study or about their influence on TDD in general. Therefore, a new concept such 
as employed in this study has to be based on a certain amount of assumptions and 
speculations which will have to be verified or falsified in the future. 
It should also be taken into account that different skin models with rodent skin 
(e.g. rat, mouse, guinea pig and several hairless breeds of those) have been widely 
used as surrogates for human skin despite substantial differences in size, skin 
thickness, lipid composition, metabolism and skin barrier function [14, 15, 145]. 
In view of this, the current selection of species and body regions of the explants 
may be justified for the scope of such a pilot study. 
The two supplement mixtures consisting of insulin plus hydrocortisone (suppl. 1) 
and BPE plus hEGF (suppl. 2) were selected according to Lasnitzky [146]. For all 
the samples, the medium supplement mixture 2 was the most effective in 
promoting health and viability of the skin specimens. This could be supported by 
a statistically significant difference between basic medium and supplement 
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mixture 1 compared to supplement mixture 2. This effect was significant in every 
species which makes usage and optimization of supplement mixture 2 the most 
promising approach for further studies. Among the cultivated samples, the porcine 
skin samples cultured with supplement mixture 1 failed as only ones to maintain a 
viability > 50 % until the end of the study and had therefore been deemed as non-
viable. While for all the species, supplement mixture 1 had a certain negative 
effect on the viability even compared to basic medium, for porcine skin which 
generally expressed the highest relative variation between the three culture 
conditions, this effect was more pronounced and statistically significant. 
Therefore, supplement mixture 1 seems less suitable for further experiments. All 
the other skin samples (except porcine + supplement mixture 1) could be kept at a 
viability level of over 50 % until the end of the study.  
In this study, no serum was used; hence some of the nutrients for the skin cells 
were introduced via these medium supplements. The positive effect of the 
supplement mixture 2 will have to be assessed in detail but may be due to the 
mitogen, proliferative and lifespan-extending effects of EGF and BPE on different 
cell types such as keratinocytes, which are described in the literature [130, 147-
150]. The negative effect of the supplement mixture 1 is most likely induced by 
hydrocortisone, as this component is known to possibly having both positive and 
negative effects which are strongly dose-dependent [151]. The higher influence of 
supplement mixture 1 on porcine skin may therefore be explained by high levels 
of stress-induced corticoids in the body of the corresponding pig at the time of 
slaughter [152]. Together with the supplement, the resulting amount of 
hydrocortisone may have been high enough to induce a viability decrease. 
However, choosing a lower concentration of hydrocortisone might be an option to 
be considered.  
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7. Conclusions 
This in vitro viable cultured skin model is a first step towards the investigation of 
canine and porcine skin diseases. In its current shape, it may be employed for 
topical application studies, percutaneous absorption and, due to its viability, basic 
cutaneous research, e.g. keratinocyte reactions to irritation. Upon further 
optimization, it may be used for assessment of skin metabolism which can be 
essential when applying xenobiotics (e.g. drugs) to the skin [137]. New cosmetic 
products or nanoformulations may be tested based on this model as well [153]. 
For these purposes, the skin viability and its structural integrity are crucial. 
Therefore, skin cultivated with the supplement mixture 2 is the most suitable 
candidate between the three tested conditions for further research. An increase of 
the current viability levels is planned for the future. Compared to the first step of 
this research [125], the life span of the skin has already been almost doubled. 
Different concentrations of the supplements, other cultivation media and 
supplements may be tested for further viability improvement.  
The development of a complex disease model may later be based on the current in 
vitro cultivated skin model, being especially relevant for canine skin as only 
relatively few models exist. [127]. Introduction of skin from other species may 
considerably expand its scope. Skin properties and permeability may be evaluated 
and categorized with the aim to create a comparable data set and standards similar 
to those in human medicine. 
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IV. DISCUSSION 
A viable in vitro cultivated skin model was established, first with human skin, and 
then expanded to porcine and canine skin. In order to assess the viability of the 
skin, a commercial LDH release assay was adapted from employment in cell 
culture systems to tissue usage. This adapted LDH assay was then validated 
according to basic criteria of the FDA bioanalytics guideline (version of 2002 
with respect to modifications in the draft version from 2013). Instability of the 
LDH enzyme used for the validation and the skin samples during the first 
measurements led to a stability study to determine the best storage conditions of 
LDH enzyme. In this stability study, usage of PEG as cryoprotector had a 
significant influence on the stability, consequently the validation was repeated 
with LDH in a medium containing PEG. The mixed species skin model was 
intended for the comparison of the viability and LDH release profile of the 
different species and to evaluate the influence of two media supplement mixtures 
on the skin viability.  
It was important, to select viable skin for the skin model to be able to assess more 
than just the permeation and passive barrier properties of the skin, and to expand 
the application of the model for research which relies also on information about 
the metabolic capacities of living skin [103]. Culture conditions aimed to imitate 
natural conditions as close as possible to ensure “well being” of the skin. The 
LDH release profile of the human skin model was similar to comparable studies 
with human skin [143, 154]. A first peak could be linked to direct necrosis, mostly 
resulting from excision and handling [144] and a second peak marked the time 
point of maximum apoptosis rate. By maintaining the skin specimens viable for 
eight days, a middle range was achieved between shorter and longer cultivation 
times described by other authors [143, 154]. Due to the simpler cultivation 
conditions and experimental setup of the current study, these results are 
sufficiently reliable and acceptable as foundation for further studies. Simple 
conditions keep costs and complications as low as possible. This way, other 
laboratories can reproduce the work without the need for expensive compounds 
and devices or specifically trained personnel. Furthermore, the likelihood of 
human error is decreased. As bovine serum is a non-standardized natural 
compound with varying composition, its effects on skin behavior and viability 
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cannot be exactly determined [155, 156]. Thus, the cultivation was conducted 
without this specific compound. In most serum-free cultures, serum or some of its 
protective and proliferative effects are replaced by various medium supplements. 
This study focused on high standardization and separate evaluation of each 
compound, to see if cultivation of viable skin is feasible under those conditions at 
all and for how long. The validation of the adapted LDH release assay according 
to FDA criteria was another way to standardize the study and increase 
reproducibility, features which are lacking in many other studies [14, 15].  
The same also holds true for the different and conflicting stability results for the 
LDH enzyme in the relevant literature. The respective LDH subtype or 
composition has to be considered, with different properties regarding stability, 
temperature and activity  [136, 157, 158]. In addition, the medium in which the 
LDH is measured has to be considered as well [136]. Plasma provides other 
features than saliva or cultivation medium supernatant. The specific activity of the 
enzyme has to be determined at any time, due to large batch to batch variations 
[124, 136]. Correspondingly, the incubation time of the samples has to be adapted 
to the catalytic activity of the enzyme as the reaction continues as long as 
substrate is available [136]. This may lead to significantly different results even 
under the same conditions. Thawing of frozen enzyme should be done gently over 
time at room temperature or with any heating system. However, heating up the 
enzyme too much results in loss of activity due to denaturation. In contrast, with 
insufficient warming the preferred temperature range of the enzyme is not reached 
and the reaction is slowed down. Either leads to incorrect and unreliable results 
[136]. These examples are some of the reasons, why a general statement about 
any results is difficult when the exact experimental conditions are not apparent in 
the publications, especially regarding enzyme assays [136]. This is why in our 
studies each step was described as detailed as possible in order to provide the 
information required for optimal reproducibility and standardization [102].  
For the expanded skin model, a variety of animal species were possible as skin 
source. Human skin was used for the investigation of human skin diseases but also 
to compare the results of this study with others to ensure accuracy. Porcine skin 
was also chosen for comparison reasons, because it is most similar to human skin 
[15], and as a representative for skin diseases in livestock. Canine skin was 
chosen, as dogs are common pets which are reported to show a general disposition 
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for skin diseases [5].  
The results of the studies about both skin models leave some questions open. 
While the human skin model could be maintained viable over eight days, the 
mixed model could be kept viable over two weeks even without supplementation. 
This might be due to a change in the protocol. For the first human-only model, the 
cultivation medium was changed every day except weekends. So for two 
consecutive days the medium was not changed. In the second model a change of 
medium occurred every day. While for cell cultures this is rather usual, it could be 
that due to the higher density of cells more nutritients are used and fresh medium 
is required every day. In addition, LDH-containing samples were initially stored 
under non-ideal conditions and thus instable, as found out during the stability 
study [157]. However, instability of LDH would lead to decreased enzyme 
activity and hence higher calculated viability values (due to the inverse correlation 
of viability and amount of released LDH) [144], so this is unlikely. Therefore, 
these variations seem to be most likely due to the different medium change 
schedule and constitute the only part of the study which is not comparable 
regarding intra- and interstudy comparability. 
In the mixed skin model, canine skin exhibited by far the highest viability over the 
whole cultivation time. There may be several possible reasons for this. Thickness 
of full skin, epidermis and SC is very variable between species, breeds,  
individuals and body regions [65]. Although some of the potential influencing 
factors such as sex, age and weight were taken into account, other factors such as 
skin thickness or lipid content and composition could not be completely excluded. 
Flank skin of dogs is relatively thin [159]. In addition, this was densely haired 
skin (although a region with rather low amount of hair follicles was selected) and 
thus the skin is thinner than that of more sparsely haired porcine (back) and 
human (abdominal) skin. Thinner skin means less cells and therefore a better 
transport of nutritients through the tissue which also uses less of them, so that the 
skin does not suffer between medium change time points. This would correspond 
to the possible explanation, why the first skin model worked badly with medium 
unchanged over the weekend. This assumption is further supported by the lowest 
viability of porcine skin which was the thickest of the three. Another skin-related 
characteristic influencing viability may be its lipid content and composition. 
Porcine skin was visibly the fattiest skin while canine skin seemed to be least 
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fatty. Reportedly, canine skin lacks epithelial lipid plugs, contributing to the 
relatively weak skin barrier of dogs [5]. Another factor to consider is the skin 
surface pH  which is usually rather alcalic for canine skin with values from 5.5 to 
8.8 [159] and more acidic in the case of human (4.5-6.0) and  porcine skin 
(slightly more basic than human, around 6.0 to 7.0) [160]. Whether the higher pH 
of canine skin may provide protective properties could not be clarified.  
One further point to consider is the time between surgery/slaughter/euthanasia and 
arrival of the skin in the laboratory. Human skin was cooled down immediately 
after surgery and the excised skin was transported in cool boxes for approximately 
two hours. This procedure was highly standardized. Canine skin was collected 
directly after euthanasia, cooled and wrapped in a damp cloth and transported in a 
cool box for approximately one hour. This was also highly standardized. Porcine 
skin, however was obtained from a local slaughterhouse in another city. There is 
no information available as to when exactly this respective pig was slaughtered 
(early morning hours) nor when the skin was excised. The excised skin was 
subsequently transported  to a local company (around 30 min), from where it was 
collected and transported in a cool box to the laboratory (another 30 min) to arrive 
at 8 am. This leaves a longer time span of around four hours, if it is assumed that 
the pig was sloughtered at 4 am. The procedure and conditions were not 
completely standardised. Therefore it is possible, that the viability of porcine skin 
is underestimated in this study. With the current results, the respective viability of 
each skin corresponds to its transportation time and conditions. 
Regarding the negative effect of the cultivation medium supplement mixture 1, 
several causes are possible. For insulin, no information about adverse effects on 
skin cultivation could be found. For hydrocortisone, however, there is evidence 
for a negative correlation to skin viability. It delayed wound healing in one study 
with mice [151] for about one week, showing antiregenerative effects. This is 
supported by other studies, where hydrocortisone in the cultivation medium  
reduced cell proliferation of especially keratinocytes, decreased skin thickness and 
downregulated the metabolism of collagen tissue [161]. These effects were only 
observed if the concentration of hydrocortisone exceeded the physiological values 
toward a therapeutically active concentration. Although the supplement 
concentrations in this study are all based on recommendations from relevant 
literature, the bad performance of supplement mixture 1 may be a due to high 
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hydrocortisone concentrations. This effect may be especially pronounced for 
porcine skin, as a high amount of stress-induced corticoids were circulating in the 
body already at the time of slaughter [152], remaining in the skin. Together with 
the supplement, a relatively high dose may have been reached and the originally 
beneficial effect may have turned into an adverse one. EGF and BPE were 
described to have only positive effects which could be further supported by 
obtaining the best viability results with this medium in this study [150]. 
With the establishment of this mixed species viable skin model, an essential step 
towards a higher degree of standardization and comparability was taken. This 
model can be employed for generic skin absorption studies both with viable and 
non-viable skin, but may find its main purpose in cutaneous basic research. The 
development of a disease model may later be based on this model. Furthermore, 
the insights and knowledge gained may be used in the development of cosmetic 
products as well. 
The model in its current shape is already a handy and useful instrument for 
pharmaceutical drug development. It is also intended to be employed for the 
development and optimization of various nanoformulations for the treatment of 
inflammatory skin diseases, exceeding the scope of this thesis.  
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V. SUMMARY 
Compared to other drug delivery systems, transdermal drug delivery has several 
advantages such as avoiding first-pass effect, lower risk of toxicity and higher 
patient compliance. While pharmaceutical drug development in vivo is 
complicated and  expensive, in vitro it may be considerably facilitated, and, from 
an ethical point of view, it minimizes animal experimentation. Although for in 
vitro drug development various models exist, validated and standardized model 
systems are lacking, particularly in veterinary drug development. Due to the high 
prevalence of skin diseases in humans and animals, this dissertation focuses on 
the development and validation of an in vitro viable human and animal skin model 
as basis for dermatological drug development. During the first experimental 
phase, a human viable skin model was developed with the LDH release assay as 
selected viability marker. This assay was adapted to tissue usage as it is originally 
designed for cell culture. The modified assay was then validated according to 
FDA bioanalytical guidelines to assess its accuracy and reproducibility. After 
detection of an instability of the LDH enzyme during the first few measurements, 
a stability study was carried out to assess suitable storage conditions for the 
enzyme and skin samples. In the second experimental part, the scope of the 
human model was extended to a mixed model with human, porcine and canine 
skin, simultaneously testing the effect of two medium supplements on the skin 
viability. The human skin samples from the first model were maintained viable for 
8 days, cultivated in basic DMEM in AIC at 37°C/5% CO2. The modified LDH 
assay was successfully validated. The LDH samples were stable stored at -20°C 
with cryoprotector (PEG). The skin specimens of the mixed model were 
maintained viable for 14 days in basic/supplemented DMEM. Canine skin had the 
highest viability, followed by human and then porcine skin. Supplement mixture 2 
had a positive effect on all the samples while mixture 1 showed a negative effect. 
The influence on porcine skin was the strongest. The successfully established skin 
model provides a basis for further refinement, but is already a useful tool for 
human and veterinary drug development. 
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VI. ZUSAMMENFASSUNG 
Das transdermale therapeutische System hat gegenüber anderen Systemen einige 
Vorteile wie zB. Vermeidung einer vorzeitigen Metabolisierung in der Leber, 
geringeres Toxizitätsrisiko und bessere Annahme durch Patienten. Während die  
Medikamentenentwicklung in vivo kompliziert und teuer ist, wird diese durch 
einen Wechsel zur in vitro Entwicklung deutlich vereinfacht. Dies ist auch unter 
ethischen Gesichtspunkten von Vorteil, da so auf Tierversuche verzichtet wird. 
Bis dato existieren zwar verschiedenste Modellsysteme, sie sind aber meistens 
nicht ausreichend validiert und standardisiert. Dies gilt insbesondere für die 
Medikamentenentwicklung für Tiere. Aufgrund der Häufigkeit von 
Hautkrankheiten bei Mensch und Tier konzentriert sich diese Dissertation auf die 
Entwicklung und Validierung eines viablen Hautmodells mit menschlicher und 
tierischer Haut, um eine Basis für die dermatologische Medikamentenentwicklung 
zu schaffen. Im ersten experimentellen Teil wurde ein humanes Hautmodell 
entwickelt, wofür der LDH-Test zur Viabilitätsbestimmung ausgewählt wurde. 
Dieser Test, ursprünglich für die Zellkultur gedacht, wurde für die Anwendung an 
komplexen Geweben optimiert und danach nach den Vorgaben der FDA-
Guidelines validiert. Wegen Instabilität des LDH-Enzyms wurde eine 
Stabilitätsstudie durchgeführt, um die besten Lagerungsbedingungen für das 
Enzym und die Hautproben zu bestimmen. Im zweiten Experimentalteil wurde 
das humane Hautmodell um Schweine- und Hundehaut erweitert, bei 
gleichzeitiger Untersuchung des Einflusses zweier Mediumsupplemente auf die 
Viabilität. Die Hautproben des ersten Modells konnten für 8 Tage am Leben 
erhalten werden, kultiviert in DMEM als AIC bei 37°C/5% CO2. Die LDH-
Proben erwiesen sich als stabil bei -20°C mit PEG als Gefrierschutz. Die 
Hautproben des gemischten Modells konnten 14 Tage lebendig gehalten werden, 
kultiviert in original und supplementiertem DMEM. Hundehaut erzielte die 
höchste Viabilität, gefolgt von Mensch und Schwein. Die Supplementmischung 2 
zeigte einen positiven Effekt auf die Hautviabilität, wohingegen Mischung 1 einen 
negativen Einfluss hatte, welcher beim Schwein am ausgeprägtesten war. Das 
erfolgreich entwickelte Hautmodel kann weiter verbessert werden, ist jedoch 
bereits ein nützliches Instrument für die human- und veterinärmedizinische 
Pharmazeutik. 
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VIII. APPENDIX 
1. Skin diseases 
Skin diseases belong to a group of the most complex disorders. Their etiology can 
be multifactorial and often remains partially or completely unclear [162-164]. 
Genetic components, microorganisms, environmental and behavioral factors 
interact with each other in a way that still leaves questions open [162, 163]. In 
these cases, therapy focuses on relieving symptoms rather than being able to cure 
the underlying cause [164, 165]. As both human and animal dermatologic diseases 
are currently remaining on a high level or increase [5-7, 166], much more research 
and new therapeutic options are currently required and will be in future. 
1.1. Human skin diseases 
With skin being the largest organ of our body it cannot be avoided that also this 
organ, like many others, becomes diseased from time to time. As border between 
us and our environment the skin is continuously exposed to various and 
potentially detrimental influences, both from the outside world but also from 
inside the body. Toxins, chemicals and other irritants do not only affect our body 
by direct skin contact but also by incorporation, e.g. via nutrition. Among other 
factors they can influence the sensitive hormonal equilibrium and contribute to 
emerging allergies and intolerances. In recent years, a worldwide increasing trend 
in skin disorders of such origins was observed [6, 7, 166]. Another alarming trend 
is the epidemic of antibiotic resistances of pathogens like Staphylococcus aureus 
and many others [111, 167, 168]. One example of such a disease, combining 
hormonal, inflammatory and bacterial causative aspects, is acne vulgaris: 
1.1.1. Acne vulgaris 
Prevalence and description: 
Acne vulgaris belongs to the most commonly seen inflammatory skin diseases. 
Affecting around 80% of adolescents, the disease often persists throughout many 
years of adulthood. The acne lesions are located in the pilosebaceous units of the 
face and back and can result in various degrees of hyperpigmentation and scarring 
[162, 163]. Even more than to the physiological symptoms and consequences of 
this disease, attention should be paid to the psychological effects, as this skin 
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condition can cause immense impact on psychological well-being, leading to 
anxiety, social isolation, clinical depression and eventually even suicidal 
tendency, while the severity of the disease does not necessarily correlate with the 
extent of psychological suffering [163]. 
 
Fig. 19: The four stages of acne: mild, moderate, moderate-severe and severe. 
 
Etiology and pathogenesis: 
The pathology of acne vulgaris is very complex and multifactorial and therefore 
not yet completely clarified but four main factors in the pathogenesis of acne can 
be defined: 
 Increased sebum production, influenced by androgens 
 Changes in keratinization within the pilosebaceous unit which eventually 
lead to comedones through building up sebum inside the blocked duct. 
 (Hyper)proliferation of the normal skin inhabitant Propionibacterium 
acnes 
 Perifollicular inflammation 
Genetic and further hormonal factors are supposed to contribute to acne 
pathogenesis as well [163]. The physical appearance of the disease condition can 
be differentiated in mild, moderate and severe acne, a classification which serves 
monitoring disease development and choice of therapy. The stages of acne lesions 
are described as micro-comedos without visible inflammation, followed by closed 
comedones which open up and become clearly inflamed papules, pustules, 
nodules and cysts which might leave scars and pigmentary changes behind [110]. 
Contrary to the conventional perception of acne pathogenesis according to which 
inflammation results from bacterial colonization of the pilosebaceous duct, 
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evidence arose, that, in fact, inflammation might be the precursor of all further 
happening. While the underlying immunochemical processes for the onset and 
aggravation of the inflammation are still subject to research, it has been shown, 
that P. acnes is not always involved in the development of inflammation and other 
pathways are existent [162].  
The sebaceous gland might be the driving force in comedogenesis and 
inflammation. Elevated levels of pro-inflammatory cytokines such as IL-1α, IL-
1β, EGF and TGFα are expressed by the sebaceous glands which lead to 
hypercornification and disorganization of the keratinocytes of the sebaceous unit. 
Genes for expression of proinflammatory mediators have been shown to be 
upregulated in skin with acne lesions, compared to normal skin. Increased sebum 
production contributes to the inflammation as sebum lipids display 
proinflammatory properties. The involvement of P. acnes might not be the source 
of inflammation but does propagate and aggravate it by triggering an innate 
immune response via activation of monocyte TLR-2 (Toll-like receptor 2), 
resulting in expression of further proinflammatory cytokines IL-8 and IL-12.  
A neuronal influence on the development of acne lesions has to be considered as 
well. An elevated expression of CRH (corticotropin releasing hormone), MC-1R 
(Melanocrtin-1 receptor) and SP (substance P) could be detected in skin with acne 
lesions. All three neuropeptides are involved in either stress response and or 
neurogenic inflammation and might be essential for stress-induced acne [162]. 
Therapy: 
All these factors contributing to the etiology of acne should be also considered in 
the selection of an appropriate therapy. The conventional treatment with 
antibiotics has next to considerable side effects also the difficulty of emerging 
resistances. Focus on direct anti-inflammatory treatment with topical retinoids 
(e.g. Tretinoin) and benzoyl peroxide, in combination with antibiotics or without, 
has provided better results, but also here adverse effects especially in long term 
treatment can occur and still some patients are not responding to the medication 
[110, 111, 163]. 
1.2. Animal skin diseases 
Animal skin diseases are often caused by parasitic, fungal or microbial infections 
[169-171]. Besides zoonotic risk, animal skin diseases are also a financial factor 
for producers and owners. Weight loss, delay in growth, low fertility, low milk 
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production, aggressive or auto-aggressive behavior and high mortality are some 
effects of acute and chronic skin diseases in livestock [172-174]. For companion 
animal-owners, long-term treatment, special foods and hospitalization are 
challenging as well [175].  
1.2.1. Companion animals (e.g. cat and dog) 
Small animals like cat and dog advanced over the years from livestock as herding 
and guard dog or professional mice-killer to family members. As such, they share 
human environment and lifestyle more closely than other animals. Unsurprisingly, 
allergies and adverse reaction disorders toward different stimuli have increased in 
prevalence and importance for both of them [5-7, 166, 176]. So does Atopic 
dermatitis affect human, dog and cat, as well as food allergies do. While some 
parasitic and bacterial diseases of small animals do not concern human, others do 
and with cutaneous leishmaniosis another example of a “shared” disease can be 
stated. 
1.2.1.1. Why dogs are especially susceptible for skin diseases  
Dogs show an over-average predisposition for skin disease, especially concerning 
bacterial skin infections. This is due to some properties of their skin even when 
the dog is completely healthy, but the risk is incomparably increased for a dog 
with an underlying disease such as atopic dermatitis, demodicosis etc. Normal dog 
skin has a very fragile skin barrier, a rather alkaline pH and lacks a follicular lipid 
plug, which can act as a drain stopper. In atopic dermatitis dog skin, the skin 
barrier is further weakened to almost non-existent and a component of the innate 
immune system, the so-called defensins, might be reduced.  
The resulting pyoderma is induced by Staphylococcus pseudointermedius as main 
pathogen but Staphylococcus schleiferii, Staphylococcus aureus and 
Pseudomonas aeruginosa can be involved as well. Since the commonly known S. 
aureus and recently also S. pseudointermedius have gained methicillin resistance, 
treatment became even more challenging. 
Pyoderma can be categorized as following and can include various types of 
lesions and levels of pain and itching.  
 surface pyoderma 
 superficial pyoderma including 
o Impetigo 
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o Bacterial folliculitis 
o Bacterial overgrowth syndrome 
 Deep pyoderma including 
o Localized furunculosis 
o Generalized furunculosis/cellulitis 
The different forms are treated with topical or systemic antibiotics depending on 
severity and bathing/spraying with chlorhexidine solutions. A sensitivity test for 
the antibiotic to be used is recommended [5].  
1.2.1.2. Atopic dermatitis 
Dog: Canine atopic dermatitis (CAD) [177] is a very common allergic skin 
disease of the dog, characterized by inflammation, potentially intense pruritus 
(itching) and associated with IgE antibodies to environmental allergens. The lack 
of a certain biomarker or metabolic profile and of pathognomonic clinical 
presentation makes  diagnosis rather difficult. The involvement of genetic factors 
and the diversity of appearance in lesions and stage as well as possible secondary 
infections or further flare factors enhance this problem even more [164]. 
CAD usually starts with pruritus which elicits rubbing, scratching, licking and 
excessive grooming in the animal. The itch can be seasonal or non-seasonal 
depending on the allergen. Most commonly affected areas are the face, ear pinnae, 
axillae, perineal and inguinal region and the distal (lower) extremities. In 
beginning stage the pruritus can be exhibited without any lesions or primary 
lesions such as erythema and papules. In the further course of the disease, 
secondary lesions, e.g. alopecia, crusting, seborrhea, excoriations etc. are inflicted 
to the dog by self-trauma, chronic inflammation and secondary infections. 
Before the diagnosis of atopic dermatitis, several differential diagnoses have to be 
excluded, as there are to consider: 
 Ectoparasitoses (flea or mite infestations such as Demodicosis, 
Cheyletiellosis, Pediculosis, nasal mites, Sarcoptes scabiei etc.) 
 Microbial infections (pyoderma due to malassezia, staphylococcus spp.) 
 Other allergies (flea/insect bite allergy, food intolerance/allergy) 
As of this wide range of similar diseases – which might be all concurrent diseases 
next to CAD as well – the so-called “work up” of the patient is crucial. By flea 
combing, hair plucking, skin scraping and cytology of skin and ear samples or in 
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some cases therapy upon suspicion to confirm or negate a previous assumption, 
the differentials may be ruled out one by one over time.  
   
Fig. 20: Atopic dog before (left) and after (right) 2 weeks treatment:  
Decreased redness in the right picture, dog can be handled without constraint=decreased 
itching/pain (Pictures friendly provided by Birgit Heichele) 
 
CAD is not curable and treatment remains symptomatic, especially as long as the 
disease-causing allergen is not found. Possible allergens include pollen, dust 
mites, food components and others. The reactivity of the skin toward different 
allergens is evaluated by intradermal testing (IDT) or detection of IgE by allergen-
specific IgE serology (ASIS) [164] After detection of the responsible allergen(s), 
allergen-specific immunotherapy can be an effective treatment option [165]. 
Cat: Although there is a lot of similarity on first sight in allergic cats and dogs, it 
should be always considered, that a cat is not a small dog and disease origin, 
clinical signs, treatment and complications can be strikingly different.  
While the other two hypersensitivity diseases, insect bite allergy/hypersensitivity 
and cutaneous adverse food reaction (CAFR), are similar between both species, 
atopic dermatitis is different. Not much is known about the pathogenesis in the cat 
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but the lack of conclusive evidence of the influence of IgE on it led to controversy 
about whether the disease can be called atopic dermatitis or not.  Therefore, the 
more exact term “non-flea non-food hypersensitivity dermatitis” (NFNFHD) was 
introduced. Although etiology and pathogenesis of this disease are still not 
completely clear, a genetic involvement is likely.  Also the pattern of 
inflammatory cells is comparable to dog and human. The exclusion of parasitary 
infections and other allergies has to be done in accordance. The concurrent 
pyoderma and Malassezia species overgrowth commonly found in dogs was 
reported less frequently in cats with NFNFHD/atopic syndrome. If this is due to a 
relative resistance of cats compared to dogs, supposedly because of decreased 
bacterial adherence to the corneocytes, or if it is a result of overlooking the less 
prominent lesions in the cat, is so far not distinguishable. The role of skin barrier 
function is also for cats as well as people and dogs, recognized as a major factor 
in disease development. 
Common symptoms in cats are pruritus and inflammation, involving head, neck 
and pinnae, causing excoriations, self-induced alopecia, miliary dermatitis, 
eosinophilic lesions and non-painful ulcerations. Next to the cutaneous reaction, 
however, other symptoms can occur, including allergic otitis, sinusitis and 
conjunctivitis, sneezing and feline asthma. 
Treatment is symptomatic as for dog and human, including fatty acid 
supplementation, antihistamines or glucocorticoids. Allergen-specific 
immunotherapy is also possible. IDT and ASIS can be used as a guide for 
immunotherapy, but do not serve as a definite diagnostic tool [165]. 
1.2.1.3. Flea bite hypersensitivity/Flea allergic dermatitis  (FAD) 
FAD is a very common dermatologic disease of cats and dogs. In moderate and 
cold climate present just during summer, the disease can persist throughout the 
year in warm and humid climate [178]. Fleas inject their saliva while feeding into 
the host animal. This saliva contains various histamine-like components, enzymes, 
amino acids and polypeptides which can induce hypersensitivity. Dogs which are 
not used to flea bites develop immediate (15-20 min) or delayed (24-48h) 
reactions, sometimes both, with elevated levels of circulating IgE and IgG 
antibodies [178, 179]. If the dog is continuously exposed to fleas, they have low 
level of these antibodies and do not display skin reactions or very mild ones. Dogs 
without immunologic tolerance through continuous exposure can exhibit intense 
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pruritus associated with crusty papules over the whole body, but typically on the 
lower back, tail-head, posterior and inner thighs, but also flanks, neck and ears. 
The affected dogs will be restless and uncomfortable, constantly scratching, 
licking and rubbing, which can result in alopecia erythema, scaling and self-
trauma and sometimes traumatic moist dermatitis (hot spots) [179]. 
Cats rather show a miliary dermatitis on face, neck and back, which is not directly 
due to flea bite, but manifestation of the allergic reaction, eczematous rash and 
potentially severe pruritus.  
 
While normally, the diagnosis of flea infestation can be easily proved by presence 
of flea or flea excrements, in allergic animals often almost nothing can be found 
due to the extensive licking and self-grooming. IDT can support a presumptive 
claim of FAD, although the reliability of the result in the cat may be variable. 
Treatment mostly consists of removing flea with insecticides such as fipronil, 
selamectin, pyrethroids etc. and additional anti-inflammatory and anti-pruritic 
medication upon necessity. Disinfection and cleaning of animal environment 
(sleeping place, blankets etc.) is recommended to eradicate the entire flea as well 
as reducing the exposure to flea bites to the absolute minimum  [179]. Besides 
flea bite hypersensitivity, a hypersensitivity towards other insects is possible, e.g. 
to mosquitos, which shares most characteristics with FAD [165]. 
1.2.1.4. Food allergy/Cutaneous adverse food reaction (CAFR) 
The pathogenesis of CAFR in cat and dog is not yet completely understood. It is 
also unclear how common this disease is. Furthermore, it should be differentiated 
between immune-modulated reactions due to food allergy and abnormal reaction 
without the immune system being involved due to food intolerance. In the former 
one, type I and type IV hypersensitivity reactions determine the categorization as 
food allergy. Non-seasonal pruritus is the main symptom for CAFR, which after 
exclusion of other allergic or parasitary diseases, has to be confirmed by a strict 
elimination diet trial [165]. The itching can be accompanied by gastrointestinal 
symptoms such as vomiting or diarrhea. By now, the most common offending 
food allergens are well-known: Dogs show the most adverse reactions against 
beef, dairy products, chicken and wheat. Cats are most sensitive toward beef, fish, 
chicken and dairy products [180]. The elimination diet starts with a complete 
change of nutrition, with either home cooked meals, hydrolyzed protein or 
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commercial protein. Important is, that the diet should preferably not contain any 
protein to which the cat or dog has been exposed before. For this purpose, horse 
or kangaroo or other relatively exotic protein sources can be used. The duration of 
the trial should be 6 to 8 weeks which gives enough time for complete remission 
in most cases. Afterwards the original diet will be gradually reintroduced. If 
symptoms reappear, the diagnosis for CAFR is possible [165, 180]. While in 
theory, this approach seems easy and promising; in practice the success depends 
to a great extent on pet owner compliance, strict abidance to the diet plan, 
suitability of the plan regarding the causative antigen and the presence or 
development of concurrent allergies[181]. 
1.2.1.5. Cutaneous leishmaniasis (dog) 
Leishmania spp. are a genus of trypanosomes, obligate intracellular parasites, 
infectious to human and animals with L. infantum and L. major being the most 
common infective species. They are transferred via sand flies as vector, which 
occur in the Mediterranean and (sub)-tropical areas. The disease can get 
manifested as cutaneous, mucocutaneous and visceral leishmaniosis (CL, ML, 
VL). Dogs infected with the cutaneous form (Canine CL, CCL) act as a major 
parasite reservoir and contribute largely to human transmission of CL and VL in 
endemic regions. On the other hand, infected dogs are also a significant veterinary 
problem [169, 170]. 
After the infection through sand fly stings, the parasites multiply in macrophages 
and other cells of the MPS right at the infection site and spread from there. They 
can leave the skin and colonize organs like spleen, liver and bone marrow and 
cause chronic, recurrent and sometimes fatal symptoms [170, 182]. CL in dogs 
usually manifests as localized ulcerative, erosive lesions which either heal or 
become chronic and can lead to massive tissue destruction and necrotizing 
dermatitis and secondary infections by bacterial overgrowth [169, 170, 183, 184]. 
Genetic composition, especially T-cell and cytokine mediated immune response, 
has been shown to significantly influence the course and severity of the disease in 
the individual. Also variations in virulence of the parasite are considerable [170, 
185].  
 
The current therapy options for leishmaniosis in dogs are with pentavalent 
antimonials, allopurinol and amphotericin B limited and toxic, and more often 
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than not, the success is limited to clinical improvement but parasitological cure is 
not possible and relapse rates of up to 74% have been reported [185].  
1.2.2. Horse 
Horses are somewhat in between companion and livestock animal. While for 
many private owners their horse is more of a friend and leisure partner, for 
breeders and sport associations the horse is the main source of income and 
therefore has to be optimized to best functionality. Skin diseases can cause a 
heavy financial burden to them [172, 173] as they may lead to the horse not being 
able to be used (riding, driving, breeding, shows, circus…) anymore, and also 
needing extensive therapy. Skin diseases of the horse may be of bacterial or viral 
origin but also due to allergic and parasitic causes. One important example is 
summer eczema. 
1.2.2.1. Insect bite hypersensitivity/Summer eczema 
As for cats and dogs, also for horses, insect bite hypersensitivity is a very 
common skin associated disease. It is described in several countries with different 
names (summer eczema, sweet itch etc.) and in different horse breeds. It can 
strongly impair a horse’s life quality, in some cases to such an extent, that the 
horse cannot be ridden anymore, and cause great financial loss to the owner [172, 
173]. Although the problem is well known for different horse breeds and most 
horses can be affected to a certain degree, it seems that exported Icelandic horses 
are specifically susceptible compared to others, which can be explained by the 
fact, that in Iceland the causing insects do not occur and the horses are not 
familiar to those antigens [172, 173, 186]. Other affected horse races are the 
Finnhorse and New Forest Pony but also Arab horse and Thoroughbreds [173]. 
Summer eczema is an allergic reaction to the bite of Culicoides species, biting 
midges which are active during the grazing season. Horses affected by the disease 
suffer from severe pruritus (itching) especially around the mane, tail and hind 
regions which causes self-excoriation leading to open wounds and secondary 
infections. In severe cases, the lesions can be spread over the entire body. The 
tendency to develop the condition is not only breed associated but also transferred 
by parental inheriting. The symptoms usually start when the horse is around five 
years old, often correspondent to experiencing their third or fourth grazing season 
which can lead to gradually increasing sensitization. Another factor is the 
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frequency and amount of Culicoides spp. the horses are exposed to which strongly 
depends on country and area. Generally, low altitude, moisture and lee at pasture 
and open water in the neighborhood are connected to a higher prevalence and 
severity [172, 173, 186].  
Treatment is challenging and mainly focuses on minimizing insect contact by 
keeping the horses inside during summer, insecticides and special blankets and 
relief of allergic symptoms with antihistamines and glucocorticoids.  
 
Fig. 21: 16 year old warm blood gelding with severe summer eczema lesions 
(Pictures friendly provided by Birgit Heichele) 
1.2.3. Livestock  
Livestock animals like swine, sheep, goats and cattle also suffer from skin 
associated diseases. Unlike in companion animals, the causative agents of these 
diseases are more often bacterial, viral or parasitic infections than allergic or 
hypersensitivity reactions. In many cases, poor hygienic conditions, bad 
husbandry and overcrowding, which result in distress, aggression and injuries, 
hence also in a weakened immune system, lead to epidemic disease outbreaks by 
opportunistic microorganisms [187, 188]. Ringworm, a zoonotic disease caused 
by dermatophyte fungi of Trichophyton spp. or Microsporum spp., and mange 
[171] can serve to exemplify such an opportunistic infection. It should be also 
considered that with large numbers of animals in a relatively small space, 
naturally the transfer of diseases of every kind is facilitated [189, 190] and might 
happen very rapidly. Treatment in this condition is often difficult. One further 
example of a livestock skin disease with also considerable economic impact [174] 
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is exudative epidermitis. 
1.2.3.1. Exudative epidermitis (greasy pig disease/facial dermatitis) 
This disease, caused by Staphylococcus hyicus, affects usually neonatal piglets 
until 8 weeks [174], but also older pigs can be concerned, especially after mixing 
following weaning, and develop aggressive behavior and have to compete about 
resources, e.g. access to water. Infected pigs show brown and scaly lesions 
beginning on the head and neck area which can spread over the whole body and 
exude a greasy liquid. The moist patches acquire dust and soon look black in 
color. The disease can be differentiated in an acute and a chronic form. In the 
acute form, along with formation of lesions, the affected pigs rapidly exhibit 
depression and dehydration symptoms and might also die. Another rare form of 
this infection can cause generalized thickening and wrinkling of the skin so such 
an extent that euthanasia might have to be considered. Main causes for the 
outbreak of the disease are: Excessive fighting between piglets resulting in skin 
damage, high humidity in stables favoring the proliferation of the normally rather 
unproblematic S. hyicus, and generally poor hygiene conditions. A correlation 
with the prevalence of sarcoptic mange was described [171]. Treatment consists 
of systemic antibiosis and hydration with electrolyte solution in case of 
dehydration [171]. Death of piglets, decreased growth rates and reduced carcass 
value because of damaged hides due to lesions and scars, can cause significant 
financial loss to the owner [174]. 
 
Fig. 22: piglet with facial lesions. Greasiness and sticking dust is demonstrated. 
(Picture friendly provided by Anna Müller-Keller)  
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